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Abstract
Vaccines against some of the most pervasive pathogens, including HIV, TB, and malaria, are desperately
needed. Available evidence suggests that both central memory and effector CD8+ T cells play a role in
mediating protective immunity against many pathogens. Recombinant adenoviruses currently under
development as vaccine carriers induce potent and sustained transgene product-specific CD8+ T cell
responses. The transgene product-specific CD8+ T cell response remains activated and is delayed in
transitioning to central memory. Here we investigate how this response is maintained.
Adenoviral vectors persist and remain transcriptionally active in vivo. We investigated the role that continuous
transgene expression plays in maintaining the effector memory-biased transgene product-specific CD8+ T cell
response. Dual expression vectors based on AdC7 expressing transgenes that could be regulated temporally
were generated. Vectors were unexpectedly unstable in vivo. Alternatively we inhibited the mTOR pathway,
which is downstream of the T cell receptor and has recently been implicated in memory development, using a
low dose of rapamycin. Rapamycin failed to enhance the quality of the transgene-product specific CD8+ T
cells.
Persisting transgene product could maintain the transgene product-specific CD8+ T cell response by
continual recruitment of naÃ¯ve CD8+ T cells, similar to some other persistent viruses. However, in an
adoptive transfer model, we demonstrate that the response is primarily maintained by antigen-experienced
cells that do not lose function over time.
Pre-existing anti-adenovirus immunity is common, particularly for the human adenoviruses currently in
development as vaccine carriers. Here we demonstrate that pre-existing anti-adenovirus neutralizing
antibodies accelerate and enhance transgene product-specific CD8+ T cell differentiation into central
memory. These cells were highly functional and responded robustly to booster immunization. Importantly,
this may be due in part to a reduction the vector's reservoir in T cells.
These data suggest that further study of transgene product expression and its functional impact on immune
responses is necessary. Further understanding this impact will allow manipulation of immune responses
induced by the adenovirus vaccine platform such that they can be tailored to specific pathogens.
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ABSTRACT 
 
 
INVESTIGATION OF THE MAINTENANCE OF CD8+ T CELL RESPONSES INDUCED BY 
PERSISTENT ADENOVIRUS VECTORS 
Juliana Small 
 
Dr. Hildegund C.J. Ertl 
 
 Vaccines against some of the most pervasive pathogens, including HIV, TB, and malaria, 
are desperately needed. Available evidence suggests that both central memory and effector 
CD8+ T cells play a role in mediating protective immunity against many pathogens. Recombinant 
adenoviruses currently under development as vaccine carriers induce potent and sustained 
transgene product-specific CD8+ T cell responses. The transgene product-specific CD8+ T cell 
response remains activated and is delayed in transitioning to central memory. Here we 
investigate how this response is maintained. 
 Adenoviral vectors persist and remain transcriptionally active in vivo. We investigated the 
role that continuous transgene expression plays in maintaining the effector memory-biased 
transgene product-specific CD8+ T cell response. Dual expression vectors based on AdC7 
expressing transgenes that could be regulated temporally were generated. Vectors were 
unexpectedly unstable in vivo. Alternatively we inhibited the mTOR pathway, which is 
downstream of the T cell receptor and has recently been implicated in memory development, 
using a low dose of rapamycin. Rapamycin failed to enhance the quality of the transgene-product 
specific CD8+ T cells.   
 Persisting transgene product could maintain the transgene product-specific CD8+ T cell 
response by continual recruitment of naïve CD8+ T cells, similar to some other persistent viruses.  
However, in an adoptive transfer model, we demonstrate that the response is primarily 
maintained by antigen-experienced cells that do not lose function over time. 
 Pre-existing anti-adenovirus immunity is common, particularly for the human 
adenoviruses currently in development as vaccine carriers. Here we demonstrate that pre-
existing anti-adenovirus neutralizing antibodies accelerate and enhance transgene product-
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specific CD8+ T cell differentiation into central memory. These cells were highly functional and 
responded robustly to booster immunization. Importantly, this may be due in part to a reduction 
the vector’s reservoir in T cells.   
 These data suggest that further study of transgene product expression and its functional 
impact on immune responses is necessary. Further understanding this impact will allow 
manipulation of immune responses induced by the adenovirus vaccine platform such that they 
can be tailored to specific pathogens.  
 vii 
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CHAPTER 1 
 
INTRODUCTION 
 2 
ADENOVIRUS PHYLOGENY 
 
 In 1953, culture of human adenoid tissues led to the isolation and identification of a 
distinct virus that was subsequently named after the tissue from which it was isolated: adenovirus 
(Ad) 1,2. After more than half a century since they were first identified, adenoviruses have been 
divided into four genera containing species isolated from many classes of the animal kingdom, 
including fish, amphibians, reptiles, birds, and other mammals. Human adenoviruses belong to 
the genus Mastadenovirus, which contains all other mammalian adenoviruses, and are further 
grouped into seven subgroups: A-G. Individual human adenoviruses are identified and assigned a 
species typically on the basis of neutralization by homologous sera. This has led to the 
identification of 57 distinct human serotypes.  
 Historically, hemagglutination properties and neutralization criteria were used to classify 
the various human adenoviruses. However, advances in genomics and bioinformatics have given 
us great insight into adenovirus phylogeny. The evolutionary relationships previously designated 
on the basis of immunological criteria have been confirmed owing to the availability of sequenced 
Ad genome reference strains. These data have also enabled the investigation of the source of 
adenovirus genome diversity. Adenoviruses exhibit potential for recombination in experimental 
co-infection models 3,4. Recently, whole genome analysis of the completed Ad genome 
sequences has confirmed that naturally occurring homologous recombination, particularly in the 
capsid proteins’ hypervariable regions 5, is a source of the wide diversity of adenoviruses 6-8. 
Additionally, such advances have allowed us to investigate the possibility of interspecies 
transmission as an additional source of adenoviral genetic diversity. High-resolution X-ray crystal 
structures and amino acid alignment of hexon suggested that a member of subgroup E, HAdV-4, 
is closely related to chimpanzee adenovirus 68 9. The close phylogenetic relationship of human 
and simian adenoviruses has lead to the simian adenoviruses’ classification within the human 
subgroups B, C, and E 6,10,11. 
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ADENOVIRUS STRUCTURE AND GENOME 
 
 Adenoviruses have a ~30-36 kilobase (kb) double-stranded DNA (dsDNA) genome 
surrounded by a non-enveloped icosahedral protein capsid 12. Each of the twenty faces of the 
adenovirus capsid contains twelve hexon trimers; thereby making hexon the most abundant 
capsid structural protein. Hexon is highly conserved between serotypes 9. However, the outer 
surface, which is subject to more intense selective pressures, is comprised of amino acid loops 
with a high degree of sequence diversity, termed hypervariable loops 9. Most serotype specific 
neutralizing antibodies are directed against these loops within hexon 13. Two other major proteins 
comprise the capsid: penton and fiber. At each vertex where three hexon facets meet, fiber 
trimers form a spike that protrudes from the penton complex. Fiber has three domains: the highly 
conserved N-terminus that binds to the penton base, a flexible shaft whose length varies between 
serotypes and influences virus internalization 14,15, and a globular head responsible for binding to 
cellular receptors 16,17. Five minor capsid proteins function to stabilize the capsid.  
 The adenoviral genome is organized based on the temporal expression of viral 
transcription units. There are four early transcription units (E1, E2, E3, and E4) each of which 
have multiple open reading frames or are alternatively spliced into several mRNAs throughout the 
course of infection 12. The four early transcription units encode non-structural proteins. E1A 
proteins are the first to be transcribed as soon as the viral DNA enters the nucleus. These 
proteins have the critical job of serving as transcription factors to stimulate transcription of the 
other viral transcription units 18-20 and promoting cell cycle progression such that the cellular 
replication machinery can be hijacked to replicate the virus 21-23. E1B proteins largely function to 
prevent apoptosis of infected cells. The E2 transcription unit encodes proteins necessary for viral 
DNA replication, including the viral DNA polymerase. Proteins encoded in the E3 transcription 
unit are responsible for subversion of the host immune response and promoting longevity of the 
infected cell through prevention of apoptosis. E4 proteins have a wide variety of regulatory 
functions, including modulation of DNA repair and cell signaling, and promoting synthesis of the 
late viral proteins. There are five late transcription units (L1-L5) that encode the virus’ structural 
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proteins. 
 
ENTRY AND LIFECYCLE 
 Early studies of adenovirus revealed that the virus is capable of attaching to HeLa cells 
16,24, an immortalized epithelial cell line derived from the cervix. Armed with the knowledge that 
Coxsackie B virus competes with adenovirus for binding to these cells 25, Bergelson et al. isolated 
the common receptor used by both viruses for attachment to target cells 26. Coxsackie and 
adenovirus receptor (CAR) is a 365 amino acid transmembrane protein 26,27 that functions in cell 
adhesion 27. It has since been confirmed that CAR is the receptor for virtually all adenoviruses, 
with the notable exception of subgroup B viruses 28.  
 Additionally, CAR is also thought to facilitate dissemination of adenovirus in vivo. The 
studies that identified CAR as the receptor were performed in vitro on non-polarized cells. 
However, in vivo, CAR expression is limited to the basolateral side of polarized epithelial cells 
27,29 below the tight junctions binding them to one another, ultimately restricting the virion’s 
access. Late in the viral life cycle fiber is produced in excess and has been demonstrated to open 
tight junctions by disrupting CAR-CAR interactions 30, thus promoting the spread of infection. 
 The studies demonstrating that fiber mediated attachment to the then unidentified 
receptor did so using the common subgroup C viruses, HAdV-2 and HAdV-5, on cell lines that 
were permissive to adenovirus infection 16. Attempts to determine if subgroup B viruses interacted 
similarly with target cells permissive to subgroup C viruses revealed that subgroup B viruses did 
not share a common receptor with subgroup C viruses 28,31. It has since been revealed that 
CD46, a ubiquitously expressed regulator of complement, serves as a receptor for subgroup B 
viruses 32. Notably, HAdV-3, HAdV-7, and HAdV-14 do not use CD46 32,33 as their primary 
receptor but instead use desmoglein 2, a calcium-binding transmembrane glycoprotein involved 
in cell adhesion of epithelial cells.  
 As adenoviruses can bind independently of CAR and CD46 to a wide variety of cells, a 
number of alternative receptors have been proposed. CD80 and CD86 have been proposed as 
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alternate receptors for some subgroup B viruses 34. Subgroup C viruses have been proposed to 
utilize a number of alternative receptors, including glycosaminoglycans in the extracellular matrix 
35 and major histocompatibility complex (MHC) class I α2 subunit 36 but this was not confirmed 37. 
Finally, subgroup D viruses are proposed to bind sialic acid at the very tip of the fiber knob 38.  
The extent to which these are used as receptors in vivo has yet to be confirmed. 
 High affinity binding of fiber with the receptor allows the virion to be held close enough to 
the cell surface to facilitate entry into the cell. However, entry is not mediated solely through 
attachment to CAR but requires binding to the integrins αvβ3 or αvβ5 39,40. Adenoviruses bind to 
these integrins using a conserved Arg-Gly-Asp (RGD) motif located on the penton base 40,41. This 
interaction triggers internalization of the virion into clathrin-coated pits 42,43. Once internalized, 
adenoviruses rapidly escape the endosome in a pH-dependent manner. As the pH drops during 
endosomal trafficking inward, the capsid undergoes a conformational change that triggers lysis of 
the endosome, thereby allowing the virus to escape 44,45. The virion then traffics to the nucleus via 
microtubules by binding the molecular motor, dynein 46. The capsid forms a stable interaction with 
the nuclear pore and the genome is then transported into the nucleus 47, where it can begin 
transcription of the gene products described earlier. 
 
CLINICAL FEATURES 
 
 Adenoviruses are a significant cause of global morbidity in humans and typically cause 
mild infections of the respiratory and gastrointestinal tracts during the first few years of life 48. 
Indeed most children will have evidence of prior exposure by the time they are five years old 48,49. 
Although infection is often asymptomatic, adenoviruses are responsible for approximately 5% of 
symptomatic upper respiratory tract and 10-15% of lower respiratory infections in children 50 and 
about 17% of gastroenteritis disease in infants 51. While not all human adenoviruses are 
associated with disease, certain species are responsible for the vast majority of adenovirus 
morbidity.  Subgroup C viruses are most associated with respiratory tract infections; while viruses 
belonging to subgroups B and D more commonly cause enteral infections. 
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 Healthy adults are normally not at risk of infection with adenovirus. However, certain 
populations are at risk for serious adenoviral infection. Military recruits are disproportionately 
infected with HAdV-4 and HAdV-7, which are responsible for between 60-80% of acute 
respiratory illness in this population 52. Ad infection is an even greater issue for those that are 
immunosuppressed either for transplants or due to HIV. Indeed, disseminated infection occurs in 
40% of hematopoietic stem cell transplant patients 53 and is common among HIV patients 54-56. In 
these cases, disease is most often severe and life threatening.  
 
ADENOVIRUS AS A PERSISTENT INFECTION 
 
 Early clinical evidence suggests that adenovirus establishes a persistent infection. 
Longitudinal analysis of adenoviral infection in families demonstrated that even after resolution of 
primary infection when adenovirus could no longer be detected in the upper respiratory tract, 
virus could be intermittently shed in stool 48,50. As adenoviruses often cause subclinical infections 
49, it was unclear that this shedding represented a new infection or reactivation of a persistent 
infection. Using serologic evidence, these longitudinal analyses demonstrated that shedding 
could be due to either scenario: in some patients reinfection was clearly the cause, but in others 
shedding was due to reactivation 50. What distinguished the two scenarios though was the 
duration of shedding. Short-term shedding was observed in individuals who were re-infected, 
whereas shedding was detected for months to years in individuals who were shedding persistent 
virus. These results were later confirmed using restriction analysis of viral isolates from infants 
persistently shedding adenovirus for over a year. The analysis revealed that viruses isolated 
throughout the study period were always identical to each other 57.  
 Experimental evidence suggested that this persistent virus was establishing a latent 
infection as opposed to a chronic infection. The first evidence of this came with the initial 
identification of adenovirus. When tonsils and adenoids isolated in the absence of adenovirus 
infection were cultured long-term small amounts of infectious adenovirus could be isolated 2,58.  
However, culture did not always result in production of infectious virus, and yet adenoviral DNA 
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could be isolated from the tissue 59. Together this suggested that while the virus was there, it was 
not replicating. In support of this, the addition of phytohaemagglutinin (PHA), a mitogen 
commonly used to stimulate lymphocytes 60, to cultures that failed to produce replication 
competent virus resulted in the successful production of infectious virus 61. These data suggested 
that adenovirus establishes a persistent but latent infection in these tissues. Since these early 
studies, adenoviruses have been isolated in the absence of productive infection from an array of 
tissues, including the gastrointestinal tract, urinary tract, circulating peripheral blood mononuclear 
cells, the central nervous system, and the conjunctiva of the eye.  
 Decades of study have been devoted to the determination of the cell type that harbors 
persistently infecting adenovirus. Initial attempts suggested that fibroblasts within the tonsils and 
adenoids were responsible 62,63. In a study to model persistent adenoviral infection of the tonsils 
and adenoids using suspensions of such tissues, Strohl and Schlesinger estimated the frequency 
of infected cells in these tissues to be 1 in 107 cells. This frequency was then correlated to the 
frequency of fibroblasts in uninfected tissue, which led to the conclusion that these cells were the 
primary source of persistent virus 63. However, evidence began to accumulate that implicated 
lymphocytes instead. First, it was demonstrated using fluorescent antibodies that lymphocytes 
isolated from oral ulcers carried adenoviral antigens 64. Additionally, infectious adenovirus could 
be cultured from a small fraction of lymphocytes purified from tonsil and adenoid explants, most 
notably when PHA was added during culture to stimulate lymphocytes 61. Finally, even when 
infectious virus could not be isolated, lymphocytes were commonly found to harbor adenoviral 
DNA 59. 
 A study to quantify the amount of adenoviral DNA in purified lymphocytes residing in 
tonsils and adenoids provided definitive evidence that adenovirus persists in lymphocytes 65.  
Garnett et al. additionally demonstrated that adenovirus DNA was enriched in a particular subset 
of lymphocytes, T cells. Subgroup C viruses are exclusively isolated from lymphocytes residing in 
tonsils and adenoids 49,65, but adenoviruses belonging to additional subgroups have since been 
isolated from lymphocytes in the gut mucosa 56,66.  
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 It is of particular interest that T cells are the source of latent adenovirus as it remains 
unclear exactly how adenovirus infects them. T cells poorly express CAR, and αvβ3 and αvβ5 are 
only upregulated during T cell activation 67. As such, T cells should be refractory to adenovirus 
infection. Indeed, experimental infection of T cells with adenovirus is difficult, often requiring 
ectopic CAR expression 39,68, immortalized lymphocyte lines with high CAR expression 69, or 
fiber-modified virus 70. This may suggest that CAR isn’t the primary receptor on T cells in vivo.  
 
MECHANISMS OF PERSISTENCE OF NATURALLY ACQUIRED ADENOVIRUS 
 
 In order for adenovirus to establish a latent infection in lymphocytes the genome would 
have to be stably maintained in these cells. Common strategies to accomplish this include 
integration into the host genome and formation of stable DNA structures that are maintained 
extrachromasomally, such as episomes. Early work suggested that the former strategy is 
employed. HAdV-12 infection of neonate hamsters leads to integration of at least the E1A and 
E1B domains, ultimately resulting in tumorigenesis 71. Studies of human tumors occasionally find 
evidence of adenoviral DNA within the tumor 72-74. However, there is a dearth of evidence that 
suggests that the virus’ presence in the tumor is due to integration 73,74, suggesting that 
adenovirus likely does not integrate into the human genome as a means of persistence. 
Integration machinery is not encoded in the adenoviral genome; therefore, the frequency of 
integration would be expected to be low and would have to occur randomly through 
recombination of the viral genome with the host genome. In vitro studies suggest that this occurs 
with a relatively high frequency, ranging from approximately 5x10-3 – 1 x10-4 integrations per cell 
75. In contrast, a recent study examining the integration frequency in the liver following gene 
transfer instead suggested that the frequency of integration was significantly less, ranging from 
about 10-6 to 10-7 integrations per cell. Alternatively, experimental infection of human T cell lines 
provided evidence that the adenovirus genome instead persists extrachromosomally as an 
episome. Southern blot analysis revealed that following restriction digest the resulting DNA 
fragments were the correct size, as predicted from virus alone 69.  
 9 
 In addition to stable maintenance of the genome, the virus would also have to subvert the 
host’s immune responses in order to persist in vivo. Indeed, a number of proteins are encoded in 
the genome that specifically function to this end. Evasion of the host innate response begins as 
early as expression of the E1 transcription unit. Proteins encoded in this unit prevent interferon-
mediated gene expression 76. The majority of adenoviruses’ immune evasion proteins are 
encoded in the E3 domain, which has long been implicated in adenovirus’s persistence. The E3 
transcription unit’s expression is induced in response to inflammation. Indeed, the E3 promoter 
contains NF-κB binding sites, which when mutated prevent expression of the E3 unit in response 
to tumor necrosis factor α (TNF-α) 77. The E3 transcription unit is alternatively spliced into a 
number of proteins that prevent CTL-mediated killing of infected cells. One such protein, E3-19K, 
is responsible for preventing MHC class I transport to the cell surface by sequestering the 
complex in the endoplasmic reticulum 78,79, thus preventing CTL-mediated lysis. While the 
function of E3-19K is conserved within adenovirus subgroups 80, there is genetic variation 
between subgroups 5,81. This is thought to influence the avidity with which E3-19K from the 
different species binds HLA alleles 81. It has been suggested this could indicate that an 
individual’s haplotype may determine if they are more susceptible or resistant to persistent 
adenoviral infection 82. Other E3 proteins function to prevent cell-mediated killing by blocking the 
infected cell’s apoptosis cascade. The RID complex, E3-14.7K, and E3-19K all function to this 
end, interfering with Fas and TRAIL-R1 83, thus preventing FasL- and TRAIL-mediated apoptosis.  
 
VECTORED ADENOVIRUS  
 
 Adenoviruses have long been explored as vectors for gene delivery, at first in order to 
correct inherited genetic disorders but more recently for vaccination. Such intense exploration has 
largely been fueled by their tropism for numerous tissues, ability to transduce both dividing and 
non-dividing cells, and their relatively low pathogenicity. Further, adenoviruses have proven easy 
to manipulate genetically and to grow in culture 84.  
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 The first generation of Ad vectors was deleted in the E1 domain, a modification that not 
only allowed for the inclusion of a transgene-expression cassette but also rendered the vector 
replication defective. As such, the E1 domain must be provided in trans in order for the vector to 
be grown in culture. These first generation vectors could also be deleted in the E3 domain in 
order to increase their packaging capacity.  Gene products from the E3 domain are not necessary 
for replication and as such do not need to be provided in trans.  
 These first generation vectors could achieve stable transgene expression in 
immunodeficient mice 85. However, transgene expression was transient in immune competent 
animals due to the robust anti-adenovirus immune response. Indeed, these responses were in 
part directed against viral gene products that continued to be expressed at low levels even 
though the vector genome was deleted in the E1 domain 86. This precipitated the development of 
vectors with fewer encoded viral genes in an effort to reduce the anti-vector response. Later 
generations of vectors are sometimes deleted in E2, E4, or are completely gutted but for the 
LTRs and packaging sequence. While these deletions reduce the number of viral antigens and 
weaken the anti-adenovirus immune response, the vectors are still capable of eliciting transgene 
product-specific responses 87. It is this characteristic induction of potent immune responses to 
encoded transgenes that has prompted the development of adenoviruses as vaccine carriers. 
 
ADENOVIRUS AS A VACCINE CARRIER 
 
 Extensive development of vaccines based on adenovirus is under way. This platform is 
currently being tested for numerous and diverse targets, including viruses, bacteria, parasites, 
and cancers. Pre-clinically, these vectors induce potent and sustained immune responses 
directed against the transgene product that can be protective in an appropriate challenge model. 
Several of these vaccine candidates, including those against malaria 88, Ebola 89, and HCV 90, 
have performed so well in preclinical models that they are now in various stages of clinical 
testing.    
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 The most widely studied Ad vector is based on HAdV-5. However, pre-existing immunity 
to this virus is common globally. Pre-existing immunity poses a serious issue because it limits 
transduction of target cells 91,92, thereby reducing transgene expression and ultimately the 
vector’s immunogenicity 93. To overcome this problem, alternative serotypes have also been 
developed as vectors. These include human serotypes that circulate less frequently in 
populations, including HAdV-26 and HAdV-35 94,95, and novel non-human primate serotypes such 
as those that circulate in chimpanzees 11,96,97. These alternative species also induce potent B and 
T cell responses against both the encoded transgene product and the Ad capsid. The CD8+ T cell 
response is particularly robust. 
 While the gold standard for vaccine-mediated protection is considered to be induction of 
neutralizing antibodies directed against a pathogen 98, CD8+ T cells are also important in vaccine-
induced immunity. The CD8+ T cell response induced by a vaccine or in response to a natural 
infection has the potential to be broad as it is not limited to antigens on the surface of a pathogen 
but can also be directed against both internal epitopes and highly conserved elements.   
 During a primary immune response, naïve CD8+ T cells are activated in lymphatic tissues 
following engagement with an antigen presenting cell (APC) displaying the T cell’s cognate 
antigen in the context of MHC class I. The APC provides additional signals in the form of 
costimulation and cytokines to fully activate these cells. Once activated, CD8+ T cells undergo a 
period of vast proliferation, during which time effector functions are acquired, including the ability 
to produce antiviral cytokines such as interferon-γ (IFNγ) and the cytotoxic granules perforin and 
granzyme needed to eliminate target cells. Fully activated effector CD8+ T cells exit the lymph 
nodes and traffic to inflamed tissues in the periphery to carry out their effector function and kill 
infected cells. Once the pathogen is cleared, the overwhelming majority of effector cells, up to 90-
95%, will undergo apoptosis. The remaining cells differentiate into memory CD8+ T cells that can 
endure for life 99. T cell vaccines specifically seek to take advantage of this natural process in 
order to generate high numbers of memory cells, which is correlated to protection 100-102.  
 The CD8+ T cell memory population is highly heterogeneous and can be broadly 
classified based on the expression of L-selectin (CD62L), a cell adhesion molecule required to 
 12 
gain entry into the lymph nodes through the high endothelial venules, and CCR7, a chemokine 
receptor that promotes migration to the T cell areas of the lymph nodes. Central memory T cells 
(TCM) express both CD62L and CCR7, which allow them to enter and reside in lymphoid tissues 
103. In contrast, effector memory T cells (TEM) express neither CD62L nor CCR7 103. This 
promotes their circulation through the periphery 104. These two subsets are also functionally 
distinct. TCM are less differentiated and metabolically quiescent 105. As such, they are slower to 
reacquire effector abilities following secondary antigen stimulation 106. However, they will robustly 
proliferate, and secrete IL-2, in response to stimulation. On the other hand, TEM are more 
activated and differentiated, which poises them to rapidly execute effector functions following 
reencounter with their cognate antigen. Additionally, they are armed with a large amount of 
cytotoxic molecules, including perforin 106 and can secrete IFN-γ and TNF-α upon restimulation 
107. However, while they will rapidly kill target cells, they have a reduced proliferative capacity 
compared to TCM cells. The number of effector memory cells declines over time while central 
memory cells are maintained at very stable frequencies through homeostatic proliferation 
primarily driven by IL-7 and IL-15 99,108.  
 A single cell is capable of giving rise to the diverse subsets of memory CD8+ T cells 109. 
There exist two models to explain how memory T cell populations arise. The first model, the linear 
differentiation model, suggests that an effector T cell will either die during the contraction phase 
or progressively transition and dedifferentiate from effector to effector memory to central memory 
over time 110-112. Alternatively, the second model, the decreasing potential model, suggests that 
the fate of a CD8+ T cell is determined early in the response by the summation of the signals it 
receives during priming 113,114. The fate decisions that give rise to these populations are thus 
influenced by several factors, including the number of naïve precursors 115,116, strength and 
duration of the signal from the T cell receptor upon engagement with the peptide-MHC complex 
117, the type of costimulation the CD8+ T cell receives 118,119, and the degree of inflammation at 
priming 114. As such, the fate of a CD8+ T cell may, potentially be determined as soon as the first 
cell division after TCR engagement 120.  
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 At the peak of the expansion phase, CD8+ T cells can already be divided into the subset 
of cells that will eventually die off, i.e. short-lived effector cells (SLEC), and those that will survive 
contraction and differentiate into memory cells, i.e. memory precursor effector cells (MPEC) 
114,121. The heterogeneity of the memory response is also established at this time; the MPEC 
population can be further divided into those cells that will become TCM and those that will become 
TEM 122.  
 
PERSISTING VACCINES 
 
 Immunization with a recombinant Ad-based vaccine induces a transgene product-specific 
CD8+ T cell response that is robust and fails to contract following its peak. Moreover, the 
population of cells that fails to contract is primarily composed of cells with effector and TEM 
phenotypes. TCM differentiation is delayed, often taking months to years to accumulate in the 
lymph nodes because the CD8+ T cells are slow to regain CD62L expression 123.  
 Reacquisition of CD62L expression on memory cells is slower with subsequent antigen 
encounters 124,125. As such, bias toward induction of a memory population primarily composed of 
more activated, effector memory cells with low CD62L expression is a function of repeated 
antigen exposure and viral persistence 125-127 and not the transgene itself 126. Indeed, adenoviral 
vectors persist in vivo following administration 123, despite deletion of the gene products 
responsible for immune evasion. As expected from the study of wild type virus, the genome is 
also enriched in T cells, where it can be detected for years following immunization of mice and 
non-human primates 123. Strong, constitutively active promoters, e.g. cytomegalovirus (CMV) 
promoter, are often used to drive expression of the encoded transgene. As such, the encoded 
transgene is continuously transcribed, presumably intermittently at low levels 123.  
 A persistent vaccine vector that maintains an effector memory pathogen-specific CD8+ T 
cell response may be highly advantageous, particularly in the development of vaccines against 
other persisting pathogens. These pathogens are not only quick to spread but also to put in place 
immune evasion mechanisms thereby preventing their clearance and allowing them to live in a 
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balance with the host 128. Many vaccine strategies that aim to mimic natural infection employ non-
persistent vectors that primarily induce central memory. However, because TCM need time in 
order to respond to re-infection, they may not be able to catch up to the pathogen once its 
immune evasion strategies are in place. Therefore, a front line of defense made up of activated 
Tem could be advantageous against both persisting and non-persisting pathogens. Indeed, many 
infection models have supported this concept. For example, intravenous transfer of CD8+ OT-1-
specific T cells, which recognize the immunodominant epitope of ovalbumin, with a more 
activated, effector memory phenotype conferred more rapid protection against challenge with 
virulent Listeria moncytogenes expressing ovalbumin than their central memory counterpart 125.  
Persistent and protective CD8+ TEM responses have also been described for other infections 
including, Plasmodium berghei 129,130, influenza virus 131,  and Salmonella enterica 132. 
 Other persistent vectors are also being explored as HIV vaccine platforms and have 
supplied encouraging results. It is generally believed that a T cell vaccine against HIV will not 
completely protect from or eliminate HIV infection but would instead lower the viral load and delay 
progression to AIDS 133. However, recent studies of vaccines based on CMV have suggested that 
a strong T cell response biased toward effector memory may be able to control infection before 
HIV can disseminate and avoid control by the immune system 134,135. A series of rhesus macaque 
CMV vectors were engineered to express SIV proteins and used to immunize rhesus macaques. 
The vaccine induced very robust, persistent effector memory responses that localized to the 
periphery. More than year after their final immunization, the monkeys were repeatedly challenged 
intrarectally with a lose dose of SIVmac239, a highly pathogenic, neutralization-resistant clone of 
a rhesus macaque SIV isolate 136. Not only did the vaccine delay the onset of progressive 
infection, it also prevented disseminated infection in 4 of 12 animals 134. CD8+ T cell depletion of 
the 4 animals did not result in SIV viremia. The presence of de novo CD8+ T cell responses to 
SIV antigens not encoded in the vaccine suggested that these animals were able to control early 
replication. A follow up study directly compared the CMV platform to others 135. Monkeys were 
immunized with the CMV vector platform alone, the CMV vectors followed by an AdHu5 boost, or 
a DNA prime followed by AdHu5 boost. Over a year after the final immunization, the monkeys 
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were challenged as described above. The results were largely consistent with the previous study. 
13 of 24 animals that received the CMV vaccines were able to rapidly control SIV infection, while 
the DNA prime/Ad5 boost platform only lowered the viral load setpoint. Control in both studies 
was mediated by effector memory CD8+ T cells; whereas, the DNA prime/Ad5 boost induced a 
more central memory-biased response. This may suggest that there is a window of opportunity in 
which TEM can mediate control. These results are encouraging for the design of vaccines that 
induce effector memory T cell responses.  
  
CONCERNS WITH A PERSISTING VACCINE 
 
  The persistence of adenoviral vectors may have important consequences on the function 
of the induced CD8+ T cell memory response. Studies of other persistent infections, including 
LCMV clone 13, have revealed that chronic antigen exposure can dramatically impair the induced 
CD8+ T cell response and, in the most severe scenarios, cause deletion of the induced CD8+ T 
cells 137-139. This can be measured by hierarchal loss of the ability to secrete IL-2, followed by 
tumor necrosis factor-α (TNF-α), and IFN-γ. Additionally, the CD8+ T cells lose their cytotoxic 
capabilities. Some groups have reported that the CD8+ T cell population induced following 
immunization with recombinant adenovirus primarily consists of effector memory cells that bear a 
partially exhausted phenotype and fail to produce IL-2 upon restimulation 140. However, it is 
important to note that these “partially exhausted” cells were protective when immunized animals 
were challenged 140. Indeed, this phenotype is more consistent with highly activated effector cells 
than exhausted cells that cannot mediate protection upon challenge. The progressive loss of 
function as cells become exhausted as described above is directly related to the amount of 
persisting antigen 137. High amounts of antigen are sufficient to drive responding CD8+ T cells to 
exhaustion. However, adenoviral vectors persist latently and presumably only produce transgene 
product intermittently 123. Therefore, levels of persisting antigen are not high enough to drive the 
transgene product-specific CD8+ T cell response to exhaustion.   
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 Even though adenoviral vectors are unlikely to drive a CD8+ T cell response to 
exhaustion, it is worth considering that TEM cells are more terminally differentiated than TCM. They 
have shorter teleomeres 141 and express less telomerase than TCM 142. While this is in agreement 
with their limited proliferative potential, this may also suggest the extent to which they can divide 
is limited. In support of this, TEM also express higher levels of killer cell lectin-like receptor G1 
(KLRG1) 143, a marker of replicative senescence 144. KLRG1 binds members of the cadherin 
family, thereby preventing IL-2 production 145 and proliferation following TCR stimulation 146. 
KLRG1 accumulates on these cells with successive rounds of antigen stimulation and is 
considered a reliable marker of antigen experience 124,147. Additionally, repetitive antigen 
stimulation drives permanent changes to the cell’s transcriptome, including increasing expression 
of genes associated with senescence 148. As such, the first line of defense generated in the 
context of a persisting vaccine could potentially be pushed to a point after which it may no longer 
mediate protection.  
 
THE ROLE OF CENTRAL MEMORY T CELLS 
 
 CD8+ central memory T cells play a role in maintaining the TEM population. Repetitive 
antigen stimulation skews the memory response in favor of increased numbers of TEM 124. 
However, in situations in which antigen does not persist, the TEM population gradually declines 
over time 132, as residual antigen is cleared from depots located in the draining lymph nodes of 
peripheral tissues 149. Once the depot is cleared, the numbers of TEM stabilize 150 and are 
replenished through homeostatic proliferation of TCM 132,149,151. It may be beneficial in vaccine 
design to induce a population of TCM that can maintain a first line of defense.  
 However, there exists controversy on the role that central memory cells play in controlling 
infection. Studies in which equal numbers of effector memory or central memory CD8+ T cells are 
adoptively transferred into mice prior to infection generally support the concept that effector 
memory cells confer more rapid control. However, in these models the use of mouse lymphocytic 
choriomeningitis virus clone 13 (LCMV), which rapidly establishes a chronic infection, 
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demonstrated that central memory cells were better able to control disseminated infection. This 
was largely attributed to their increased proliferative capacity that resulted in large numbers of 
effector cells during the anamnestic response that likely compensated for an overwhelmed TEM 
response at the periphery 107,152. Other lines of evidence also support a role for TCM. In the context 
of the HIV vaccine model described earlier, a DNA prime following by an Ad5 boost generates a 
more central memory T cell population 135,153. While this response does not protect against 
infection, it serves to ameliorate the course of disease by reducing the SIV viral load 135,153. 
Interestingly, while the CMV-based SIV vaccine described above protected more than 50% of the 
animals from SIV challenge, those that were unable to control the initial infection also had high 
viral load setpoints. This was attributed to the lack of expansion in the memory CD8+ T cell 
response after challenge. These studies highlight the importance of TCM as a second line of 
defense.  
 
GOALS OF THE STUDY 
 
 Available evidence thus suggests that both subsets of memory CD8+ T cells play 
important roles in control of infection. The contribution of each subset into control of infection will 
likely depend on several factors, including the pathogen’s route of entry, how quickly it can 
replicate and disseminate, and where the pathogen may localize in the host. In designing vaccine 
platforms it will be important to assess these factors in order to optimize the vaccine. The studies 
presented in this thesis were designed to investigate strategies to balance the CD8+ T cell 
response induced following immunization with adenoviral-based vaccines. More specifically, as 
vectors based on adenovirus induce robust CD8+ T cell responses that are biased toward effector 
memory, we explored methods to create a CD8+ T cell memory response with a better balance 
between central and effector memory cells.  
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AIM 1 
 
 Adenoviral vectors persist and remain transcriptionally active in activated T cells in vivo. 
This correlates with two features of the transgene product-specific CD8+ T cell response induced 
by immunization with adenoviral vectors. First, the transgene product-specific CD8+ T cell 
response fails to contract following immunization. Second, there is a marked delay of more than a 
year in the accumulation of transgene product-specific CD8+ T cells with a central memory 
phenotype. As levels of persistent antigen are known to influence anti-viral CD8+ T cell 
responses, we hypothesized that continued production of transgene product from the adenoviral 
vector genome prevents the contraction of the transgene product-specific CD8+ T cell pool, 
thereby maintaining them in an activated effector and effector memory state. In chapters 2 and 3 
of this dissertation we address this hypothesis in two ways. In the first approach, we aimed to 
generate vectors with transgenes whose expression could be temporally regulated. We 
hypothesized that discontinuing transgene expression would allow the transgene product-specific 
CD8+ T cell response to contract and differentiate into the central memory compartment. In a 
second approach, we aimed to manipulate the mTOR pathway that is downstream of T cell 
receptor signaling and recently has been implicated in memory development 154. We 
hypothesized that inhibition of mTOR activity following adenoviral immunization would accelerate 
the formation of a pool of central memory transgene product-specific CD8+ T cells. To this end, 
we inhibited mTOR activity in a mouse model using a low dose of rapamycin at different phases 
of the CD8+ T cell response following immunization with an adenoviral vector. Mice were assayed 
for CD8+ T cell numbers and memory phenotypes in several tissues. 
 
AIM 2 
 The CD8+ T cell pool that fails to contract following induction with an adenoviral vaccine 
bears some resemblance to those induced by other persistent viruses. The CD8+ T cell pool is 
phenotypically heterogeneous, composed primarily of effector and effector memory cells, but is 
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highly functional and protective. A common strategy for maintaining such activated and functional 
responses necessary for combating ongoing, low-level viral replication is to continuously prime de 
novo CD8+ T cells. However, adenoviral vectors are replication-defective, although transgene 
product continues to be expressed at low levels during persistence, which may give responding 
transgene product-specific CD8+ T cells an opportunity to rest from antigenic stimulation and 
transition to central memory. Therefore we hypothesized that the transgene product-specific 
CD8+ T cell pool is maintained by recall of antigen-experienced CD8+ T cells instead of 
asynchronously primed CD8+ T cells. The hypothesis was explored in chapter 4 by adoptively 
transferring naïve or antigen-experienced CD8+ T cells into adenovirus-immunized mice and 
following the transferred cells’ responses over time. 
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CHAPTER 2 
	  
OPTIMIZATION OF ADENOVIRAL VECTORS TO INVESTIGATE 
THE INFLUENCE OF PERSISTENT TRANSGENE EXPRESSION 
ON CD8+ T CELL RESPONSES INDUCED FOLLOWING 
IMMUNIZATION
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ABSTRACT 
 
 Adenoviral vectors persist and remain transcriptionally active in vivo. This persistent 
transgene expression is correlated to the failure of the transgene product-specific CD8+ T cell 
response to contract and transition to central memory following immunization. In order to directly 
investigate these correlations, we utilized a well-characterized recombination system that would 
allow us to temporally regulate expression of the encoded transgene. This required the 
construction of adenoviral vectors capable of expressing two transgenes at once. In the first part 
of this chapter, we describe the optimization of a series of replication-defective adenovirus 
vectors designed to express transgene products from two expression cassettes placed into the 
deleted E1 and E3 domains. Vectors with fewer shared elements in E1 and E3 expression 
cassettes optimally expressed transgenes and induced B and T cell responses to encoded 
transgenes. In the second the part of this chapter, we constructed vectors based on the optimal 
design from part 1 to generate vectors encoding a transgene that could be temporally regulated.  
However, these vectors were unexpectedly unstable. Alternative approaches to regulating 
transgene expression from an adenoviral vector will have to be utilized. 
 
 
 
 
 
 
 
 
First part adapted from: 
Construction and Characterization of E1- and E3-Deleted Adenovirus Vectors Expressing 
Two Antigens from Two Separate Expression Cassettes. Small JC*, Kurupati RK*, Zhou X*, 
Bian A, Chi E, Li Y, Xiang Z, and Ertl HCJ. Human Gene Therapy. 25, 328-338 (2013). 
*These authors contributed equally 
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INTRODUCTION 
 
 Ad vectors persist in a transcriptionally active state at low levels in mice and non-human 
primates 123 and naturally acquired adenoviruses persist in human lymphatic tissues, particularly 
in tonsils and adenoids 65. Additionally, Ad vectors induce a robust population of activated 
transgene product-specific CD8+ T cells that fails to contract over time and is delayed in 
differentiating into the central memory compartment. Studies of other pathogens suggest that 
persisting antigen is sufficient to maintain this type of response. Therefore, we aimed to 
investigate the influence of persistent transgene expression on the differentiation of transgene 
product-specific CD8+ T cell responses following immunization with adenoviral vectors. This 
necessitated the development of Ad vectors carrying transgenes whose expression could be 
regulated in vivo. The first part of this chapter concerns the optimization of vectors encoding 
multiple transgenes, the results of which were applied in the second part in the construction of 
vectors generated to explore the question described above.   
 Ad vectors are deleted in the E1 to limit their replication in vivo. Deletion of the E1 
domain allows exogenous DNA sequences up to 4.7 kilobases (kb) to be inserted into the vector 
genome 155. Insertion of foreign DNA enables us to direct an immune response to an antigen from 
a particular pathogen. However, protection against many pathogens may require vaccines that 
express multiple antigens. Historically, several approaches to achieve this goal have been 
explored. One approach is to mix vectors expressing different target antigens 156; however, this 
approach requires generation of multiple vectors, which is both cumbersome and costly, 
especially for large-scale, clinical applications. Alternatively, multiple transgenes, either in the 
form of a single fusion gene or separated by an internal ribosomal entry site (IRES), whose 
expression is driven by a single promoter, can be inserted into the E1 domain. This approach is 
not without limitations, as insertion of long coding sequences into the E1 domain results in 
diminished transgene expression that ultimately reduces induction of transgene product-specific 
immune responses 157. A third approach that has been explored is to insert independent 
expression cassettes with identical promoters into the deleted E1 domain 158, but this often results 
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in homologous recombination between the promoters and, consequently, the removal of one 
expression cassette from the Ad genome.  
 To avoid these complications, a different approach is necessary. Secondary generations 
of Ad vectors are deleted in multiple domains, including the E3 domain, which encodes genes 
that are unnecessary for viral replication. Deletion of the E3 domain increases the packaging 
capacity of Ad vectors to 7.5 kb 159. This was taken advantage of in the study presented here. A 
series of vectors based on chimpanzee Ad serotype 7 (AdC7), also called SAdV-24, were 
generated that carried one expression cassette in the deleted E1 domain and a second different 
expression cassette in the deleted E3 domain. Each expression cassette carried a different 
promoter to drive their respective transgene’s expression. Additionally, combinations of various 
regulatory elements, including introns and enhancers, and expression cassette orientation were 
tested for their impact on transgene expression and subsequent induction of immune responses.   
 The results indicate that the orientation of the E3 expression cassette dramatically affects 
vector fitness and transgene expression. Vectors with E3 expression cassettes inserted parallel 
to E3 transcription (5’ to 3’, or forward oriented) could commonly not be rescued whereas 
insertion in the opposite orientation resulted in fitter vectors, although this was influenced by the 
choice of the promoter in the E3 cassette. Additionally, the presence of shared sequences, such 
as introns and enhancers, between the E1 and E3 expression cassettes impacted transcription of 
each transgene and thereby induction of transgene product-specific immune responses.  
 In the second part of this chapter, the above results were applied to generate AdC7 
vectors encoding a transgene whose expression could be temporally controlled. Vectors were 
designed such that the E1 expression cassette contained a transgene flanked by loxP sites 
(floxed) and the E3 expression cassette contained CreERT2, a fusion protein of Cre 
recombinase, which recombines loxP sites, and a mutated version of the ligand-binding domain 
of the human estrogen receptor (ER). The mutation makes CreERT2 activity inducible as only the 
synthetic ligand and estrogen antagonist, 4-hydroxytamoxifen (4-OHT), can bind to the ER 160.  
Administration of 4-OHT would therefore provide conditional and temporal control over 
expression of the floxed transgene and thus enable studies into its role in maintaining the 
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elevated and prolonged transgene product-specific effector/effector memory CD8+ T cell 
response. Floxed dual expression vectors were constructed and results indicated that transgene 
expression could be regulated in vitro. However, upon further inspection it was discovered that 
the vectors recombined at the loxP sites during viral expansion. 
 
RESULTS A.	  OPTIMAL DESIGN OF ADENOVIRAL VECTORS EXPRESSING DUAL 
TRANSGENES  
 
Vector construction and quality control 
 In order to optimize vectors expressing transgenes from both the E1 and E3 loci, a series 
of shuttle vectors was designed to insert expression cassettes encoding transgenes and various 
regulatory elements into the E1- and E3-deleted AdC7 vector genome. Expression cassettes 
designed for insertion into the deleted E1 domain used the cytomegalovirus (CMV) promoter to 
drive expression of the inserted transgene and the bovine growth hormone (BGH) poly(A) tail. 
The expression cassette was further modified by deletion of the CMV enhancer, intron, or both. 
Shuttle vectors designed to insert expression cassettes into the deleted E3 domain contained 
expression cassettes whose transgene’s expression was driven either by the Rous Sarcoma 
Virus (RSV) promoter or by the chicken β-actin (CB) promoter. All expression cassettes encoded 
the rabbit globin poly(A) tail. E3 expression cassettes were further modified by deletion of the 
CMV enhancer sequence, the intron, or both. Additionally, E3 shuttle vectors were designed to 
insert the E3 expression cassette in the same direction as E3 transcription, 5’ to 3’ (forward), or 
the opposite orientation, 3’ to 5’ (reverse). Once constructed, the E1 and E3 shuttle vectors were 
used to construct pAdC7 molecular clones. Completed pAdC7 clones were linearized and 
transfected into HEK 293 cells in order to rescue AdC7 virus. Rescued viruses were further 
expanded on 293 cells. A list of the different vectors generated and their qualities is shown in 
Figure 2.1. 
 If three attempts failed to rescue virus that could be further expanded, the virus was 
considered unfit. Most recombinant AdC7 molecular clones bearing an E3 cassette with the RSV 
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promoter were unfit. When this cassette was forward-oriented, all viruses failed to rescue, 
regardless of whether or not an E1 expression cassette was included. One viral clone with only a 
reverse-oriented E3 expression cassette was also unable to be rescued. However, when an E1 
expression cassette was included in that construction, the virus was successfully rescued. Use of 
the CB promoter in the E3 cassette yielded more promising vectors. Two of four molecular clones 
yielded infectious viral particles when this cassette was in the forward-orientation; all viruses 
containing this cassette in the reverse-orientation were rescued.   
 All rescued viruses were quality controlled following expansion by assessing genetic 
integrity, viral particle yields, and infectivity. Genetic integrity was confirmed by restriction digest 
of isolated viral DNA from expanded virus; enzymes were chosen to specifically identify the 
unique expression cassettes. All viruses showed expected banding patterns for their expression 
cassettes. Viral particle yield was determined following expansion on 109 HEK 293 cells. 
Expansion of traditional AdC7 vectors encoding a single transgene in E1 typically yield between 
0.1 to 2x1014 viral particles (vp) (Figure 2.2A). All viruses capable of being rescued, regardless of 
E3 promoter and orientation, yielded similar numbers of virus particles and were comparable to 
the traditional vector. However, removal of sequences (intron, enhancer, or both) shared between 
the E1 and E3 cassettes tended to result in superior yields. Infectivity, or the number of viral 
particles needed to productively infect a single cell, is determined by the ratio between the 
number of viral particles isolated and the multiplicity of infection (MOI), which is assessed by 
titrating vector on HEK 293 cells. Traditional AdC7 vectors typically have an infectivity ratio of 
<1:500 (Figure 2.2B). All rescued dual expression vectors had infectivity ratios that were 
comparable to that of the single expression AdC7 vector. The pattern of variation observed 
between groups followed that observed in the differences in viral particle yields. The infectivity 
ratio was highly variable within each construct family but this appeared to be dependent on the 
type of transgene encoded in each expression cassette. 
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FIGURE 2.1. Diagrams of dual expression vectors’ expression cassettes and their 
qualities 
 
For each vector discussed in Figures 5.2 - 5.7, a schematic of the expression cassettes inserted into the E1 
and E3 domains are shown with the vector number and the long form list of E1 and E3 characteristics is 
included. The first four vectors described are the control vectors, the following six are the experimental 
vectors presented in all figures, and the final two vectors are the two that carried the RSV promoter and are 
discussed only in Figure 2. The a key for list of characteristics provided in the E1 makeup/E3 makeup 
column is included: Domain into which the cassette was inserted: promoter (cytomegalovirus (CMV), 
chicken β-actin (CB), or rous sarcoma virus (RSV)), cassette orientation (forward (f) or reverse (r)), 
enhancer (e), intron (i), transgene (influenza nucleoprotein (NP) or gag of simian immunodeficiency virus 
(SIV gag)). If the list does not contain an “e” or “i”, then the cassette does not contain them. If there is no 
expression cassette in one domain that domain is listed as “empty”. 
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FIGURE 2.2. Dual expression vectors’ growth characteristics and infectivity  
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[A] Shows the virus particle yield per 109 HEK 293 cells as medians + interquartile range (IQR). Each bar 
represents the growth characteristics for pooled lots of viruses with the same basic vector design described 
on the X-axis. Vectors that conform to the appropriate design are listed in parentheses. Their characteristics 
are described in Figure 5.1. 
 
[B] Graph shows the vp to MOI ratios as a representation of infectivity for the same types of vectors shown 
in [A] as median + IQR. 
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Transgene product expression 
 We specifically focused on vectors that carried gag of Simian Immunodeficiency Virus 
(SIV) and nucleoprotein (NP) of influenza A/PR8 as transgenes in either E1 or E3. These vectors 
drove expression from the E1 domain using the CMV promoter and used the CB promoter in E3. 
Controls for the remaining experiments included AdC7 vectors that encoded gag or NP in either 
E1 or E3. Transgene expression from each cassette was measured using reverse transcription 
real-time PCR (qRT-PCR). HEK 293 cells were infected with 1000 vp per cell and total RNA was 
isolated and reverse transcribed 24 hours later. Real time PCR analysis showed that transcription 
of each transgene varied between vector types. This variation was only partially explained by 
differences in vector infectivity (vp to MOI ratio shown in Figure 2.2). 
 As expected, NP was not expressed in cells infected with vectors that did not encode NP 
(E1175, E1043, Ad-GFP) (Figure 2.3A). Single expression control vectors encoded with NP in E1 
(E1288) or in E3 (E1219) demonstrate that moving the position of the NP expression cassette 
from E1 to E3 reduces its transcription. This phenomenon was largely recapitulated in the dual 
expression vectors. Those vectors that carried NP in the E3 domain (E1492, E1324) expressed 
NP at levels comparable to E1219. However, the reduced NP expression in cells infected with 
E1492 was likely due to its high vp to MOI ratio, implying that there were fewer infectious viral 
particles available to infect the 293 cells. Dual expression vectors with NP encoded in the E1 
domain tended to express higher levels of NP. The highest NP expression level was observed 
when the NP expression cassette was accompanied by the forward-oriented E3 expression 
cassette (E1310). Reversing the orientation of the E3 expression cassette dampened NP 
expression (E1174).  Further modification of the two expression cassettes gave mixed results. As 
expected, removal of the regulatory elements from the E1 NP expression cassette (E1301) 
resulted in decreased in NP expression. Interestingly, removal of regulatory elements from the E3 
cassette (E1303, E1302) enhanced NP transcription. 
 Different patterns of gag expression were observed. While moving NP to E3 expression 
cassettes resulted in lowered expression, encoding gag in E3 resulted in overall higher gag 
expression (Figure 2.3B). This phenomenon was observed for both the control vectors (E1175, 
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E1043) and for the dual expression vectors. Orientation of the E3 cassette affected gag 
transcription in the opposite manner it affected expression of NP in the E1 cassette – gag 
expression was lowest when the E3 cassette was in the forward orientation (E1310). Reversal of 
the E3 expression cassette resulted in higher levels of gag transcription. Removal of the 
regulatory elements from the E1 domain had little effect on gag transcription from the E3 domain. 
We expected that removal of the regulatory elements from the E3 gag expression cassette would 
reduce gag expression, similar to what was observed for NP expression (E1301, Figure 2.3A). 
Instead, gag expression was the highest in cells infected with the vectors from which the 
enhancer element was removed (E1303) or both the enhancer and intron were removed from the 
E3 expression cassette (E1302).  
 Protein expression was measured by western blot on protein lysates harvested 24 hours 
after infection with the dual expression vectors. NP protein expression was measured in 293 cells 
infected with either 1000 or 10,000 vp per cell of the dual expression vectors that carried NP in 
E1 (E1174, E1303, E1302, E1301) and the two control vectors encoding only NP in E1 or in E3 
(E1219, E1228). As shown in Figure 2.4A, NP expression was comparable between all vectors 
at each dose. More vectors were included (E1175, E1310, E1324, E1492) and tested for Gag 
expression by infecting cells with 10,000 vp per cell (Figure 2.4B). Gag expression was more 
variable than that of NP protein but the results largely mirrored those seen for gag RNA 
transcripts. As expected, if gag was not encoded in the vector, Gag protein was not detected. The 
lowest amount of Gag was detected in lysates from cells infected with E1310, the vector carrying 
NP in E1 and gag in the forward-oriented E3 expression cassette. Gag was most highly 
expressed in cells infected with the vector that encoded NP in the standard E1 expression 
cassette and encoded gag in E3 in the reverse-orientated expression cassette that lacked the 
enhancer element (E1302). Both of these results were consistent with those observed for RNA 
transcription (Figure 2.3). 
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FIGURE 2.3. Levels of NP and gag transcript expression 
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Graphs show quantitative reverse transcriptase PCR results indicating levels of transcript expression 
achieved within 24 hours by 106 HEK 293 cells infected with 1010 vp of the indicated vector. Experiments 
were conducted twice for most vectors and bars show median levels + IQR range. [A] shows results for NP 
transcripts, [B] shows results for gag transcripts as median + range. Numbers above the bar show the vp to 
MOI ratio of the indicated vector. H2O and an Ad vector expressing green fluorescent protein (GFP) were 
used as negative controls.  
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FIGURE 2.4. NP and Gag protein expression 
  
 
 
 
 
Graphs show Western Blots for NP [A] and Gag [B]. To determine expression levels of NP, 106 HEK 293 
cells were infected with 109 or 1010 vp of indicated vector. Gag expression was tested in 106 HEK 293 cells 
infected with 1010 vp of indicated vector. Cell lysates were collected 24 hours after infection for both [A] and 
[B]. Blots were probed for β-actin as a loading control. 
 32 
Vector Immunogenicity 
 
 As the vectors were demonstrated to express well in vitro, their immunogenicity was next 
measured. Outbred ICR mice were immunized intramuscularly (IM) with 1010 vp of the more 
promising vectors that express NP and Gag. As controls, groups of mice were immunized with 
vectors expressing NP or Gag from E1 or E3. Mice were bled six weeks after immunization and 
serum was tested for NP- and Gag-specific antibodies by ELISA. Each dual expression vector 
induced detectable antibody responses to both the NP and Gag antigens (Figure 2.5). E1303, 
which lacked both the intron and enhancer elements in the E3 expression cassette, induced a 
NP-specific antibody titer of approximately 200 µg/mL, the highest of all the dual expression 
vectors (Figure 2.5A). The lowest anti-NP antibody titer (less than 100 µg/mL) was induced by 
E1302, which did not carry an enhancer in the E3 expression cassette, despite a similar 
expression pattern in vitro to that of E1303. Two other dual expression vectors were tested for 
induction of NP-specific antibody responses: E1301, which lacked the intron and enhancer in the 
E1 expression cassette, and E1174, which contained both the enhancer and intron in both the E1 
and E3 expression cassettes. Both vectors induced NP antibody titers comparable to those 
induced by the two NP-only control vectors, approximately 125-150 µg/mL (E1288, E1219). 
Immunization with the dual expression vectors induced higher titers of Gag-specific antibodies 
than NP-specific antibodies (Figure 2.5B). The E1303 vector induced a Gag-specific antibody 
titer of ~800 µg/mL, which was the highest titer induced. The other vectors tested induced titers of 
approximately 500 µg/mL, which was comparable to titers induced by the control vectors, E1043 
and E1175.  
 Induction of CD8+ T cell responses specific to each transgene was also measured as a 
test of vector immunogenicity. Groups of C57Bl/6 mice were immunized IM with 1010 vp of the 
indicated vectors; a group of naïve mice was included as a control. Two and six weeks following 
immunization, peripheral blood mononuclear cells (PBMCs) were isolated and tested for CD8+ T 
cell responses specific to NP and Gag by intracellular cytokine staining (ICS) for IFN-γ, TNF-α, 
and IL-2 following in vitro stimulation with corresponding peptides. Boolean gating was used to 
determine the sum of all possible cytokine responses and background was subtracted. All vectors 
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with the exception of E1174 and E1301 induced NP-specific CD8+ T cell responses (Figure 
2.6A). The control vector only carrying NP in E1 (E1288) induced, as expected, a robust NP-
specific CD8+ T cell frequency of about 6% at two weeks after immunization that contracted to 1% 
at six weeks post-immunization. The vector in which the E3 cassette was in the forward 
orientation, E1310, induced an equally potent NP-specific CD8+ T cell response that contracted 
less than that of the control vector at six weeks. This corresponded well with its expression data, 
which demonstrated that NP was most highly expressed from this vector (Figure 2.3). Complete 
removal of the regulatory elements that were shared between E1 and E3 resulted in a vector that 
induced a more modest NP-specific CD8+ T cell frequency of 2% at two weeks following 
immunization. However, the response contracted less than that of the other dual expression 
vectors. The similar vector, E1302, which has the intron in the E3 cassette, induced a response at 
two weeks comparable to that induced by the control vector and E1310. The NP-specific CD8+ T 
cell response contracted and was maintained at a frequency similar to that of E1302. Gag-
specific CD8+ T cell responses were overall lower and more delayed than the NP-specific CD8+ T 
cell response (Figure 2.6B). E1310 induced a very robust NP-specific CD8+ T cell response but 
failed to induce a Gag-specific response at either timepoint; whereas, E1174 failed to induce an 
NP-specific response but did induce a very modest Gag-specific CD8+ T cell response of less 
than 1% that was sustained throughout the experiment. E1301, which also did not induce a 
detectable NP-specific CD8+ T cell response, induced a modest Gag-specific CD8+ T cell 
response at 2 weeks that did not peak until 6 weeks after immunization. E1302 and E1303 both 
induced robust Gag-specific CD8+ T cell responses. While E1302’s peak response was more 
delayed than that of E1303, it was maintained at a higher level.  
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FIGURE 2.5. NP- and Gag-specific antibody responses 
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Pooled sera from mice immunized with the indicated vectors were tested for antibodies to NP [A] or Gag [B] 
by ELISA four weeks after vaccination. The graphs show area under the curve for two replicates of serially 
diluted sera. Lines indicate significant differences between the samples determined for by one-way ANOVA 
with Tukey correction.  
 
* indicates level of significance as follows: * p >0.05-0.01, ** p < 0.01 – 0.001, *** p < 0.001-0.0001, **** p < 
0.0001. 
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FIGURE 2.6. Kinetics of NP- and Gag-specific CD8+ T cell responses 
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PBMCs from individual mice were tested 2 and 6 weeks after immunization for NP- [A] and Gag- [B] specific 
CD8+ T cell responses by ICS. Graphs show the % of CD8+ T cells over total CD8+ T cells that produced 
cytokines after stimulation with the specific peptides after subtraction of background data obtained with 
cultures stimulated with an irrelevant peptide. Differences from results obtained with PBMCs from naïve 
mice were assessed with one-way ANOVA and uncorrected Fischer’s LSD.   
 
* indicated level of significance as follows: * p >0.05-0.01, ** p < 0.01 – 0.001, *** p < 0.001-0.0001, **** p < 
0.0001. 
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RESULTS B. DEVELOPMENT OF NOVEL ADENOVIRAL VECTORS WITH 
CONDITIONAL TRANSGENE PRODUCT EXPRESSION  
 
Test of concept with single expression vectors 
 A primary goal of this thesis was to directly investigate the role of persistent transgene 
expression from the Ad vector genome on the maintenance of the transgene product-specific 
CD8+ T cell response. This necessitated the generation of Ad vectors whose transgene 
expression could be temporally regulated. One system often used to this end is the Cre/lox 
system that conditionally induces site-specific recombination 160. As a test of concept, Ad vectors 
based on chimpanzee serotype 7 were generated that carried green fluorescent protein (GFP) 
flanked by loxP sites (5’-ATA ACT TCG TAT AGC ATA CAT TAT ACG AAG TTA T-3’) in an 
expression cassette inserted into the E1 domain (AdC7-GFPloxP) (Figure 2.7A). In order to 
determine if the expression of the transgene could be regulated using this method, HEK 293 cells 
were engineered to stably express CreERT2 (293-CreERT2. 106 293-CreERT2 cells were 
infected with 107 or 108 vp AdC7-GFPloxP. At the time of infection, cells were treated with either 
0.2 µM, 2 µM 4-OHT, or the equivalent volume of vehicle. Flow cytometry was used to measure 
GFP expression 24 hours after infection. Results indicated that even a low dose of 4-OHT was 
capable of inducing Cre activity in the cell line and thereby excision of the floxed GFP from the Ad 
genome (Figure 2.7B). This experiment suggested that transgene expression from the Ad 
genome could be regulated using the Cre/lox site-specific recombination system.   
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FIGURE 2.7. Test of concept – Ad vectors can have inducible transgene 
expression. 
A.  
 
B.  
 
 
Transgene expression can be regulated from the Ad genome using Cre/lox recombination. [A] Shows a 
schematic of the E1 cassette carried by AdC7-GFPloxP, which was used to infect cells for [B]. The E1 
cassette used the cytomegalovirus (CMV) promoter to control expression of GFP. Additionally, the CMV 
enhancer and an intron were used to enhance expression. The Bovine Growth Hormone (BGH) 
polyadenylation signal was inserted 3’ to the GFP coding sequence. LoxP sites (5’-ATA-ACT-TCG-TAT-
AGC-ATA-CAT-TAT-ACG-AAG-TTA-T-3’) were inserted 5’ to the CMV enhancer and 3’ to the poly(A) tail in 
parallel orientation, so that the flanked sequence is excised from the genome upon Cre-mediated 
recombination. LoxP sites and directionality are indicated by black triangles. This expression cassette was 
inserted 5’ to 3’ (forward orientation) into the genome of an E1- and E3-deleted AdC7 molecuar clone.  
 
[B] 108 and 107 viral particles (vp) of AdC7-GFPloxP were used to infect HEK 293 cells stably expressing 
inducible Cre recombinase (293-CreERT2 cells). 1 hour prior to infection, 293-CreERT2 cells were treated 
with 9.5 µL 2 µM or 0.2 µM 4-hydroxytamoxifen (4-OHT) to activate Cre-ERT2 activity. To demonstrate that 
Cre activity is inducible, cells were treated with the equivalent volume of vehicle (95% EtOH).  As a negative 
control for expression, groups of uninfected cells were treated with both doses of tamoxifen and vehicle. 24 
hours after infection, cells were assayed for GFP expression by flow cytometry. Graph shows percentage of 
GFP positive 293-CreERT2 cells over all cells. 
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Dual expression vector construction  
 Use of Ad vectors carrying only a floxed transgene would limit the use of these vectors to 
a transgenic mouse model that ubiquitously expressed CreERT2, vectors were engineered to 
carry CreERT2 as a transgene in the deleted E3 domain. The previous set of experiments 
demonstrated that vectors containing fewer shared sequences between the E1 and E3 
expression cassettes had more optimal, balanced expression of both transgenes. As such new 
series of dual expression vectors was constructed following the design of the best performing 
vector (E1302) described above. Their design is shown in Figure 2.8A. The E1 expression 
cassette was constructed such that the CMV promoter controlled expression of the inserted 
transgene, which, in the following studies, was either gag of HIV-1 or GFP.  Removal of the CMV 
enhancer and the intron from the E1 expression cassette was shown to dampen expression of 
the E1 transgene without having much effect on expression from E3; therefore, we included both 
elements in the cassette. Finally, the expression cassette was floxed. The E3 expression cassette 
encoded CreERT2 under the control of the CB promoter. It was demonstrated earlier that the 
orientation of the E3 expression cassette dramatically influences the expression of both encoded 
transgenes. Although placing the E3 cassette in the forward (5’ to 3’) orientation lead to very 
robust E1 transgene expression, expression from the E3 cassette was not optimal. Optimal 
expression of CreERT2 needed to be achieved to ensure excision of all floxed sequences; 
therefore, as vectors carrying the E3 cassette in the reverse orientation tended to have better 
expression of the E3 transgene, the CreERT2 expression cassette was inserted into E3 in the 
reverse orientation. Additionally, only an intron was included in the E3 expression cassette 
because inclusion of both the intron and enhancer, which were shared between both expression 
cassettes, reduced expression of the E3 transgene.  
 
In vitro transgene expression and regulation 
 In order to confirm that both the floxed transgene, in this case HIV gag, and CreERT2 
were expressed and that CreERT2-mediated recombination of loxP sites could be induced, 106 
Chinese hamster ovary (CHO) cells expressing the coxsackie and adenovirus receptor (CAR) 
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were infected with 109 vp of AdC7-HIVgagloxP-CreERT2 and treated with either 4-OHT or the 
equivalent volume of vehicle. As a positive control for gag expression, a group of cells was 
infected with 109 vp of AdC7-HIVgagloxP. One week later, total RNA and protein lysates were 
collected. Reverse transcription of total RNA revealed that gag was expressed in the absence of 
CreERT2 activity but following treatment with 4-OHT gag RNA was no longer detected (Figure 
2.8B). Of note, gag expression from AdC7-HIVgagloxP-CreERT2 was reduced compared to the 
positive control vector. 
 Gag and CreERT2 expression were also confirmed by Western blot of infected cells 
(Figure 2.8C). Doses ranging from 108 vp to 1010 vp were used to infect 106 CHO-CAR cells. 109 
vp of AdC7-HIVgagloxP was used as a positive control. Groups of cells were again treated either 
with 4-OHT or vehicle. Protein lysates were collected one week later. In the absence of 4-OHT, 
the highest expression of Gag was achieved with the 1010 vp dose of AdC7-HIVgagloxP-CreERT2, 
which was slightly greater than that of the positive control. As expected, Gag expression 
decreased as the vector dose was decreased. The same expression pattern was observed for 
CreERT2. These results demonstrate that while CreERT2 is expressed, it is not active in the 
absence of tamoxifen treatment. However, CreERT2 activity was induced following tamoxifen 
treatment as evidenced by only faint detection of Gag one week after infection. Taken together, 
these results indicate that both transgenes are expressed in vitro and, importantly, CreERT2 
activity, and thereby Gag expression, can be regulated with tamoxifen. 
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In vivo transgene expression 
 As the transgenes were demonstrated to express well in vitro, transgene expression was 
next determined in vivo. BALB/c mice were injected IM with 1011 vp of AdC7-GFPloxP-CreERT2 or 
the equivalent dose of AdHu5-GFP as a positive control for GFP expression. Two days later, the 
injected muscle was visualized for GFP expression as shown in Figure 2.9A. Very robust GFP 
expression was observed in the legs of mice injected with the positive control vector.  
Unexpectedly, GFP was unable to be detected in mice injected with AdC7-GFPloxP-CreERT2.    
  The lack of expression in vivo could perhaps be explained if AdC7-GFPloxP-CreERT2 had 
a very high infectivity ratio (vp to MOI), although this would impact in vitro expression as well. 
However, the ratio was 182:1, which is considered average. Another possible explanation for the 
lack of expression could be that the integrity of the vector’s genome was compromised. To this 
end, viral DNA was purified from all dual expression vectors carrying a floxed transgene in E1 
and CreERT2 in E3. Both the viral DNAs and the corresponding molecular clones used for viral 
rescue were subjected restriction digest with an enzyme chosen specifically to screen the floxed 
transgene (Figure 2.9B). Some banding pattern differences between the plasmid and viral DNA 
were expected, because the viral DNA lacks some sequences present in the molecular clone. 
However, a 2.2 kb band was missing from the isolated viral DNA. This band corresponded to the 
restriction sites that flanked the E1 cassette that the floxed transgene. Lack of this band indicated 
that the cassette was no longer present in the genome. The viral DNAs were sequenced to 
confirm loss of the E1 expression cassette. Sequencing data was in agreement with the 
restriction digests (schematic in Figure 2.9C). Only a single loxP site was detected in each 
genome and no expression cassette sequences were detected. This indicated that the viral 
genome recombined at the loxP sites during viral expansion, which most likely gave the mutant a 
growth advantage over the original recombinant vector. Interestingly, restriction digestion of the 
vectors that carried a floxed transgene in the E1 domain but did not carry CreERT2 revealed that 
the genome of these vectors remained intact during rescue and expansion.   
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FIGURE 2.8. Construction and expression of AdC7 vectors dually expressing a 
floxed transgene and CreERT2. 
 
  
 
[A] Shows a schematic of the E1 and E3 expression cassettes. The E1 cassette was identical to that 
described in Figure 2.7. A. The transgenes used for the following experiments were gag of HIV-1  (shown in 
[B] and [C]) and GFP (shown in Figure 2.9A and B). The E3 expression cassette was modeled after that 
carried in E1302 (described in Figure 2.1). The vectors will be referred to as AdC7-HIVgagloxP-CreERT2 or 
AdC7-GFPloxP-CreERT2. 
 
[B] Expression of HIV gag (p24) as measured by reverse transcriptase PCR. 106 CHO-CAR cells were 
infected 109 vp AdC7-HIVgagloxP-CreERT2. 1 hour prior to infection cells were treated with either 2 µM 4-
OHT or the same volume of vehicle. Cells were infected with 109 vp AdC7-HIVgagloxP as a positive control 
for gag expression. As a negative control cells were infected with 109 vp AdC7 expressing rabies virus 
glycoprotein. Total RNA was isolated 1 week following infection and 2 µg was reverse transcribed. Gag was 
then amplified in a regular PCR from 1 µL of cDNA template. The resulting PCR fragments were visualized 
on a 1% TAE agarose gel stained with EtBr.  
 
[C] Protein expression of HIV gag (p24) and CreERT2 as measured by Western Blot. . 1x106 CHO-CAR 
cells were infected 1010,109, or 108 vp AdC7-HIVgagloxP-CreERT2. 1 hour prior to infection cells were treated 
with either 2 µM 4-OHT or the same volume of vehicle. Cells were infected with 109 vp AdC7-HIVgagloxP as a 
positive control for gag expression. They were also treated either with vehicle (V) or 2 µM 4-OHT (T). 
Uninfected cells were used as a negative control. 
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FIGURE 2.9. Dual expression vectors carrying floxed transgene and inducible Cre 
recombinase fail to express in vivo.  
 
 
[A] Shows GFP expression in hind limbs following immunization with GFP-expressing Ad vectors. BALB/c 
mice were immunized with 1011 vp AdC7-GFPloxP-CreERT2 or, as a positive control from GFP expression, 
1011 vp AdHu5-GFP. 48 hours later, mice were sacrificed and legs were removed and visualized for GFP 
expression using Illumatool Lighting System. A Kodak DCS14N digital SLR camera with a 60-mm Micro 
Nikkor lens at f3.5 using 1:2.2 magnification was used to take photographs.  
 
 
FIGURE LEGEND CONTINUED ON PAGE 43 
 
 
 43 
[B] The molecular clone (plasmid) DNA of all dual expression vectors carrying floxed transgenes and the 
corresponding viral DNA isolated from expanded viruses were subjected to restriction digestion with BglII 
enzyme for 1 hour at 37°C. Additionally, AdC7-GFPloxP viral DNA was subjected to restriction digest with 
SphI for 1 hour at 37°C Digests were visualized on a 1% TAE agarose gel stained with EtBr. “M” indicates 
the 1 kb plus ladder. For the dual expression vector digests: the grey arrow indicates an expected band 
because the plasmid DNA is circular while the viral DNA is linear. The black arrow indicates an unexpected 
missing band at 2.2 kb corresponding to the floxed E1 expression cassette. For the sing expression vector: 
the white arrow indicates the expected 2.7 kb band corresponding to the floxed E1 expression cassette. 
Shown here are digestions for AdC7-GFPloxP-CreERT2 plasmid and viral DNA. Identical results were 
obtained for all other vectors tested. 
 
[C] Shows a schematic of results. The missing band corresponded to a 2281 kb fragment that encompassed 
the floxed expression cassette in the E1 domain. The viral DNA was additionally sequenced (not shown) and 
the sequencing data corresponded with the restriction digestion. It revealed that the two BglII sites now 
encompassed a fragment that no longer contained the E1 expression cassette but contained only a single 
loxP site and the remaining base pairs between each BglII and loxP site.  
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DISCUSSION 
 
 Ad vectors elicit potent immune responses not only to their viral antigens but also to the 
products of encoded transgenes. Their consistently potent induction of transgene product-specific 
B and CD8+ T cell responses has made them ideal vaccine platform candidates. As such, Ad 
vectors derived from a variety of serotypes have been extensively developed as vaccine carriers 
and are currently being tested in clinical trials.  
 For some pathogens it may be necessary to direct a broader immune response that is not 
limited to a single antigen. To this end, multiple Ad vectors, each expressing a different antigen of 
interest, could be used for immunization. This approach has been used with success 156 but it is 
both cumbersome and costly. Therefore, several strategies have been employed to express 
multiple transgenes from a single Ad vector. Two of the most commonly used strategies are to 
encode a long fusion protein of the genes of interest or to separate two transgenes by an internal 
ribosomal entry site (IRES). The former strategy may interfere with folding of the resultant fusion 
protein, which may alter protein functionality and immunogenicity. Dual expression Ad vectors 
have been designed using the latter method 161,162. While both transgenes separated by an IRES 
are expressed, very often the downstream transgene is expressed at lower levels than the 
upstream transgene. This would be problematic if stoichiometric amounts of each transgene are 
required. It is worth noting that long transgenes inserted into the Ad genome are not expressed 
as well as shorter transgenes, leading to dampened immune responses 157. Therefore, this would 
be problematic for all the strategies described above.  
 Insertion of tandem expression cassettes into the deleted E1 domain has also been used 
to design dual expression Ad vectors. The earliest vectors encoded two identical expression 
cassettes that only differed in the transgene each cassette carried 158. However, serial passaging 
of vectors carrying identical expression cassettes often reveals that vectors with large regions of 
homology, e.g. identical promoters or other shared sequences, are genetically unstable and often 
recombine, resulting in excision of one expression cassette 163. Others have designed vectors 
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using different promoters alone 164,165 or in combination with different regulatory elements, such 
as the polyA tail 163, to drive expression of the transgenes inserted into the E1 domain. 
 Ad vectors are often deleted in multiple gene domains or are fully gutted. These deletions 
not only reduce immune responses to viral antigens but also increase the carrying capacity of the 
vector 155. One group used this approach to design vectors that expressed three transgenes by 
encoding one in the E1 domain under the CMV promoter and using a bidirectional promoter to 
drive expression of two other transgenes inserted into the region between the E4 domain and 
fiber 166. 
 In the study presented here, we designed a series of AdC7 vectors encoding transgenes 
in the deleted E1 and E3 domains and systematically tested how the components of each 
cassette impact transgene expression. As use of identical expression cassettes has been shown 
to promote homologous recombination in Ad5- and Ad35-based vectors 163,167 and use of 
heterologous expression cassettes inserted into E1 and E3 have been shown to express well in 
Ad5-based dual expression vectors 168,169, we chose to control expression of each transgene with 
heterologous promoters. The CMV promoter is widely used to drive ubiquitous and high levels of 
gene expression, although it is sensitive to silencing 170,171. Despite this, we constructed our dual 
expression vectors such that the CMV promoter always drove E1 transgene expression. Two 
other widely used promoters, the RSV and chicken beta-actin (CB) promoters, were used to drive 
expression of the E3 transgene, in most cases gag of SIV. Others have used the RSV promoter 
in dual expression Ad vectors in the E3 domain 172. However, our attempts to generate Ad vectors 
with this promoter often yielded unstable vectors that could not be rescued. Vectors’ growth 
characteristics were improved by using the CB promoter in the E3 cassette.  
 Expression cassette orientation is an important consideration in the construction of 
adenoviral vectors. Others have demonstrated that orienting transgenes in the same direction as 
E1 transcription (5’ to 3’) leads to better growth characteristics 173 and transgene expression 174. 
While E1 orientation was not tested in these studies, the findings concerning E3 cassette 
orientation are in contrast with this, even though E3 transcription also occurs 5’ to 3’. When the 
E3 cassette was inserted in that direction (forward orientation), vectors were often unable to be 
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rescued. Use of the RSV promoter in this orientation did not yield viable vectors, whereas, some 
vectors encoding the CB promoter in the forward orientation were able to be rescued and 
propagated. Interestingly, the vectors that could be rescued (E1310) had the highest level of 
transcription from the E1 cassette but lower levels of expression from the E3 cassette. Switching 
the orientation to the opposite of E3 transcription (3’ to 5’) improved growth characteristics of 
these vectors and led to more balanced expression of the E1 and E3 transgenes.  
 The presence of shared introns and enhancer sequences in both E1 and E3 directly 
affected expression of the E1 transgene. Removal of one or both regulatory elements from the E3 
domain tended to increase expression from E1 without having much impact on expression from 
the E3 domain. This may suggest that the shared elements are competing for limited factors. 
 In vitro expression data for each transgene suggested that the position of each transgene 
within the Ad genome influenced expression. NP was more highly expressed from the E1 domain 
than the E3 domain, while gag was more highly expressed from the E3 domain. Therefore, it was 
important to consider if the position of the transgene within the Ad genome also impacted 
corresponding B and T cell responses, which could be affected by expression in vivo, processing 
of each transgene, and presentation. In vitro expression data did not predict transgene product-
specific antibody responses from control vectors. Those expressing NP alone in either the E1 
(E1288) or E3 (E1219) domain induced comparable NP-specific antibody titers, despite unequal 
expression in vitro. Whereas, Gag expression was higher from the vector carrying gag in the E3 
domain (E1175) but induced a slightly lower Gag-specific antibody response than the vector 
carrying gag in the E1 domain (E1043). Taken together these results may indicate that the impact 
of position on induced immune responses may be dependent on the transgene itself and not on 
processing and presentation of the transgene.  
 Immune responses to the transgenes in some dual expression vectors were predicted by 
their respective expression in vitro. E1310, the vector in which NP was encoded in E1 and gag in 
the forward-oriented E3 cassette, had high levels of NP expression but low levels of Gag 
expression in vitro and accordingly had the highest NP-specific CD8+ T cell responses but failed 
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to induce Gag-specific CD8+ T cells. Other vectors followed this pattern as well, including E1301 
and E1174. 
 In some cases, immune responses to the dual expression vectors were not predicted by 
in vitro expression patterns. The E1302 and E1303 vectors, which differ only in that E1303 lacked 
both the enhancer and intron in E3 while E1302 only lacked the enhancer, showed similar levels 
of NP and Gag expression in vitro. However, T cell responses to the two vectors were opposite – 
E1302 induced a robust NP-specific CD8+ T cell response, while E1303 induced a modest NP-
specific CD8+ T cell response. Responses followed the opposite pattern for Gag-specific CD8+ T 
cell responses – E1302 initially induced a modest response that became more robust later, while 
E1303 induced a very robust and sustained response. It is possible that E1302 and E1303 
expressed NP and Gag differently in vivo. While this may be part of the explanation, it is also 
possible that the immunodominance of each transgene product influenced the resulting CD8+ T 
cell responses.  In a similar study of an AdHu35-based dual expression vector encoding HIV Env 
gp-160 and malaria antigens, the CD8+ T cell responses to the malaria antigen encoded in the E3 
domain were very low, while the Env-specific response was robust 167. This observation was 
attributed to Env’s immunodominance over the malaria antigen and was overcome by increasing 
the vector dose. The dual expression vectors designed this study would be expected to express 
NP and Gag in the same cells. It is therefore possible that NP is more immunodominant than 
Gag. As such, the E1302 vector appears to induce NP- and Gag-specific CD8+ T cell responses 
that suggest this – the NP-specific CD8+ T cell response is rapid and robust and the Gag-specific 
CD8+ T cell response is initially very modest but peaks following contraction of the NP-response. 
Perhaps removal of all regulatory elements from the E3 domain resulted in increased Gag 
expression that could overcome the immunodominance of the NP antigens to induce a more 
robust Gag-specific CD8+ T cell response sooner after immunization. 
  An additional goal of this study was to generate a dual expression vector encoding a 
transgene whose expression could be regulated temporally. This vector was designed to give 
insight into how continued transgene expression from the adenoviral genome during its 
persistence alters the corresponding CD8+ T cell responses against the transgene. To this end, 
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we chose the Cre/lox system of recombination to regulate transgene expression from AdC7-
derived vectors. In a preliminary study, we demonstrated that inducible CreERT2 recombinase 
stably expressed in HEK 293 cells could be used to recombine loxP sites in the adenoviral 
genome. In order to make the system more translatable to animal models, floxed transgenes and 
CreERT2 were cloned into an AdC7 dual expression vector modeled after the E1302 vector 
described above. The E1302 vector was chosen as the model for the floxed dual expression 
vectors because it was shown to express both transgenes well in vitro and it induced a robust 
CD8+ T cell response against the transgene product from the E1 domain. Therefore, a cassette 
carrying a floxed transgene was inserted into the E1 domain and a cassette carrying CreERT2 
was inserted into the E3 domain. While expression of both the floxed transgene and CreERT2 
could be detected in vitro, expression could not be measured in vivo. Analysis of genome stability 
revealed that the floxed transgene had unexpectedly been deleted from the genome during viral 
rescue. One potential explanation for this is that adenoviruses are known to recombine 
homologous sequences between two genomes during replication 175. However, if this were the 
case, we would expect to see similar deletion of transgenes in vectors that carry the floxed 
expression cassette only. However, we only observed this deletion in the dual expression vectors 
carrying both the floxed expression cassette and CreERT2, suggesting that the observed deletion 
is Cre-mediated recombination. It is important to note that CreERT2 is constitutively expressed in 
infected cells but is sequestered in the cytoplasm by Hsp90 160. Only when tamoxifen is 
introduced can the recombinase translocate into the nucleus to recombine loxP sites.  
Alternatively, the size of the vector genome can directly influence the genome’s stability. Larger 
genomes generated by inserting overly long transgenes into a deleted E3 domain tend to be 
slightly less stable than if no transgene was inserted 159. The E3 deletion provides space for an 
expression cassette 3.5 kb in length. While the CreERT2 expression cassette was shorter than 
this (3.3 kb), it is possible that its inclusion in the dual expression vector made the vector less 
stable than the matched single expression vectors, which ultimately promoted rearrangement of 
the genome at the homologous loxP sites.  
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 In order to continue to investigate the question the floxed dual expression vectors were 
designed to answer, alternative approaches must be used. Future studies could be undertaken in 
CreERT2 transgenic mice that are available to us using the AdC7 vectors encoding only the 
floxed transgene. Alternatively, vectors could be designed using inducible promoters to 
temporally control transgene expression. This may be a more ideal approach, as it would avoid 
the homologous recombination that potentially could occur between the loxP sites.  
 In conclusion, the studies presented here demonstrate that genetically stable dual 
expression vectors based on AdC7 can be generated. These vectors express both transgenes 
well and induce potent B and T cell responses. These studies also highlight that factors other 
than the strength of the promoters used in each expression cassette influence gene expression 
and the corresponding immune responses raised against each transgene. Careful consideration 
of the choice of transgenes and elements to enhance expression must be made.  These studies 
will aid in the development of future Ad-based vaccines.  
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MATERIALS AND METHODS A.  
OPTIMAL DESIGN OF ADENOVIRAL VECTORS EXPRESSING DUAL TRANSGENES 
 
Adenovirus vector construction 
 Ad vectors were deleted in the E1 and E3 domains. Shuttle plasmids were used to sub-
clone transgenes together with regulatory elements into these deleted domains. Shuttle plasmids 
designed to insert transgenes into the deleted E1 domain contained an expression cassette 
composed of the transgene of interest and regulatory elements to control the transgene’s 
expression, including the cytomegalovirus promoter and enhancer, an intron, and a poly(A) tail. In 
some cases, a second transgene was inserted into the deleted E3 domain. The shuttle plasmids 
facilitating this contained an expression cassette comprised of the transgene and its regulatory 
elements, including the chicken beta-actin promoter or the RSV promoter and the rabbit beta-
globin poly(A) tail. Transgenes were inserted into the Ad molecular clone using rare-cutting 
restriction enzymes. Insertion into the E1 domain was facilitated by digestion with I-CeuI and PI-
SceI followed by ligation. The resulting expression cassette was oriented 5’ to 3’. Insertion into 
the E3 domain was achieved by digestion with SceI followed by ligation. The resulting expression 
cassette was oriented 3’ to 5’ or 5’ to 3’. 
 Viruses were rescued following successful cloning, as follows. 5 µg of the molecular 
clone were linearized by digestion with PacI for 1 hour at 37°C in a final volume of 50 µL. 
Linearized DNA was then transfected into HEK 293 cells (at 50% confluency) using CaCl2 
transfection kit (Invitrogen, Grand Island, NY). The protocol was modified slightly from the 
manufacturer’s protocol. The digested DNA was added to 37 µL of 2M CaCl2 and the final volume 
was brought to 300 µL with sterile H2O. The DNA-CaCl2 solution was then slowly dripped into 300 
µL of HEPES-buffered saline solution while gently vortexing. After 30 minutes of incubation at 
room temperature, the precipitate was added to the cells. Transfected cells were then returned to 
a 37°C incubator and monitored for 7-10 days for cytopathic effect (CPE), which would be 
indicative of replicating virus. When CPE was extensive, the cells and media were collected. 
Three consecutive rounds of rapid freezing and thawing were performed to release virus 
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contained in cells. Rescued virus was then expanded by serially passaging on HEK 293 cells. 
The final product was purified on a CsCl2 gradient and concentration of virus particles (vp) was 
measured by spectrophotometry. 
 
RT-PCR Analysis 
 Total RNA from HEK 293 cells transduced with AdC7 vectors 24 hours earlier was 
isolated using RNeasy Mini prep kit (Qiagen, Valencia, CA). The quantity of RNA was determined 
by spectrometry. RNA samples were stored at -80 °C till use. For each sample, 2 µg of RNA were 
reversed transcribed using the High Capacity cDNA Reverse Transcription kit (Life Technologies, 
Carlsbad, CA) following the manufacturer’s protocol. The real-time PCR reaction was 
subsequently carried out using Fast SYBR Green Master Mix (Applied Biosystems; Carlsbad, CA) 
at a final volume of 25 µl. For amplification of NP, the following primers were used at 5 pmol/µl: 
forward: 5’-AGC-AGG-TAC-TGG-GCC-ATA-AGG-3’ and reverse: 5’-ACT-GAG-AAC-GTA-GGT- 
TGT-ATG-CTG-3’. For amplification of SIV gag, the following primers were used at 5 pmol/µl: 
forward: 5’-AAG-CCC-ATC-AAG-TGC-TGG-AAC-3’ and reverse: 5’-TCT-TGC-CGC-ACT-TC-
CAC-3’. The housekeeping gene GAPDH was used as an internal control and was amplified 
using 5 pmol/µl of the following primers: forward: 5’-TGC-CCC-CAT-GTT-GTG-ATG-G-3’ and 
reverse: 5’-AAT-GCC-AAA-GTT-GTC-ATG-GAT-GAC-C-3’. 1 µL of cDNA was used as template. 
Quantitative RT-PCR amplification of each gene was performed as follows: initial amplification of 
primers was performed at 95°C for 20 seconds, followed by 40 cycles of denaturation at 95°C for 
3 seconds and amplification at 60°C for 30 seconds. All real-time PCR reactions were carried out 
on ABI Prism 7500 Fast Sequence Detection System. Reactions were run in triplicate in two 
separate experiments. Standard curves used to calculate amounts of NP and SIV gag RNA in 
each sample were determined by serially diluting plasmids encoding NP and SIV gag from 5 
ng/well to 0.31625 ng/well. Expression data for NP and SIV gag were normalized to GAPDH to 
control for variability in samples.  
 
Western Blots 
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HEK 293 cells plated on 6-well plates were infected with two different doses of viral vectors (103 
and 104 vp/ cell). 24 hours post infection cells were harvested and treated with RIPA buffer 
containing HALT protease inhibitors (Thermo Fisher Scientific, Pittsburgh, PA). Protein samples 
were prepared by diluting in a reducing sample buffer and electrophoresed on 4-15% SDS-PAGE 
gels (Bio-Rad, Hercules, CA) with Tris running buffer (Bio-Rad), transferred to PVDF membrane, 
and probed with either primary monoclonal antibody anti-NP (Southern Biotech, Birmingham, AL) 
or primary monoclonal anti-SIV Gag p27 (NIH AIDS Research and Reference Reagent Program, 
Germantown, MD) at 4 °C overnight. Horseradish peroxidase-conjugated goat anti-mouse 
secondary antibody (KPL, Gaithersburg, MD) was added and protein expression was detected by 
autoradiography using ECL substrate kit (Thermo Fisher Scientific). β-actin was used as protein 
loading control and probed with an anti-mouse β-actin primary antibody (Sigma-Aldrich, St. Louis, 
MD).  
 
Mice 
Thy1.1+ C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor, ME). ICR mice 
were purchased from ACE Animals (Boyertown, PA). Mice were housed in the vivarium at the 
Wistar Institute (Philadelphia, PA). All experiments and procedures were performed in 
accordance with approved animal protocols. 
 
ELISA   
Sera of individual mice were pooled and tested for Gag- or NP-specific antibodies by ELISA. 
Briefly, 96-well plates were coated overnight at 4°C with Gag protein at 10 µg/ml or A/PR8 virus 
at 32 HAU/ml. Wells were washed with PBS/0.05% Tween-20, followed by overnight blocking at 
4°C with PBS/3% BSA/0.05% Tween-20. Wells were then washed and incubated with serial-
diluted samples (in duplicates) for 2 hours at room temperature. Wells were subsequently 
washed, and bound IgG was detected with a goat anti-mouse IgG alkaline phosphatase 
conjugate (Sigma-Aldrich). Bound enzyme was detected with DEA substrate (KPL) and read on a 
microplate reader at 405 nm. 
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Tetramer and ICS 
ICS to detect Gag- and NP-specific CD8+ T cell responses was performed as follows. 
Lymphocytes were stimulated either with a peptide (2 µg/ml) carrying the immunodominant H2kb-
restricted class I epitope of NP (ASNENMETM) or with a peptide pool (3 µg/ml) of 15-mers 
overlapping by 11 amino acids covering the entire SIVmac239 Gag sequence. A rabies virus 
glycoprotein peptide or a peptide of the H2kb-restricted class I epitope of ovalbumin, SIINFEKL, 
were used as a negative stimulation controls; both negative peptides were used at the same 
concentration ad the positive peptides. After stimulation, lymphocytes were stained with anti-CD8, 
and anti-CD44 antibodies and with a stain identifying dead cells. Cells were stained for 30 
minutes at 4°C then washed twice with PBS. Following permeablization, samples were stained for 
30 minutes at 4°C with APC-labeled anti-IFNγ, Alexa700-labeled anti-IL-2, and PE-Cy7-labeled 
anti-TNFα. All antibodies (Biolegend, San Diego, CA) were diluted at 1:100 in 1X Perm/Wash. 
After washing, cells were fixed with Fixative Buffer (BD Biosciences, Franklin Lakes, NJ). Cells 
were run on an LSRII (BD Biosciences) and data were analyzed with FlowJo (TreeStar, Ashland, 
OR).  
 
Statistical analysis 
Experiments were conducted repeatedly using 3-4 mice per group. Results show the median ± 
IQR. Significances between groups were analyzed by one-way ANOVA. 
 
MATERIALS AND METHODS B. 
 
DEVELOPMENT OF NOVEL ADENOVIRAL VECTORS WITH CONDITIONAL TRANSGENE 
PRODUCT EXPRESSION  
 
Construction of loxP single and dual expression vectors 
 Shuttle vectors were constructed to insert transgenes flanked by loxP sequences (floxed) 
into the deleted E1 domain. LoxP sites (5’- ATA ACT TCG TAT AGC ATA CAT TAT ACG AAG 
TTA T-3’) were cloned into the empty shuttle vector such that they flanked the regulatory 
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elements of the empty expression cassette. Both loxP sites were oriented in the same direction 
(5’ – 3’). This was achieved by generating forward and reverse primers, each with loxP sites, to 
amplify the region of the empty expression cassette in the shuttle plasmid. Additionally, each 
primer contained a restriction site to facilitate cloning the amplified fragment into the shuttle 
vector. The amplified PCR product was then sub-cloned into the in shuttle plasmid by restriction 
enzyme digestion and ligation. Successful cloning was confirmed by sequencing over regions 
containing loxP sites. The transgene, either gag of HIV-1 or GFP, was inserted into the empty 
loxP shuttle plasmid using the multiple cloning site (MSC) downstream from the intron and 
upstream of the poly(A) tail. The resulting shuttles were used to sub-clone the floxed expression 
cassette into the deleted E1 of the AdC7 molecular clone, as described above. 
 Additionally, dual expression vectors were generated that encoded floxed transgenes in 
E1 (as described above) and CreERT2 in the deleted E3 domain. CreERT2 is a fusion protein of 
Cre recombinase and mutated version of the human estrogen receptor that can only bind the 
synthetic estrogen ligand 4-hydroxytamoxifen. CreERT2 was cloned into the MCS of a shuttle 
vector used to insert transgenes into the E3 domain. The chicken beta-actin promoter (CB) was 
used to drive CreERT2 expression. Additionally, the CreERT2 expression cassette lacked an 
intron and contained the rabbit beta-globin poly(A) tail sequence. CreERT2 was then cloned into 
the E3 domain as described above. All vectors were rescued and quality controlled as described 
above. 
 
Cre-293 cell line  
 For in vitro studies of Ad vectors containing a single floxed transgene, generation of a cell 
line stably expressing the inducible recombinase CreERT2, which identifies and recombines loxP 
sites, was necessary. 5 µg of a plasmid that expressed CreERT2 under the control of the CMV 
promoter and encoded the neomycin resistance gene was linearized and transfected into HEK 
293 cells with CaCl2 in the method described above. The following day, the antibiotic geneticin 
(G418) (Sigma-Aldrich) was added to the culture media at a concentration of 0.5 mg/mL to select 
for cells that were stably transfected with the plasmid that carried a G418-resistance gene. Fresh 
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media and G418 were added to cultures every 3 days. When individual colonies could be 
observed, they were harvested and transferred to individual wells of a 24-well plate to continue to 
be cultured under selective conditions. Ten days later colonies were transferred to T-75 flasks 
and expanded. When these cultures were confluent, cells were trypsinized and plated on a 6-well 
plate. 24 hours later, both reverse transcriptase PCR and Western Blot were used to confirm 
CreERT2 expression.   
 
LoxP Site Functionality 
 1x106 293-CreERT2 cells were infected with doses ranging from 1000 vp/cell to 10 
vp/cell of AdC7 encoding floxed GFP (AdC7-GFPloxP). 2 µM or 0.2 µM 4-hydroxytamoxifen (4-
OHT or tamoxifen) (Sigma-Aldrich) was added at time of infection. As a negative control, cells 
were treated with equal volume of vehicle (95% EtOH). Importantly, the volume of vehicle and 
tamoxifen was less than 10 µL per well, which contained 3 mL of culture media. Cells remained 
viable through the experiment as they remained attached to the plate. GFP expression was 
analyzed 48 hours later by flow cytometry.   
 LoxP site functionality was tested in dual expression vectors by infecting 1x106 chinese 
hamster ovary (CHO) cells stably transfected with the coxsackie-adenovirus receptor (CHO-CAR) 
with AdC7 vectors dually expressing floxed Gag from E1 and CreERT2 from E3 (AdC7-gagloxP-
CBr-CreERT2). Doses ranged from 1010 vp to 108 vp. 2 µM 4-OHT and vehicle treatment was 
started 1 hour prior to infection. 3 and 7 days after infection, Gag and CreERT2 expression were 
confirmed by Western blot and reverse transcriptase PCR. As a control, groups of cells were 
infected 109 vp of AdC7-HIVgagloxP and treated with either vehicle or 2 µM 4-OHT.   
 For Western blot, cells were washed 3 times with ice cold PBS without Ca2+ or Mg2+ then 
lysed for 1 hour on ice in RIPA Buffer containing Complete protease inhibitors (Roche; 
Indianapolis, IN). Protein samples were then diluted in loading buffer containing NuPAGE 
reducing reagent (Life Technologies) and electrophoresed on NuPAGE 4-10% SDS-PAGE gels 
(Life Technologies) with Tris running buffer. Samples were then transferred to PVDF membrane 
and probed overnight at 4°C with mouse monoclonal anti-HIV gag p24 or rabbit polyclonal 
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antibody anti-Cre recombinase (Abcam, Cambridge, MA). After washing with 0.1% PBS-T, HRP-
conjugated secondary antibodies (anti-mouse for Gag, anti-rabbit for CreERT2) were diluted in 
5% blotto and incubated for 1 hour at room temperature. PBS-T was used to wash the 
membranes a final time and protein expression was detected on membranes using ECL substrate 
kit (Thermo Fischer Scientific). 
 Total RNA was isolated for reverse transcriptase PCR using TRI reagent (Sigma-Aldrich) 
according to the manufacturer’s protocol. RNA was reverse transcribed using SuperScript II 
Reverse Transcriptase (Life Technologies) according to the manufacturer’s protocol. HIV gag and 
CreERT2 were amplified by regular PCR using Platinum Taq polymerase (Life Technologies), 
resulting in a 250 bp fragment and a 200 bp fragment, respectively. 5’ and 3’ primers used for 
amplification of gag were: 5’-ACC-ACA-TCT-ACC-CTG-CAG-GAA-CAG-3’ and 5’-AGG-GTC-
TCT-GTC-ATC-CAA-TTC-TTC-3’. The PCR consisted of 30 cycles of 94°C for 30 seconds, 57°C 
for 30 seconds, and 72°C for 1 minute. The 5’ and 3’ primers used for amplification of CreERT2 
were: 5’-ACG-GCG-CTA-AGG-ATG-ACT-CTG-G-3’ and 5’-ATC-CGC-CGC-ATA-ACC-AGT-
GAA-AC-3’, respectively. The PCR consisted of 30 cycles of 94°C for 30 seconds, 57°C for 30 
seconds, and 72°C for 1 minute.  Amplicons (5 µL) were visualized on a 1% TAE agarose gel.  
   
Muscle imaging 
 BALB/c mice were immunized IM in the lower leg with 1011 vp of AdC7-GFPloxP-CBr-
CreERT2. Legs were removed 48 hours later and GFP expression was visualized using 
Illumatool Lighting System (Lightools Research, Encinitas, CA). A Kodak DCS14N digital SLR 
camera (Kodak, Rochester, NY) with a 60-mm Micro Nikkor lens of f3.5 using a 1:2.2 
magnification (Nikon, Tokyo, Japan) was used to take photographs. Raw images were converted 
to TIFF files. 
 
Quality control of isolated viral DNA 
 Isolated viral DNA from vectors encoding floxed GFP or gag and matched plasmid 
molecular clones used to rescue the vectors were subjected to restriction digest to determine if 
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the transgene had been excised from Ad genome during viral rescue and expansion. DNAs were 
digested with BglII and SphI (both from New England BioLabs, Ipswich, MA) for 1 hour at 37°C.  
Digestion products were run on a 1% TAE agarose gel.  
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CHAPTER 3 
	  
INHIBITION OF THE MAMMALIAN TARGET OF RAPAMYCIN 
FAILS TO AUGMENT FORMATION OF CENTRAL MEMORY CD8+ 
T CELLS IN THE PRESENCE OF PERSISTING ANTIGEN
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ABSTRACT 
 
 Inhibition of the mammalian target of rapamycin (mTOR) pathway enhances 
differentiation of anti-viral central memory CD8+ T cells induced during acute viral infections. 
Recombinant adenovirus (Ad) vectors persist at low levels and remain in a transcriptionally active 
form. A consequence of this persistence is that Ad vector vaccination induces potent and 
sustained transgene product-specific CD8+ T cell responses that fail to transition into central 
memory.  Here we tested in mice if treatment with rapamycin, which blocks mTOR activity, could 
promote formation of central memory transgene product-specific CD8+ T cells following 
vaccination with Ad vectors. Our results demonstrate that rapamycin given early after Ad vector 
vaccination transiently increases the magnitude of the transgene product-specific CD8+ T cell 
response while a delayed treatment has no such effect. Neither regimen improves formation of 
central memory CD8+ T cells. These results show that transient inhibition of the mTOR pathway 
does not override the effect of persisting antigen on continuous CD8+ T cell activation.        
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INTRODUCTION 
 
 In recent years, CD8+ T cell metabolism has been extensively studied and it has been 
revealed that along their path of differentiation, CD8+ T cells undergo two major switches in their 
metabolism 105. Mature, naïve CD8+ T cells are actively maintained in a quiescent state. As such, 
these cells are locked in G0 and rely on catabolic metabolism for their energy needs. This is 
mediated by mitochondrial oxidative phosphorylation of glucose, amino acids, and lipids. 
However, full activation of CD8+ T cells results in vast clonal expansion and upregulation of 
effector molecules. As such, CD8+ T cells shift to an anabolic metabolism in order to keep up with 
increased energy demands. Glucose uptake is dramatically increased and effector CD8+ T cells 
switch from oxidative phosphorylation to primarily aerobic glycolysis, which is unusual as 
glycolysis is less efficient but enables synthesis of the cells’ building materials. Following 
pathogen clearance the vast majority of effector cells will undergo apoptosis, but those that 
remain and differentiate into memory will again switch their metabolism and revert back to a 
catabolic, quiescent state.      
 Mammalian target of rapamycin (mTOR) is a key regulator of cellular metabolism that 
tightly controls cellular growth and proliferation. mTOR is a serine/threonine kinase that exists in 
two distinct complexes: mTORC1 and mTORC2 176. A key difference in these two complexes is 
that mTORC1 is sensitive to inhibition by rapamycin, an immunosuppressant often administered 
to prevent rejection of organ transplants, while mTORC2 is not. mTORC1 is directly inhibited by 
the TSC1/TSC2 complex, whose activity is controlled by the PI3K-AKT and AMPK pathways. 
Given this, mTOR integrates environmental signals to regulate protein synthesis predominantly 
via S6K1 and 4E-BP1 and to promote glycolysis and lipid biosynthesis.    
 Emerging evidence has demonstrated that mTOR is intimately involved in shaping CD8+ 
T cell metabolism and differentiation. In order for naïve T cells to maintain quiescence, mTOR 
activity must be held in check. T cells that are deficient in the TSC complex, and thus unable to 
inhibit mTOR, are activated, proliferate, and are prone to apoptosis 177. In activating naïve CD8+ T 
cells, TCR engagement and co-stimulation activates a signaling cascade that results in optimal 
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mTOR activation, the level of which is directly dependent on amount and duration of antigen 
stimulation 105. This causes dramatic upregulation of the glucose transporter 105 thus allowing the 
cell to switch metabolic programs and acquire effector functions. Simultaneously, mTOR activity 
promotes downregulation of CD62L and CCR7 178, thereby allowing the activated effector cells to 
traffic to sites of inflammation. When antigen is cleared and the TCR is no longer engaged, the 
glucose transporter is downregulated and effector cells are effectively starved. Those cells that 
survive contraction transition into memory and metabolically switch back to autophagy for energy 
demands. Sensing glucose deprivation, AMPK blocks mTORC1 activity 179 and promotes 
autophagy in the form of fatty acid oxidation 180, allowing effector cells to transition to memory. As 
such, drugs that activate AMPK or block mTOR activity, like rapamycin, promote transition into 
memory 154,180. Additionally, mTOR alters transcriptional programs crucial for T cell fate decisions. 
It has been demonstrated that inhibition of mTOR activity blocks the transcription factor T-bet 
while promoting Eomesodermin 181, which control differentiation of effector and memory cells, 
respectively 182.   
 Manipulation of the mTOR pathway was shown to enhance formation of central memory 
CD8+ T cells, suggesting the potential of mTOR inhibitors as vaccine adjuvants. Araki et al. 
demonstrated in mice that treatment with a low dose of rapamycin during the T cell expansion 
phase following LCMV infection enhanced the quantity of memory CD8+ T cells, while treatment 
during contraction enhanced the quality of these cells 154. Similar results were observed in rhesus 
macaques treated with rapamycin during vaccinia virus infection 183. These studies suggest that 
rapamycin could potentially be used as a vaccine adjuvant.  
Replication-defective adenoviral (Ad) vectors have garnered much attention as vaccine 
platforms. An attractive feature of Ad vectors is that they are known to induce very potent and 
sustained transgene product-specific CD8+ T cell responses following immunization 184. The 
failure of this CD8+ T cell response to contract is due to persistent transgene product expression 
from Ad vectors maintained in activated T cells 123. Transgene product-specific CD8+ T cells that 
remain following primary immune responses bear an effector or effector memory phenotype and 
their differentiation to central memory is markedly delayed 123. While a large pool of armed 
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effector-like CD8+ T cells standing guard at a pathogen’s port of entry may be beneficial in 
preventing acquisition of viruses 134,185, a larger pool of long-lived central memory CD8+ T cells, 
with their vast potential for expansion following antigenic reencounter, could be beneficial to 
protect against systemic dissemination of reinvading pathogens 185. 
 Here we tested if inhibition of mTOR through rapamycin could override the continuous 
stimulation of CD8+ T cells by low levels of transgene product produced by persisting Ad vaccine 
vectors. To this end mice were treated with a low dose of rapamycin either early during the CD8+ 
T cell expansion phase following immunization or later after responses had peaked. We 
demonstrate that early rapamycin treatment transiently increases the magnitude of the transgene 
product-specific CD8+ T cell responses in blood and, less so, in spleen, but fails to alter 
frequencies of CD8+ T cells that migrated to lymph nodes. Beginning treatment with rapamycin 
several days following immunization fails to enhance the magnitude of the CD8+ T cell responses. 
Neither regimen increases formation of central memory CD8+ T cells. While rapamycin treatment 
enhances the formation of central memory CD8+ T cells to non-persisting pathogens, our data 
show that it is not effective in overriding the effect of persisting antigen on continuous CD8+ T cell 
activation.  
 
RESULTS 
 
The effect of early rapamycin treatment of CD8+ T cell responses to the transgene product 
of an Ad vector 
 
 Low dose rapamycin treatment given to limit mTOR activity during the CD8+ T cell 
expansion phase was demonstrated to increase the number of CD8+ memory precursors and 
thus increase the resulting number of memory cells following infection with lymphocytic 
choriomeningitis virus (LCMV) 154. To test if rapamycin affected the quantity of transgene product-
specific CD8+ T cell responses induced following immunization with an Ad-based vaccine, 
BALB/c mice were intramuscularly (IM) vaccinated with 1010 vp of an E1-deleted adenovirus 
based on human serotype 5 expressing Gag of HIV-1 (AdHu5-gag). Groups of mice were treated 
daily for 10 days starting on the day of immunization either with 75 µg/kg of rapamycin or with 10 
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µL/g of sham as a control. Mice were bled or euthanized periodically and numbers of Gag-
specific CD8+ T cells were measured by staining isolated lymphocytes with a tetramer specific to 
the immunodominant, H-2d-restricted immunodominant epitope of Gag (AMQMLKETI). As shown 
in Figure 3.1A, Gag-specific CD8+ T cells from both rapamycin-treated and sham-treated groups 
expanded in all compartments until day 21 post-immunization, after which point modest 
contraction was observed in the blood and spleen. Gag-specific CD8+ T cells remained fairly 
stable in the lymph nodes. The most robust expansion of Gag-specific CD8+ T cells was observed 
in blood. Here, rapamycin treatment significantly increased the absolute number of Gag-specific 
CD8+ T cells at the peak response as compared to those from mice that had only received sham 
treatment. Although numbers remained elevated for the duration of the experiment, the difference 
was only significant at the peak of the response.  
 Analysis of the CD8+ T cells at the peak of their response has revealed that they are a 
heterogeneous population consisting of terminally differentiated short-lived effector cells (SLEC) 
and memory precursor effector cells (MPEC) fated to become memory cells with high proliferative 
capacity, and cells with more intermediate phenotypes 186. MPEC and SLEC can be defined by 
differential expression of the interleukin-7 receptor α chain (CD127), which is required for 
formation of memory cells 187, and killer cell lectin-like receptor subfamily member G1 (KLRG1), 
which is a marker of terminally differentiated antigen-experienced CD8+ T cells 143. As such, 
MPEC are defined by high CD127 expression and low KLRG1 expression; whereas, the opposite 
expression pattern is observed on SLEC 186. Inhibition of mTOR during the CD8+ T cell expansion 
phase increased the overall magnitude of the response by enhancing the number of memory 
precursors formed following LCMV infection but did not alter the quality of the induced CD8+ T 
cells 154. In order to determine if rapamycin treatment increased memory precursor numbers and 
altered the memory phenotype of the transgene product-specific CD8+ T cells following Ad 
vaccination, KLRG1, CD127, and CD62L, which can be used to distinguish between effector 
memory and central memory T cells based on low or high expression, respectively, were 
measured over time on Gag-specific CD8+ T cells isolated from blood, spleen, and lymph nodes 
(Figure 3.1B). In both groups, the frequency of Gag-specific CD8+ T cells that had converted to a 
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CD62Lhi phenotype were modest in all tissues tested, with the highest conversion occurring in 
lymph nodes. Rapamycin treatment did not significantly alter frequencies of CD62Lhi Gag-specific 
CD8+ T cells except 10 days after cessation of treatment (day 21) in blood, however this increase 
was modest and transient. Percentages of CD127hi Gag-specific CD8+ T cells were also similar 
between the two cohorts at most time points in all tissues. Significant differences were measured 
in blood on day 10 and 49 and in both lymph nodes and the spleen on day 21. Additionally, 
rapamycin treatment had no effect on the numbers of cells expressing decreased levels of 
KLRG1. Therefore, rapamycin treatment did not increase the MPEC frequency. 
 One measure of T cell quality is their capacity to produce multiple cytokines in response 
to re-stimulation. It is generally considered that an antigen-specific CD8+ T cell population that is 
capable of producing multiple cytokines, or is more polyfunctional, is more effective. To test if 
rapamycin treatment affected polyfunctionality of Gag-specific CD8+ T cells, we measured 
production of the cytokines interferon−γ (IFN-γ), tumor necrosis factor-α (TNF-α) and interleukin-2 
(IL-2) in blood and spleen. Additionally, the chemotactic cytokine macrophage inflammatory 
protein-1α (MIP-1 α) was measured in T cells from spleen. As shown in Figure 3.2A, rapamycin 
treatment increased the magnitude of cytokine producing Gag-specific CD8+ T cells in blood and 
spleen, although this reached significance only in cells isolated from the blood. Cytokine profiles 
were measured following in vitro re-stimulation of Gag-specific CD8+ T cells isolated from blood 
and spleen at 12 weeks following immunization (Figure 3.2B). Gag-specific CD8+ T cell cytokine 
profiles were largely similar between the two cohorts of mice and consisted of cells producing 
mainly IFN-γ  alone or in combination with TNF-α; in the spleen, these combinations 
included MIP−1α. Again, although the profiles were largely the same between the two groups, 
rapamycin treatment preferentially expanded the number of cells producing these combinations of 
effector cytokines. In some cases, rapamycin treatment also lead to a small increase in 
polyfunctional cells, although this was not significant. 
 As an additional measure of the functional quality of the induced Gag-specific CD8+ T cell 
response, both the rapamycin- and sham-treated groups were boosted 12 weeks after 
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immunization with 1010 vp of a heterologous Ad vector based on chimpanzee serotype 7 carrying 
the HIV-1 Gag transgene (AdC7-HIVgag). A group of mice primed with this virus alone was 
included as a control. In all compartments, Gag-specific CD8+ T cells from both groups robustly 
expanded following booster immunization regardless of treatment (Figure 3.3). Rapamycin-
treated mice developed higher numbers of Gag-specific CD8+ T cells than sham treated mice. 
Nevertheless the fold of expansion as assessed by the ratio of the numbers of Gag-specific CD8+ 
T cells before and after the boost was very similar between the rapamycin- and sham-treated 
groups in the blood, 10.5 and 9, respectively, (Figure 3.3A) and lymph nodes, each boosted 1.7-
fold (Figure 3.3C). In spleen (Figure 3.3B), the sham-treated group actually showed a more 
pronounced expansion of Gag-specific CD8+ T cells compared to rapamycin-treated mice, 2.8-
fold compared to 4.2-fold, respectively. Taken together, these results demonstrate that rapamycin 
treatment did not enhance the ability of the Gag-specific CD8+ T cells to expand following 
secondary exposure to their cognate antigen and therefore did not enhance the quality of the 
induced Gag-specific CD8+ T cell response.  
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FIGURE 3.1. Early rapamycin treatment transiently increases Gag-specific CD8+ T 
cells without altering memory phenotype. 
 
 
 
 
Groups of 5 BALB/c mice were immunized intramuscularly with 1010 vp AdHu5-HIVgag. At the time of 
immunization and continuing until day 10 post-immunization, one group was treated intraperitoneally (IP) 
with 75 µg/kg/day of rapamycin. As a control, the other group was IP injected with sham (0.1% DMSO in 
PBS) treatment given at 10 µL/g. Rapamycin-treated group is indicated by black boxes while sham-treated 
group is indicated by white boxes. The grey area indicates the treatment phase. Significance was 
determined using multiple t-tests with Holm-Sidak correction for multiple comparisons.  
 
[A] All mice were bled for PBMCs or euthanized for splenocytes and lymphocytes at the indicated time 
points. Graphs show the mean number of Gag-specific CD8+ T cells over 106 live cells ± standard deviations 
(SD). The following p-values were obtained: Blood: Day 35: p=0.0011; Lymph nodes: Day 49: p=0.0019.  
 
[B] Shows the longitudinal phenotyping of Gag-specific CD8+ T cells from indicated time points and tissues. 
Graphs show the mean frequency of Gag-specific CD8+ T cells with the indicated phenotype (CD127+, 
CD62L+, or KLRG1lo) over the total Gag-specific CD8+ T cell response ± SD. The following p-values were 
obtained: Blood: CD127: Day 10: p=0.0057, Day 49: p<0.0001; Spleen: CD127: Day 10: p=0.0089.  
 
Significant differences are indicated by * for p-values ≤ 0.05-0.01, ** p-values < 0.01-0.001, *** p-values ≤ 
0.001-0.0001, **** p-values < 0.0001.  Lines show the comparison groups. 
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FIGURE 3.2. Early rapamycin treatment transiently increases cytokine production. 
 
 
 
 
 
Shows the kinetics of total cytokine-producing cells [A] and the cytokine profile 12 weeks following 
immunization [B]. IFN-γ (G), TNF-α (T), and IL-2 (2) production was measured for PBMCs. IFN-γ, TNF-α, IL-
2, and MIP-1α (M) production was measured for splenocytes. For determination of the kinetics, mice were 
bled or euthanized at the indicated time points and PBMCs or splenocytes were isolated, respectively. The 
lymphocytes were stimulated with either the Gag peptide AMQMLKETI or the equivalent amount of an 
irrelevant peptide to measure background stimulation. Line graphs show the mean number of cytokine 
producing cells following the subtraction of background stimulation and summation of Boolean gates used to 
determine the cytokine profile ± SD. Significance between rapamycin- and sham–treated groups was 
determined for each time point using multiple t-tests with Holm-Sidak correction for multiple comparisons.  
The following p-values were obtained: [A] Blood: Day 21: p=0.002, Day: 35: p=0.006, Day 84: p=0.0038. 
 
Significant differences are indicated by * for p-values ≤ 0.05-0.01, ** p-values < 0.01-0.001, *** p-values ≤ 
0.001-0.0001, **** p-values < 0.0001.  Lines show the comparison groups. 
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FIGURE 3.3. Early rapamycin treatment causes a more robust peak recall 
response.  
 
 
 
 
BALB/c mice treated with either rapamycin or sham were boosted with 1010 vp AdC7-HIVgag 12 weeks after 
first vaccination. A group of naïve mice was primed with this vaccine in order to serve as a control. Gag-
specific CD8+ T cell responses in blood [A] were measured 2 days prior to the boost and again at 15 and 56 
days after the boost. In the spleen [B] and lymph nodes [C], Gag-specific CD8+ T cell responses were 
measured 2 days prior to the boost and 56 days after the boost. Graphs show mean number of Gag-specific 
CD8+ T cells identified by staining with the tetramer over 106 live lymphocytes ± SD. In the blood [A], the 
rapamycin-treated group is indicated by the black bar, the sham-treated group is indicated by the grey bar, 
and the prime only group is indicated by the white bar. In spleen [B] and lymph nodes [C], the white bar 
indicates the prebleed 2 days prior to boosting and the black bar indicates the day 56 post-boost time point.  
 
Statistical significance was determined by 2-way ANOVA with Holm-Sidak correction for multiple 
comparisons. The following p-values were obtained: [A] Day 15: rapamycin vs. prime only: p<0.0001, sham 
vs. prime only: p=0.0058, rapamycin vs. sham: p=0.0021; Day 56: rapamycin vs. prime only: p=0.0446; 
Rapamycin: prebleed vs. day 15: p=0.001, day 15 vs. day 56: p<0.0001; Sham: prebleed vs. day 15: 
p=0.002 day 15 vs. day 56: p=0.0028; [C] Day 56: rapamycin vs. prime only: p=0.0006.   
 
Significant differences are indicated by * for p-values ≤ 0.05-0.01, ** p-values < 0.01-0.001, *** p-values ≤ 
0.001-0.0001, **** p-values < 0.0001.  Lines show the comparison groups. 
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The effect of late rapamycin treatment of CD8+ T cell responses to the transgene product 
of an Ad vector 
 
 Araki et al. demonstrated that limiting mTOR activity during the contraction phase 
accelerated CD8+ T cell differentiation into the central memory compartment. To assess if 
inhibition of the mTOR pathway at a later stage of T cell activation following Ad immunization 
affected the transgene product-specific CD8+ T cells’ fate decisions, BALB/c mice were 
immunized IM with 1010 vp AdHu5-HIVgag and then treated daily from days 10 to 30 post 
immunization with either rapamycin or sham. Mice were bled or euthanized and Gag-specific 
CD8+ T cells were measured at the time points indicated in Figure 3.4A. Gag-specific CD8+ T 
cells from both the rapamycin- and sham-treated groups expanded in the blood, spleen, and 
lymph nodes, reaching a peak at 3 weeks in the spleen and lymph nodes and at 5 weeks in blood 
following immunization. Numbers of Gag-specific CD8+ T cells then remained stable in blood but 
contracted in the spleen and lymph nodes. There was no significant difference in the overall 
magnitude of the Gag-specific CD8+ T cell response in the two cohorts.  
 We measured expression of CD62L, CD127 and KLRG1 following immunization to 
determine if delaying rapamycin in relation to vaccination increased formation of Gag-specific 
central memory CD8+ T cells. As shown in Figure 3.4B, we found that differences between the 
two groups were subtle and only reached significance for expression of CD127 and KLRG1 at 
some time points. Specifically CD127+ Gag-specific CD8+ T cells were more frequent in blood on 
day 21 while KLRG1 was differentially expressed in blood on day 10, in spleen on day 49 and in 
lymph nodes on days 21 and 49. Taken together, these results indicate that the delayed 
rapamycin treatment did not enhance memory differentiation.     
 Ad vector-induced CD8+ T cells were tested following peptide stimulation in vitro for 
production of IFN-γ, TNF-α, and IL-2 in blood and spleen. MIP-1α was again only included for 
splenocytes. Rapamycin treatment only transiently increased numbers of cytokine-producing 
Gag-specific CD8+ T cells in the blood on day 21 (Figure 3.5A). Otherwise, the delayed drug 
treatment did not affect the cytokine profile of Ad vector-induced CD8+ T cells (Figure 3.5B), 
similar to Figure 3.2B. 
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 At 12 weeks post-immunization both the rapamycin- and sham-treated groups were 
boosted with 1010 vp of AdC7-HIVgag. In all compartments, Gag-specific CD8+ T cells from all 
groups expanded robustly following immunization (Figure 3.6). In the blood (Figure 3.6A) 
rapamycin treatment led to transiently higher numbers of Gag-specific CD8+ T cells than sham 
treatment. Comparison of the fold increase of Gag-specific CD8+ T cells revealed that Gag-
specific CD8+ T cells from rapamycin-treated mice had expanded more robustly (20.5-fold) than 
those from sham-treated mice (10.7-fold). In the spleen and lymph nodes there were no 
significant differences in numbers of Gag-specific CD8+ T cells between the rapamycin- and 
sham-treated groups (Figures 3.6B and 3.6C), although each group boosted robustly and 
similarly. These results further support the notion that later rapamycin treatment did not enhance 
the quality of the induced the Gag-specific CD8+ T cell response.  
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FIGURE 3.4. Later rapamycin treatment neither increases numbers nor alters 
phenotype of Gag-specific CD8+ T cells. 
 
 
 
Groups of 5 BALB/c mice were immunized intramuscularly with 1010 vp AdHu5-HIVgag. 10 days after 
immunization and continuing until 30 days after immunization, one group was treated intraperitoneally (IP) 
with 75 µg/kg/day of rapamycin. As a control, the other group was IP injected with sham (0.1% DMSO in 
PBS) treatment given at 10 µL/g. Rapamycin-treated group is indicated by black boxes while sham-treated 
group is indicated by the white boxes. The grey area indicates the treatment phase. Significance between 
rapamycin- and sham-treated groups was determined using multiple t-tests with Holm-Sidak correction for 
multiple comparisons.  
 
[A] All mice were bled for PBMCs or euthanized for splenocytes and lymphocytes at the indicated time 
points. Graphs show the mean number of Gag-specific CD8+ T cells over 106 live cells ± SD.  
 
[B] Shows the longitudinal phenotyping of Gag-specific CD8+ T cells from indicated time points and tissues. 
Graphs show the mean frequency of Gag-specific CD8+ T cells with the indicated phenotype (CD127+, 
CD62L+, or KLRG1lo) over the total Gag-specific CD8+ T cell response ± SD. The following p-values were 
obtained: Blood: CD62L+: Day 10: p=0.00372; Spleen: KLRG1lo: Day 21: p=0.0056, Day 49: p<0.0001; 
Lymph nodes: KLRG1lo: Day 21: p=0.0056, Day 49: p=0.00529. 
 
Significant differences are indicated by * for p-values ≤ 0.05-0.01, ** p-values < 0.01-0.001, *** p-values ≤ 
0.001-0.0001, **** p-values < 0.0001.  Lines show the comparison groups. 
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FIGURE 3.5. Later rapamycin treatment transiently increases cytokine production. 
 
  
 
 
Shows the kinetics of total cytokine-producing cells [A] and the cytokine profile 12 weeks following 
immunization [B]. IFN-γ (G), TNF-α (T), and IL-2 (2) production was measured for PBMCs. IFN-γ, TNF-α, IL-
2, and MIP-1α (M) production was measured for splenocytes. For determination of the kinetics, mice were 
bled or euthanized at the indicated time points and PBMCs or splenocytes were isolated, respectively. The 
lymphocytes were stimulated with either the Gag peptide AMQMLKETI or the equivalent amount of an 
irrelevant peptide to measure background stimulation. Line graphs show the mean number of cytokine 
producing cells following the subtraction of background stimulation and summation of Boolean gates used to 
determine the cytokine profile ± SD. Significance between rapamycin- and sham–treated groups was 
determined for each time point using multiple t-tests with Holm-Sidak correction for multiple comparisons.  
The following p-values were obtained: [A] Blood: Day 21: p=0.0078.  
 
Significant differences are indicated by * for p-values ≤ 0.05-0.01, ** p-values < 0.01-0.001, *** p-values ≤ 
0.001-0.0001, **** p-values < 0.0001.  Lines show the comparison groups. 
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FIGURE 3.6. Later rapamycin treatment transiently improves recall response. 
 
 
BALB/c mice treated with either rapamycin or sham were boosted with 1010 vp AdC7-HIVgag 12 weeks after 
first vaccination. A group of naïve mice was primed with this vaccine in order to serve as a control. Gag-
specific CD8+ T cell responses in blood [A] were measured 2 days prior to the boost and again at 15 and 56 
days after the boost. In the spleen [B] and lymph nodes [C], Gag-specific CD8+ T cell responses were 
measured 2 days prior to the boost and 56 days after the boost. Graphs show mean number of Gag-specific 
CD8+ T cells identified by staining with the tetramer over 106 live lymphocytes ± SD. In the blood [A], the 
rapamycin-treated group is indicated by the black bar, the sham-treated group is indicated by the grey bar, 
and the prime only group is indicated by the white bar. In spleen [B] and lymph nodes [C], the white bar 
indicates the prebleed 2 days prior to boosting and the black bar indicates the day 56 post-boost time point.  
 
Statistical significance was determined by 2-way ANOVA with Holm-Sidak correction for multiple 
comparisons. The following p-values were obtained: [A] Rapamycin: Prebleed vs. Day 15: p<0.0001, Day 
15 vs. Day 56: p<0.0001; Sham: Prebleed vs. Day 15: p=0.007, Day 15 vs. Day 56: p=0.0099; Day 15: 
prime only vs rapamycin: p<0.0001, prime only vs. sham: p=0.0084, rapamycin vs. sham: p=0.0459 [B] 
Rapamycin: Prebleed vs. Day 56: p=0.0179; Day 56: rapamycin vs. prime only: p=0.0056 [C] Rapamycin: 
prebleed vs. day 56: p=0.0226; Sham: prebleed vs. day 56: p=0.0029; Day 56: p=0.0071. 
 
Significant differences are indicated by * for p-values ≤ 0.05-0.01, ** p-values < 0.01-0.001, *** p-values ≤ 
0.001-0.0001, **** p-values < 0.0001.  Lines show the comparison groups. 
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DISCUSSION 
 
 mTOR was elegantly demonstrated to play a critical role in memory CD8+ T cell 
differentiation. Araki et al. demonstrated that limiting mTOR activity at different phases of the 
CD8+ T cell response enhanced the induction of memory cells 154. Specifically, low doses of 
rapamycin given during the T cell expansion phase to inhibit mTOR activity increased numbers of 
memory cell precursors by increasing expression of Bcl-2, an anti-apoptotic protein, ultimately 
leading to their increased survival during the contraction phase. Consistent with this, low dose 
rapamycin treatment was demonstrated to dramatically decrease apoptosis following 
immunization with a recombinant poxvirus 188. Additionally, Araki et al. demonstrated that low 
doses of rapamycin given during the contraction phase accelerated differentiation into central 
memory. These results suggest that rapamycin may be a beneficial vaccine adjuvant to enhance 
memory differentiation.   
The current study was performed to test the potential of mTOR inhibition to increase 
central memory development of transgene product-specific CD8+ T cells induced by an Ad vector-
based vaccine. The results presented here are partially in contrast with those described above. 
As expected, treatment with low doses of rapamycin during the early expansion phase following 
Ad immunization resulted in higher transgene product-specific CD8+ T cell numbers at the peak of 
the response, but the effect was transient. Additionally, low dose rapamycin treatments given 
later in the response failed to enhance transgene product-specific CD8+ T cell differentiation into 
central memory. These differences could possibly be due to the differences in timing of 
rapamycin treatment with the kinetics of the induced CD8+ T cells. In the Araki et al study early 
rapamycin treatments coincided with the entire T cell expansion phase and ended at the peak 
response and later rapamycin treatments coincided with the entire contraction phase beginning at 
the peak response. However, the early rapamycin treatments given in the study presented here 
only coincided with about half of the expansion phase and the later treatments covered the late 
expansion and early contraction phases.    
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The differences observed in these studies could also be due to the nature of the viral 
models each used. The Araki et al. study infected mice with lymphocytic choriomeningitis virus 
(LCMV). As an acutely infecting virus, this pathogen is cleared completely from the host within 8 
days 139. TCR/CD28 signaling subsides as the virus is cleared and mTOR activity subsequently 
subsides, allowing responding T cells to become more quiescent and differentiate. On the other 
hand, adenoviruses, whether naturally acquired 65 or rendered replication-defective 123, establish 
persistent infection in activated T cells. Studies using Ad vectors carrying transgenes under the 
control of strong and ubiquitous promoters have revealed that Ad vectors remain transcriptionally 
active at low levels 123. The continued presence of transgene product in turn maintains a pool of 
activated effector and effector memory transgene product-specific CD8+ T cells and delays their 
differentiation into central memory cells. It is unknown how persistent antigen produced by 
adenovirus transduced T cells maintains activation of other T cells. Following vaccination, Ad 
vectors induce transgene product-specific CD8+ T cells primarily through cross-presentation of 
transgene product by antigen presenting cells (APC) 189 rather than directly infecting them. During 
Ad persistence, CD8+ T cells could be stimulated directly by the T cells harboring persistent 
vector or by cross-presentation of transgene product when transduced cells eventually become 
apoptotic. Regardless, as TCR stimulation continues mTOR would be expected to be active to 
some degree.  
Much of our knowledge of the role mTOR plays in CD8+ T cell differentiation comes from 
in vitro studies and mouse models with various members of the PI3K/Akt/mTOR pathway 
knocked out. Only a few studies have examined this pathway in the context of acute viral 
infections. Even less is known about the role of mTOR in CD8+ T cells during persistent 
infections. It appears that mTOR phosphorylation gradually declines during persistent infection 
with LCMV clone 13 but, importantly, phosphorylation is not ablated 190, which could reflect 
continued TCR stimulation. Transplant recipients persistently infected with CMV who were treated 
with the rapamycin analog everolimus showed a specific increase in the magnitude of CMV-
specific CD8+ effector and effector memory T cells without affecting their quality and 
polyfunctionality 191, consistent with what was presented here. A recent study in which rapamycin 
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was administered for 35 days following vaccination with Ad revealed that the effector memory 
population of transgene product-specific CD8+ T cells was enhanced in this model 192. This 
response was magnified and central memory development was enhanced only when additional 
co-stimulation was provided through OX40 agonism. The results presented here are not in 
complete agreement with their report, which could be due to differences in the study design, in 
particular the vector dose. Using a dose 100 –fold lower than was used in the study presented in 
this chapter, rapamycin treatment alone increased the formation of MPECs. It could be argued 
that increase in memory differentiation was due to lower antigenic load present during the priming 
that prevented the establishment of a persisting reservoir. Indeed, in a later experiment they use 
the same immunization dose used here and the combined treatment did not increase central 
memory development. However, both doses of Ad vector and each treatment regimen selectively 
increased the proportion of effector memory cells. The results presented here (Figure 3.1) 
indicate that rapamycin treatment increases, albeit transiently, the absolute number of effector 
and effector memory cells without shifting the subset distribution. During the periods of rapamycin 
treatment, limiting mTOR activity may have favored the formation of memory cells, as a transient 
and subtle increase in CD127+ cells was observed following early rapamycin treatment. However, 
this was expected to be transient once rapamycin treatment was discontinued because continued 
stimulation from persistent antigen could recall transgene product-specific CD8+ T cells. This 
would ultimately increase the overall size of the response without changing the makeup of the 
pool. Consistent with the idea that persistent transgene expression prevents rapamycin treatment 
from enhancing central memory development, extinguishing transgene expression from an Ad 
vector during the combined rapamycin and OX40 treatment enhanced central memory 
development 192.  
In conclusion, the studies presented here demonstrate that rapamycin treatment following 
immunization with a vector that is known to persist at low levels does not enhance CD8+ T cell 
differentiation into central memory but increases the number of activated effector cells. Further 
elucidation of the role that mTOR plays in regulating T cell metabolism during chronic infections is 
necessary. 
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MATERIALS AND METHODS 
 
Mice, immunizations, and rapamycin treatments 
 Groups of BALB/c mice were immunized intramuscularly (IM) with 1010 vp of the AdHu5-
HIVgag vector diluted in 100 µL of sterile PBS. In one series of experiments, groups of mice 
received daily intraperitoneal (IP) injections of 75 µg/kg rapamycin (Sigma-Aldrich, St. Louis, MD) 
diluted in 0.1% DMSO in sterile PBS for 10 days following immunization 154. In a second series of 
experiments, groups of mice received daily IP injections of 75 µg/kg rapamycin from day 10 after 
immunization until day 30 after immunization. In both series of experiments, control mice received 
daily IP injections of 10 µL/g 0.1% DMSO in PBS for the indicated length of time. In one 
experiment, both groups of mice (control- and rapamycin-treated) received a second 
immunization with 1010 vp AdC7-HIVgag 12 weeks after the primary immunization with the AdHu5 
vector. A group of naïve mice were immunized concurrently with 1010 vp of AdC7-HIVgag as a 
control.  
 
Tetramer staining 
 Tetramer staining was preformed by staining cells in PBS with an APC-labeled tetramer 
against the immunodominant MHC class I H-2Kd restricted epitope of Gag (AMQMLKETI). 
Additionally, cells were stained with PerCP-Cy5.5-labeled anti-CD8, PE-labeled anti-KLRG1 
(Southern Biotech, Birmingham, AL), anti-CD62L (BD Biosciences, Franklin Lakes, NJ), 
Alexa700-labeled anti-CD44, anti-CD127 (eBioscience, San Diego CA), PE-Cy7-labeled anti-
CD44 (eBioscience), and PacBlue-labeled anti-CD62L, anti-CD127 (eBioscience). Unless 
otherwise indicated, antibodies are from Biolegend (San Diego, CA). Antibodies labeled with 
identical fluorophores were used in separate samples. All samples included a dye that labels 
dead cells. Staining was preformed for 30 min at 4ºC. Cells were fixed with BD fixative after 
staining.  
 
Intracellular cytokine staining (ICS) 
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 In order to detect a Gag-specific CD8+ T cell response, PBMCs and splenocytes were 
stimulated in the presence of Golgi Plug (BD Biosciences) for 5 hours at 37 °C with 1.25 µg/mL of 
Gag peptide, AMQMLKETI, or with 1.25 µg/mL of a non-specific peptide, WIZX-2 from rabies 
virus, to measure background stimulation. Peptides were prepared in DMEM containing 2% 
mixed lymphocyte culture media (MLC). Following stimulation and surface staining, 
Cytofix/Cytoperm (BD Biosciences) was used to permeabilize the cells, which were subsequently 
stained intracellularly with PacBlue-labeled anti-IFNγ, FITC-labeled anti-TNFα (BD Bioscience), 
Alexa700-labeled anti-IL-2 (BD Bioscience); splenocytes were additionally stained with APC-
labeled anti-MIP-1α (R&D Systems; Minneapolis, MN). Staining at both steps was performed as 
described in the previous section. 
 
Data acquisition and analysis 
All samples were collected on a BD-LSR II and analyzed using FlowJo software. For 
tetramer staining, numbers of Gag-specific CD8+ T cells were determined as follows. Acquired 
lymphoid cells were first gated to remove doublets and dead cells, then were gated on CD8+ T 
cells. The remaining cells were plotted as tetramer (tet) compared to CD44.  Numbers were 
determined by normalizing the numbers of double positive (tet+CD44+) cells to total live cells. 
Data are shown as tet+CD8+ T cells/106 PBMCs, splenocytes, or lymphocytes, depending on the 
compartment presented. Additionally, tet+CD44+ cells were phenotyped for the markers 
described. A gate on the CD44lo CD8+ T cells served an internal, naïve control for phenotyping. 
For analysis of ICS, live CD8+ T cells were gated as described above, then cells positive for each 
cytokine were gated. Boolean gates were generated to determine cytokine profile in each sample. 
Numbers of cells acquired for each cytokine and combination of cytokines were first normalized to 
total live cells per 106 PBMCs or splenocytes. The background obtained by stimulation with 
negative peptide was then subtracted from the samples stimulated with the positive peptide. Data 
are represented as cytokine+CD8+/106 PBMC or splenocytes, depending on compartment 
presented.  
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Statistical analysis 
 Each experiment was preformed with groups of 5 mice, unless otherwise indicated, and 
repeated 3 times. Statistical significance was determined using either multiple t-tests with Holm-
Sidak correction for multiple comparisons or 2-way ANOVA with Holm-Sidak correction for 
multiple comparisons. 
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CHAPTER 4 
	  
ANTIGEN-EXPERIENCED CD8+ T CELLS MAINTAIN THE CD8+ T 
CELL RESPONSE FOLLOWING ADENOVIRUS IMMUNIZATION 
 81 
ABSTRACT 
 
 Persistent adenoviral vectors induce transgene-product CD8+ T cells responses that fail 
to contract and are phenotypically heterogeneous. Studies of other persistent viruses have 
demonstrated that asynchronous priming of naïve CD8+ T cells throughout infection is a 
mechanism by which CD8+ T cell pools can be maintained and remain functional during 
persistent infection. Alternatively, functional antigen-experienced CD8+ T cells may respond to 
persistent antigen and thus replenish the response. Here we designed a series of adoptive 
transfer experiments to distinguish between these two possibilities. Our results indicate that naïve 
CD8+ T cells are primarily not responsible for maintaining the transgene product-specific CD8+ T 
cell response. Instead it is likely that persisting transgene product recalls antigen-experienced 
cells back into the response. 
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INTRODUCTION 
 
 Vectors based on adenovirus (Ad) are being extensively developed as vaccine platforms 
against numerous diseases. These highly immunogenic vectors have received such attention in 
part due to their ability to induce potent CD8+ T cell responses. CD8+ T cells are important 
mediators of immune responses and are indispensible in the control of viral infections. The CD8+ 
T cell response following infection with a pathogen that is cleared from the host, termed an acute 
infection, is composed of three distinct stages 110. The first phase is termed the expansion phase 
and occurs following antigenic encounter and activation. During this stage, a CD8+ T cell 
undergoes vast and rapid clonal expansion. Such rapid expansion requires that the cells alter key 
metabolic pathways, including the PI3K-Akt-mTOR pathway, to promote the synthesis of raw 
materials needed to make new cells 105. Armed with antiviral cytokines, such as IFN-γ, and 
cytolytic effector molecules, these newly generated cells traffic to inflamed tissues in the 
periphery to carry out their task of targeting and killing infected cells. After the pathogen is cleared 
from the host, the CD8+ T cell response reaches a maximal peak that delineates the next stage of 
the response, contraction. At the peak of this response, the CD8+ T cell pool is largely made up of 
short-lived effector cells (SLEC) but some memory precursor effector cells (MPEC) can be 
identified 114,121. During the contraction phase, SLEC will die through apoptosis, resulting in a 90-
95% reduction of the peak population. The final phase of the primary CD8+ T cell response is 
memory differentiation. The MPEC that survived the contraction phase contribute to this 
population, which can be composed of effector memory and central memory cells that 
preferentially home to the periphery and lymph nodes, respectively. These cells further 
differentiate and are maintained through self-renewal in the absence of antigen. 
 However, not all pathogens are acutely infecting and instead establish persistent 
infections that are not cleared from the host. Much of our knowledge of the CD8+ T cell response 
during persistent infection comes from models of highly pathogenic, chronically infecting mouse 
lymphocytic choriomeningitis virus (LCMV) clone 13. These studies demonstrate that responding 
CD8+ T cells are significantly impaired and undergo functional exhaustion or are deleted from the 
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T cell repertoire 138,193. Functional exhaustion is characterized by the hierarchical loss of T cell 
functions 110. As the cells become progressively more exhausted, the ability to produce IL-2 is the 
first to be lost followed by TNF-α and then IFN-γ. Additionally, they gradually lose their ability to 
kill target cells and cannot be recalled robustly following secondary antigen encounter.  
 Adenoviruses fall into the group pathogens that establish persistent infections.  
Adenoviruses establish a reservoir in the lymphatic tissues and the genome is especially enriched 
in T cells 65,194. While the viral genome can be isolated tissues following their surgical removal, 
infectious virus cannot be recovered from culturing the tissues 2,58. However, in vitro stimulation 
with mitogens causes virus reactivation and replication 61. As such, it was determined that Ad 
establishes a latent infection with intermittent periods of reactivation.   
 Adenoviral vectors also persist in vivo. Following intramuscular vaccination, the genome 
is enriched in activated CD8+ T cells 123. Importantly, low levels of transgene expression can be 
detected for a year after immunization 123. Many have demonstrated that following immunization 
the transgene product-specific CD8+ T cell response fails to contract 140,195. Additionally, the CD8+ 
T cell population that survives past the peak response to transition into the memory phase 
consists effector and effector memory cells. These qualities of the CD8+ T cell response are 
consistent with those from other persistent viral infection models 152. Indeed there has been a 
report that suggests the Ad-induced CD8+ T cell response becomes exhausted over time 196. 
However, exhaustion and functional impairment are directly linked to the antigen load that 
persists during chronic infection 137,196,197. The LCMV clone 13 model, from which we have 
derived much information about T cell exhaustion, establishes a persistent infection characterized 
by high levels of viremia 198, which progressively pushes the anti-viral CD8+ T cell response 
toward extreme functional impairment 193,197,198. In contrast, adenovirus establishes a latent 
infection with periods of reactivation. Replication-deficient vectors follow a similar pattern.  
Transgene expression can be detected long after immunization, although it is not consistently 
expressed 123. Therefore, the induced antigen-specific CD8+ T cell responses are not constantly 
exposed to high levels of antigen and likely form functional memory responses that may be 
boosted upon antigen re-encounter. Indeed, transgene product-specific CD8+ T cells gradually 
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accumulate in the lymph nodes and reacquire both IL7R-α (CD127) and CD62L many weeks 
after immunization. Further, Ad-induced CD8+ T cells are polyfunctional and undergo robust recall 
responses following secondary exposure to antigen 97,123,130,195.  
 While persistent transgene expression is responsible for maintaining the transgene 
product-specific CD8+ T cell response following Ad immunization, it is unknown how it does so. 
There are two models that may explain how the memory population may be maintained during 
latency. The first is that naïve virus-specific CD8+ T cells are continuously recruited into the 
response by viral antigens expressed during persistence, thus replenishing the population as 
memory cells decay. This asynchronous priming results in a highly heterogeneous virus-specific 
CD8+ T cell population with variable CD62L expression 199. Such variability is generated because 
the individual cells composing the overall population would be primed in different contexts 
depending on when priming occurred during the persistent infection. This also would cause 
functional variability within the population. CD8+ T cells primed during the acute phase of the 
infection can gradually progress toward exhaustion while those primed past the acute phase are 
more functional 200. Asynchronously primed CD8+ T cell responses are common in persistent 
infection models, including polyoma virus 201, γ-herpesviruses 202, and to some extent CMV 203. 
Alternatively, the transgene product-specific CD8+ response induced following Ad immunization 
could be maintained by existing memory cells that are recalled when re-stimulated with 
persistently expressed transgene product. This study was designed to distinguish between these 
two models. The results presented here suggest that naïve CD8+ T cells are primarily not 
responsible for the maintenance of the CD8+ T cell pool following vaccination.  
 
RESULTS 
 
Antigen-specific CD8+ T cells continue to proliferate well after immunization 
 The transgene product-specific CD8+ T cell response following immunization fails to 
contract. In order to determine if the cells that remain continue to proliferate, a bromodeoxyuridine 
(BrdU) incorporation assay was performed. Briefly, C57BL/6 mice were immunized with 1011 vp of 
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an E1-deleted adenoviral vector based on chimpanzee serotype 68 expressing influenza 
nucleoprotein fused to GFP by SIINFEKL, the MHC class I H2kb restricted immunodominant 
epitope of ovalbumin (AdC68-NPOVAGFP). Mice were euthanized ten days, one month, and five 
months after immunization.  72 hours prior to euthanasia, mice were pulsed intraperitoneally (IP) 
with 2 mg/mL BrdU and the drinking water was supplemented every 24 hours with 0.8 mg/mL 
BrdU. Upon euthanasia, lymphocytes were isolated from blood, spleen, and pooled popliteal and 
inguinal lymph nodes. OVA-specific CD8+ T cells were measured using a MHC class I tetramer 
against SIINFEKL. Figure 4.1 shows the frequency of OVA-specific CD8+ T cells that 
incorporated BrdU during the three days of treatment, as well as the frequencies of antigen-
experienced CD8+ T cells (CD44hi) and naïve CD8+ T cells (CD44lo) that incorporated BrdU.  
During the expansion phase following immunization dramatic incorporation of BrdU in the OVA-
specific CD8+ T cells was observed in all tissues. Additionally, high frequencies of other antigen 
experienced CD8+ T cells (CD44hi) had incorporated BrdU. This was likely because there are 
other antigens besides SIINFEKL present in the vaccine that triggered a T cell response. Taken 
together, the high rates of BrdU incorporation reflect the massive amount of proliferation these 
cells undergo following their induction. By normalizing the percentage of BrdU incorporation to 
that of the CD44hi cells, it can be seen that the OVA-specific CD8+ T cells proliferate more 
robustly than the general CD44hi population. One month after immunization, BrdU incorporation 
was reduced in all tissues but was still elevated. The frequency of OVA-specific CD8+ T cells that 
had incorporated BrdU at this time typically ranged between 10-15%, except in the lymph nodes, 
where about 50% continued to incorporate BrdU (Figure 4.1C). In all tissues only 10% of the 
CD44hi cells incorporated BrdU. Five months after immunization, BrdU incorporation was further 
reduced in all tissues but continued to be detected in the lymph nodes, where about 10% of OVA-
specific CD8+ T cells incorporated BrdU (Figure 4.1C). While the frequency of incorporation was 
not particularly high, the OVA-specific cells still proliferated about 3.5 times more than CD44hi 
cells. Taken together these results suggest that following induction with an Ad-based vaccine, 
transgene product-specific CD8+ T cells proliferate robustly and this proliferation continues for at 
least five months after immunization, particularly in the lymph nodes. 
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FIGURE 4.1. Transgene product-specific CD8+ T cells continue to proliferate 
 months after induction. 
 
 
 
Shows Bromodeoxyuridine (BrdU) incorporation by CD8+ T cells isolated from blood [A], spleen [B], and 
lymph nodes [C]. Briefly, C57BL/6 mice were immunized with 1011 vp of AdC68-NPOVAGFP and 
euthanized at the indicated times. 72 hours prior to euthanasia, mice were pulsed with 2mg/mL BrdU and 
drinking water was supplemented with 0.8 mg/mL BrdU. Frequencies of OVA-specific CD8+ T cells that had 
incorporated BrdU were determined from individual mice by staining with an OVA-specific tetramer. As 
controls, BrdU incorporation was analyzed on antigen-experienced (CD44hi) cells and naïve (CD44lo) cells. 
Data are represented as mean frequency (%) ± standard deviation (SD) of BrdU+CD8+ per CD8+. The 
second column of charts show the data represented as fold change in relation to CD44lo BrdU incorporation. 
Frequencies were compared to CD44lo population and were compared using multiple t-tests by Holm-Sidak 
method. The following p values were obtained: [A] Day 10: OVA: p<0.0001, CD44hi: p=0.0007; 1 month: 
OVA: p=0.0135, CD44hi: p=0.0262; 5 month: CD44hi: p=0.0185; [B] Day 10: OVA: p<0.0001, CD44hi: 
p=0.0001; 1 month: OVA: p=0.002, CD44hi: p=0.001; 5 month: OVA: p=0.0008, CD44hi: p=0.0048; [C] Day 
10: OVA:p<0.0001, CD44hi: p<0.0001; 1 month: OVA: p=0.0049, CD44hi: p<0.0001; 5 month: OVA: 
p=0.0089.	  Significant differences are indicated by * for p-values ≤ 0.05-0.01, ** p-values < 0.01-0.001, *** p-
values ≤ 0.001-0.0001, **** p-values < 0.0001. Lines show the comparison groups. 
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Naïve cells fail to respond to low-levels of persistent antigen following adenoviral 
immunization 
 
 Studies of other persistent infections have revealed that the CD8+ T cell pool that persists 
during infection is made up of asynchronously primed naïve T cells 201,204. In order to determine if 
naïve T cells proliferate in response to low-levels of transgene that persist following immunization, 
3.14 x 106 naïve Thy1.1+ CD8+ T cells were isolated from the spleen and adoptively transferred 
into congenic Thy1.2+ C57BL/6 mice that had been immunized 3 weeks earlier with either 1011 vp 
AdC68-NPOVAeGFP or 1011 vp AdC7-HIVgag, as a negative control. Mice were bled at the 
indicated times and the number of transferred OVA-specific CD8+ T cells was determined by 
staining with a MHC class I tetramer specific to SIINFEKL and an antibody to Thy1.1 to 
distinguish donor from host cells. As shown in Figure 4.2A, in general naïve cells did not expand 
following transfer into immunized mice. In a notable exception, naïve cells transferred into one 
mouse not only engrafted but also robustly expanded and persisted for many months after 
transfer (Figure 4.2B). 
 Such disparate results between the one animal and the others may indicate that 
insufficient naïve precursors specific to OVA were transferred into the four mice in which naïve 
CD8+ T cells did not expand. The precursor frequency of naïve CD8+ T cells specific to a given 
antigen is rare. Estimates vary from epitope to epitope but generally range from as low as 1 
precursor per million naïve CD8+ T cells to ~80 precursors per million naïve CD8+ T cells 205,206. 
The frequency of CD8+ T cells specific to SIINFEKL (OVA) bound to H2kb was estimated to be 
approximately 1 cell for every 150,000 CD8+ T cells, which translates into approximately 130 cells 
within the total CD8+ T cell population from the lymph nodes and the spleen 207. Therefore, it is 
possible that the number of naïve OVA-specific CD8+ T cells transferred ranged from three cells, 
on the lower end of the spectrum, to twenty cells at the higher end of the spectrum per mouse. As 
the size of the precursor population affects the magnitude of the primary response 207,208 and 
because it was possible that OVA-specific CD8+ T cell precursors were not transferred, it was 
important to determine if sufficient numbers of naïve OVA-specific CD8+ T cells were transferred. 
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To this end, 3.14 x 106 naïve Thy1.1+ CD8+ T cells were transferred via tail vein injection into 
naïve Thy1.2+ C57BL/6 mice. After 18 hours, mice were immunized with either 1011 vp AdC68-
NPOVAGFP or 1011 vp AdC68-rab.gp, as a negative control. The donor OVA-specific response 
was measured in the blood two weeks later. The donor OVA-specific CD8+ T cells expanded very 
robustly following immunization (Figure 4.2C). This observation indicates that sufficient numbers 
of naïve precursors were transferred in order to observe a measurable response. Therefore, 
these results suggest that the antigenic load that persists three weeks after immunization with an 
adenovirus-based vaccine in general does not suffice to prime a de novo CD8+ T cell response. 
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FIGURE 4.2. Naïve transgene product-specific CD8+ T cells generally do not 
respond to persistent transgene product. 
 
 
Groups of Thy1.2+ C57BL/6 mice were immunized with 1011 vp AdC68-NPOVAGFP or 1011 vp AdC7-
HIVgag, as a negative control. Three weeks later, 3.14 x 106 naïve congenic (Thy1.1+) CD8+ T cells were 
adoptively transferred via tail vein injection into each group. Mice were bled at the indicated time points for 
[A] and [B]. Figure [B] shows a single mouse with exceptionally numbers of high donor cells. Frequencies 
of donor-specific (Thy1.1+) OVA-specific CD8+ T cells were determined by staining with an OVA-specific 
tetramer. Data for [A] and [B] are represented as mean numbers of Thy1.1+ OVA+ CD8+ T cells per 106 live 
PBMCs. Lines in [A] represent SD. [C] shows that sufficient naïve precursors specific to OVA were 
transferred in [A] and [B]. Briefly, groups of Thy1.1+ C57BL/6 mice were adoptively transferred with 3.4 x 
106 naïve congenic (Thy1.2+) CD8+ T cells. 18 hours later, each group was immunized with 1011 vp of 
AdC68-NPOVAGFP or 1011 vp AdC68-rab.gp. Mice were bled 2 weeks later and OVA-specific CD8+ T cells 
were determined. Data shown for each plot is represented as mean ± SD. Significance was determined by 
unpaired t-test resulting in a p-value of 0.0241.  
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Antigen experienced cells continue to expand in response to low-level of 
persistent transgene product 
 
 The antigenic load that persists three weeks following immunization with an adenoviral 
vector is not enough to prime a de novo CD8+ T cell response. Therefore, it is likely that antigen-
experienced cells are recalled when they encounter persistent antigen. To further investigate if 
antigen-experienced cells respond to the low levels of persistent antigen, we transferred antigen-
experienced CD8+ T cells using the same protocol as described above. Briefly, C57BL/6 Thy1.1+ 
mice were immunized IP with 107 PFU of vaccinia virus expressing the NPOVAGFP transgene 
(vac-OVA). These mice were euthanized one week after immunization, which coincides with the 
peak of the OVA-specific CD8+ T cell response. At the time of euthanasia, splenocytes were 
isolated, CD8+ T cells were negatively selected and then 3.14 x 106 cells were transferred via tail 
vein injection into congenic (Thy1.2+) C57BL/6 mice that were immunized three weeks earlier with 
1011 vp AdC68-NPOVAGFP or, as a negative control, 1011 vp AdC7-HIVgag. Mice were bled at 
the indicated times and the donor (Thy1.1+) OVA-specific CD8+ transferred T cell response was 
measured.  
 Figure 4.3 shows the OVA-specific CD8+ T cell responses of donor CD8+ T cells that 
were transferred 1 week after their induction with vac-OVA. OVA-specific CD8+ T cells transferred 
into Ad-gag mice engrafted and persisted through the course of the experiment without any 
measurable expansion. However, the opposite was observed following transfer into Ad-OVA 
immunized mice. Over the course of eight weeks, the transferred cells steadily expanded, 
reaching approximately 300 cells per 106 live PBMCs (Figure 4.3A). Several months after 
transfer, the donor cell numbers showed variation. Numbers from 3 mice were largely stable but 
remained elevated. However, donor OVA-specific CD8+ T cells in two Ad-OVA immunized mice 
continued to proliferate extensively until about 8 months after transfer. These results indicate that 
antigen-experienced transgene product-specific CD8+ T cells can be maintained and further 
respond to low-levels of persistent transgene expression for many months. 
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Low levels of persistent antigen maintains an effector-like phenotype 
 In order to measure the consequences of long-term stimulation with a low-level antigen 
on the fate of the transferred cells, expression of CD62L and CD127 were measured on OVA-
specific CD8+ T cells circulating in blood eight weeks following transfer into Ad-OVA or Ad-gag 
immunized mice. OVA-specific CD8+ T cells transferred into Ad-gag immunized mice were 
CD62Lhi and had CD127 expression that was comparable to naïve cells (Figure 4.4A), indicating 
that these cells had rested down and transitioned into memory. On the other hand, OVA-specific 
CD8+ T cells transferred into the Ad-OVA mice were predominantly CD62Llo with CD127 
expression also comparable to naïve cells (Figure 4.4A). KLRG1 was included at a later time 
point to measure for stimulation history. At the peak response eight months after transfer, the 
transferred OVA-specific CD8+ T cells largely remained CD62Llo. However, they had higher levels 
of CD127 than naïve cells. Taken together, these three markers indicate that these cells are 
maintained in an effector memory phenotype. Supporting the notion that the expansion observed 
(Figure 4.3A) is due to continuous antigenic stimulation, the transferred OVA-specific CD8+ T 
cells were predominantly KLRG1hi, which reflects stimulation history and may indicate that these 
cells are reaching a point after which they may no longer continue to divide.  
 CD8+ T cells responding to chronic infections are at risk of losing effector functions. This 
is characterized by progressive loss of ability to produce multiple cytokines. IL-2 production is the 
most sensitive to chronic stimulation and, as such, is the first cytokine to be lost. This is followed 
by loss of TNF-α production and, upon exhaustion, IFN-γ production is also lost 209. Persistent 
transgene product expression appears to lead to the continued stimulation of antigen-
experienced transgene product-specific CD8+ T cells (Figure 4.3). There has been some debate 
over whether or not adenovirus vaccination drives responding CD8+ T cells toward some degree 
of exhaustion 140,196. Therefore, in order to test the functionality of antigen-experienced cells in the 
presence of low levels of persistent transgene product, intracellular cytokine staining was 
performed. Briefly, Thy1.1+ C57BL/6 mice were immunized IM with 1011 vp AdC68-NPOVAGFP 
or 1011 vp AdC7-HIVgag, as a negative control. Three weeks later, CD8+ T cells from congenic 
Thy1.2+ C567BL/6 mice were adoptively transferred into them. One week prior to transfer, donor 
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mice had been vaccinated with 107 PFU vac-OVA and the following day they had been injected 
with 5 x 106 splenocytes from transgenic OT-1 C57BL/6 Thy1.2+ mice.  CD8+ T cells from OT-1 
mice are specific to the SIINFEKL epitope encoded in the Ad-OVA vector. Therefore, they were 
transferred to increase the frequency of responding OVA-specific CD8+ T cells in order to enable 
better detection during intracellular cytokine staining. Mice were bled at the indicated time points 
and in vitro re-stimulation was performed to detect donor OVA-specific CD8+ T cell production of 
IFN-γ, TNF-α, and IL-2.   
 Transfer of OVA-specific CD8+ T cells into Ad-OVA immunized mice results in a number 
of OVA-specific CD8+ T that produce cytokines upon re-stimulation that remain fairly stable over 
time (Figure 4.5A), although there was some fluctuation in the response at certain time points. 
This fluctuation may be due to an internal boosting effect from the persistent antigen that is not 
consistently expressed 123.  Additionally, the cells could be producing cytokines other than those 
measured in this assay. The CD8+ T cells transferred into Ad-gag immunized mice did not 
produce cytokines following restimulation. This could be due to their egress from the blood as 
they transitioned into memory. The profile of the OVA-specific CD8+ cytokine secreting T cells 
was fairly stable as well. Two weeks after transfer, the cytokine secreting cells were largely 
composed of cells that produce IFN-γ alone or in combination with TNF-α following re-stimulation, 
which is consistent with highly activated effector cells  (Figure 4.5B). Although the total number 
of cytokine secreting cells was reduced six months following transfer (Figure 4.5C), the profile 
was similar to that of the cytokine producing cells at two weeks following transfer. However, the 
response was clearly dominated by cells that produce IFN-γ alone following re-stimulation. While 
the antigenic load clearly supports effector and effector memory cells (Figures 4.4, 4.5B, 4.5C), 
these cells do not appear to be greatly losing effector functions.  
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FIGURE 4.3. Antigen-experienced CD8+ T cells respond and expand in response to 
persistent antigen. 
 
 
Groups of Thy1.2+ C57BL/6 mice were immunized with 1011 vp AdC68-NPOVAGFP or 1011 vp AdC7-
HIVgag, as a negative control. Three weeks later, 3.14 x 106 congenic (Thy1.1+) CD8+ T cells were 
adoptively transferred via tail vein injection into each group. Transferred cells were isolated from mice 
immunized 1 week earlier with 107 PFU vaccinia virus expressing NPOVAGFP (vac-OVA). Mice were bled 
at the indicated time points. Frequencies of donor-specific (Thy1.1+) OVA-specific CD8+ T cells were 
determined by staining with an OVA-specific tetramer. Data are represented as mean numbers ± SD of 
Thy1.1+ OVA+ CD8+ T cells per 106 live PBMCs. The bar indicates the mean of the group. Differences 
between numbers of OVA-specific CD8+ T cells transferred into Ad-OVA and Ad-gag mice were determined 
at each time point using multiple t-tests with Sidak-Bonferroni correction. The following p-values were 
obtained: [A]: 6 weeks: p=0.0372, 8 weeks: p=0.0336 [B]: 8 months: p=0.0295.  
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FIGURE 4.4. Antigen-specific CD8+ T cells maintain an effector memory phenotype 
regardless of presence of persistent antigen. 
 
 
 
 
 
Expression of CD62L and CD127 was measured on donor (Thy1.1+) OVA-specific CD8+ T cells 8 weeks [A] 
and 8 months [B] after transfer into mice immunized with 1011 vp AdC68-NPOVAGFP (top row of graphs) or 
AdC7-gag (bottom row of graphs). KLRG1 was included at 8 months after transfer. Grey histograms 
represent staining for naïve host CD8+ T cells. Open histograms represent concatenated data from 5 mice 
for each group.  
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FIGURE 4.5. Antigen-experienced CD8+ T cells do not lose function over time in 
response to persistent antigen.  
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Shows the kinetics of total cytokine-producing donor cells [A] and the cytokine profile 12 weeks following 
immunization Groups of Thy1.1+ C57BL/6 mice were immunized with 1011 vp AdC68-NPOVAGFP or 1011 vp 
AdC7-HIVgag, as a negative control. Three weeks later, 3.14 x 106 congenic (Thy1.2+) CD8+ T cells were 
adoptively transferred into each group. Congenic mice were transferred with 5 x 106 OT-1 cells and 
immunized with 107 PFU vac-OVA 1 week prior to transfer into Thy1.1+ mice. Mice were bled at the 
indicated time points and PBMCs were stimulated with either SIINFEKL peptide or the equivalent amount of 
an irrelevant peptide to measure background stimulation. [A] Shows the number of cytokine producing cells 
following the subtraction of background stimulation. The profiles of donor CD8+ cells producing cytokine 
combinations are shown for 2 weeks after transfer [B] and 6 months after transfer [C] and were determined 
by summation of Boolean gates for each cytokine. Data in each figure is represented as the number of 
donor (Thy1.2+) CD8+ producing cytokines per 106 live PBMC. Standard deviation is included for [B] and 
[C]. In [A], the bar represents the mean. Significance between rapamycin- and sham–treated groups was 
determined for each time point using multiple t-tests with Holm-Sidak correction for multiple comparisons for 
[A] and 2way ANOVA with Holm-Sidak correction for multiple comparisons for [B] and [C].  The following p-
values were obtained: [A] 4 weeks: p=0.0003, 6 weeks: p=0.0003; [B] G+T+: p=0.0048; G+: p=0.0002 [C] 
G+:p<0.0001
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DISCUSSION 
 
 The experiments presented in this chapter were designed to address how the CD8+ T cell 
pool that fails to contract following immunization with an Ad-based vaccine is maintained. Two 
possible scenarios can be envisioned. Naïve CD8+ T cells could be recruited continuously into the 
response as they encounter their cognate antigen during Ad persistence. These cells would 
ultimately replace the terminally differentiated cells as they decay, thereby maintaining a stable 
response. Alternatively, CD8+ T cells primed early in the response that differentiated into central 
memory cells could be restimulated as they encounter antigen during Ad persistence and thus 
replenish the on-going CD8+ T cell response. The data presented here largely support the latter 
scenario. 
 Asynchronous priming of naïve CD8+ T cells is a strategy commonly employed to 
maintain stable memory T cell numbers during various persistent infections, including mouse 
polyoma virus and CMV. Antigen-specific CD8+ T cells that respond and persist during these 
infections are characterized by a large degree of heterogeneity in their expression of such 
markers as CD62L, CD127, and CD27 201,204.  As transgene product-specific CD8+ T cells elicited 
by Ad vector vaccination are also highly heterogeneous 123,140,195, it stood to reason that this 
heterogeneity could reflect that the transgene product-specific CD8+ T cells are in various stages 
of differentiation due to priming with their antigen at different times during the response. However, 
when naïve cells were transferred into Ad immunized mice after clearance of most of the acutely 
transduced cells, the overall pattern was that the cells did not expand in response to transgene 
product. This suggests that naïve CD8+ T cells are not recruited to maintain the elevated 
transgene product-specific CD8+ T cell response. Indeed, while adult mice immunized with an Ad-
based vaccine 8 weeks after being thymectomized mount slightly lower transgene product-
specific CD8+ T cell responses, the kinetics of the response are not altered and the cells do not 
have a more distinct contraction as would be expected if naïve cells were responsible for 
maintaining the CD8+ T cell pool 140. Interestingly though, transferred naïve CD8+ T cells in one 
animal showed robust expansion and persisted for many months. Statistically, this was 
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considered an outlier. However, the results may be biologically relevant, perhaps indicating that 
at the time of transfer the Ad genome was more transcriptionally active, and thus producing more 
transgene product, in that mouse than in the others.  
 While these data do suggest that naïve CD8+ T cells are primarily not responsible for 
maintaining the elevated CD8+ T cell response, it is important to recognize the limitations of my 
approach. Despite demonstrating that enough transgene product-specific CD8+ T cell precursors 
were transferred (Figure 4.1B), the recipient mice may not have permitted their engraftment. The 
recipient mice could not be T cell depleted prior to transfer as this would have removed the cells 
that harbor persisting Ad vector genomes and thus may not have had available niches in which 
the congenic naïve cells could engraft. Other groups have demonstrated a role for naïve CD8+ T 
cells in responding to persistent infection by creating partial hematopoietic chimeric mice 
201,202,204. To accomplish this, persistently infected mice were treated with a low dose of busulfan, 
a non-immunosuppressive myeloablative agent, and then partially reconstituted with naïve, 
congenic bone marrow. This creates a population of stem cells to give rise to naïve CD8+ T cells. 
While it has been reported that busulfan does not disturb virus-specific CD8+ T cell responses 201, 
it would be critical to determine that the adenovirus reservoir is not affected and it persists in the 
lymphatics. It has been demonstrated that bone marrow is a reservoir for central memory CD8+ T 
cells 210. Whether or not these bone marrow-derived cells harbor persistent adenovirus has yet to 
be confirmed.  
 To test if antigen-experienced transgene product-specific CD8+ T cells maintain the CD8+ 
T cell pool, splenic OVA-specific CD8+ effector T cells were transferred into Ad immunized mice. 
Vast and continuous accumulation of donor OVA-specific CD8+ T cells was observed. This largely 
indicates that antigen-experienced cells are responsible for the maintenance of the CD8+ T cell 
pool following vaccination with an Ad-based vaccine. However, these experiments do not reveal 
the nature of the antigen-experienced cell responsible. We would expect that the population of 
OVA-specific CD8+ T cells present in the donor spleen seven days after immunization with vac-
OVA would be heterogeneous, containing both short-lived effector cells and memory precursor 
cells. Therefore, we cannot rule out the possibility that a small number of memory cells were 
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transferred. In general, we would expect that those cell types would be responsible as terminally 
differentiated antigen-specific CD8+ T cells have a limited capacity for proliferation and would be 
expected to decay over time. Further experiments would be warranted to determine the cell type 
involved in this expansion. 
 The cells that continued to accumulate in this transfer model had at 8 months after 
transfer an effector memory phenotype and expressed high levels of KLRG1, a marker that 
reflects the history of antigen stimulation. Therefore, the high expression of KLRG1 on these cells 
likely reflects that they continue to encounter their antigen. As such it would be important to 
assess if the donor derived antigen-specific CD8+ T cell response requires antigen in order to 
persist. In some models of chronically infecting viruses, especially LCMV clone 13, virus-specific 
CD8+ T cells become addicted to antigen. Once antigen is removed from the system, or the 
CD8+T cells are transferred to a naïve environment, the cells die because they minimally express 
receptors for IL-7 and IL-15, which drive the homeostatic turnover over memory cells, thereby 
promoting their survival 99. However, LCMV clone 13 is not equivalent to adenovirus. There is 
some evidence to suggest that transgene product-specific memory CD8+ T cells induced following 
Ad immunization do not require antigen to be maintained. Utilizing Ad vectors encoding a 
SIINFEKL expression cassette that could be temporally regulated using the Tet-OFF system, the 
Bramson group demonstrated that the primary SIINFEKL-specific CD8+ T cell response only 
requires SIINFEKL expression for the first two months following immunization, after which they 
become antigen-independent 211. However, whether these cells remain antigen-independent 
many months following immunization remains to be elucidated. Therefore, it would be critically 
important to assess at a longer interval after Ad immunization the antigen-specific CD8+ T cells’ 
responsiveness to IL-7 and IL-15 as a measure of their capacity for homeostatic self-renewal and 
dependency on antigen.   
 The continuous accumulation observed in some mice resembles a phenomenon termed 
memory inflation, which is used to describe the accumulation of CD8+ T cells responding to 
certain epitopes following cytomegalovirus infection. CD8+ T cells that respond to inflationary 
epitopes have an effector memory phenotype and are highly functional, thus capable of both 
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producing cytokines following restimulation and lysing target cells 204. This phenomenon occurs in 
the absence of viral replication, CMV vectors limited to a single cycle of replication continue to 
induce CD8+ T cell inflation212.  Indeed, memory inflation has recently been described following 
immunization with a β-galactosidase expressing adenovirus 213. Antigen-specific CD8+ T cell 
inflation occurs in response to immunodominant epitopes that due to their high affinity 
outcompete lower affinity peptides for MHC class I binding 214. The immunodominant MHC class 
I-restricted epitope of ovalbumin, SIINFEKL, is a high affinity epitope that causes inflation in the 
context of a CMV vector 215. It is therefore likely, that we observed a similar effect in the study 
presented here. Inflation following Ad immunization was followed for two epitopes from β-
galactosidase 213, one was inflationary and the other was not. As such different epitopes 
processed from the same protein have different capacities to induce inflation. As the SIINFEKL 
epitope included in the Ad vectors used here was part of a larger transgene, the CD8+ T cell 
response to additional epitopes in the transgene should be monitored for their inflationary ability. 
This could have important implications in the design of transgenes used in adenoviral vaccines to 
elicit protective immune responses against many pathogens, particularly those which a large pool 
of effector memory CD8+ T cells are required for protection.  
 Given that antigen-experienced transgene product specific CD8+ T cells appear primarily 
responsible for the maintenance of their memory pool following Ad immunization, it would be 
likely that these cells periodically reencounter transgene product, which promotes their continued 
expansion. Interestingly this indicates that the cells harboring persistent adenovirus vector, whose 
transgene’s expression is controlled by a constitutively active promoter, are not destroyed by the 
on-going transgene product-specific CD8+ T cell response. The mechanism by which this occurs 
is unclear. Gene products from the E3 domain are responsible for immunomodulation, including 
blocking MHC-I antigen presentation and mediating resistance to T cell cytolysis and cytokines 
that promote cell death, such as TNF-α 79,81,83. However, later generation Ad vectors, including 
those used in this study, are deleted in this domain but still retain the ability to persist in vivo 123. 
Alternatively, the persistence of an antigen depot in activated T cells could demonstrate that 
these cells are resistant to CD8+ T cell-mediated lysis.  
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MATERIALS AND METHODS 
 
Vectors and immunizations 
 All experiments were performed with E1-deleted adenovirus vectors based on 
chimpanzee serotype 68 (AdC68) or chimpanzee serotype 7 (AdC7). Mice were injected IM with 
1011 viral particles (vp) of either a vector encoding influenza nucleoprotein fused to green 
fluorescent protein and the immunodominant MHC class I restricted epitope of ovalbumin 
(SIINFEKL) (AdC68-NPOVAGFP), a vector encoding the rabies virus glycoprotein (AdC68-
rab.gp), or a vector encoding gag of HIV-1 (AdC7-HIVgag). Additional experiments used a 
vaccinia virus vector encoding the NPOVAGFP fusion protein (vac-OVA). Vectors for 
immunization were diluted to the appropriate concentration in sterile PBS (Cellgro; Manassas, 
VA). Mice were immunized intramuscularly (IM) with 50 µL of diluted vector in each hind limb, for 
a total of 100 µL per mouse. Where indicated, mice were immunized intraperitoneally (IP) with 
200 µL of diluted vector. 
 
Mice 
 Female 4 to 6 week old mice Thy1.2+ C57BL/6 mice were purchased from the National 
Cancer Institute (Frederick, MD). Thy1.1+ C57BL/6 mice were purchased from Jackson 
Laboratories (Bar Harbor, ME). Mice were housed in the vivarium at the Wistar Institute 
(Philadelphia, PA). All experiments and procedures were performed in accordance with approved 
animal protocols. C57BL/6 OT-1+ breeding pairs were purchased from Jackson Laboratories and 
were then bred at Wistar following approved breeding protocols.  
 
Lymphocyte isolation 
 Blood was collected via submandibular bleeding into 1 mL of 4% sodium citrate. 1 mL of 
L-15 (Cellgro) was added after collection. Peripheral blood mononuclear cells (PBMC) were 
isolated by Histopaque-1083 (Sigma-Aldrich; St. Louis, MO) gradient purification. PBMC were 
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collected and washed in L-15 containing 1% fetal bovine serum (FBS) (Gemini Bio Products; 
West Sacramento, CA). Red blood cells were lysed for 5 minutes at room temperature using RBC 
lysis buffer (eBioscience; San Diego, CA).   
 Spleens were homogenized against a 70 µm filter screen and collected in pre-warmed L-
15 containing 1% FBS. Cells were pelleted at 1500 rpm for 5 minutes. Pellets were resuspended 
in RBC lysis buffer for 5 minutes at room temperature to lyse red blood cells.  
 Popliteal and inguinal lymph nodes were collected from both hind limbs and 
homogenized against a 70 µm filter screen. Lymphocytes were collected in L-15 containing 1% 
FBS and washed once with the same media. Lymphocytes isolated from peritoneal lavage were 
collected by flushing the peritoneal cavity with 10 mL L-15 containing 1% FBS and washing once. 
 
BrdU Assay 
 C57BL/6 mice were immunized with 1011 vp AdC68-NPOVAGFP. Mice were euthanized 
10 days, 1 month, or 5 months after immunization. Three days prior to euthanasia, mice were 
injected IP with 2 mg bromodeoxyuridine (BrdU) (Sigma-Aldrich) dissolved in 200 µL PBS. 
Additionally, drinking water was supplemented with 0.8 mg/mL BrdU and 1% sucrose (Sigma-
Aldrich). Water was changed and fresh solution was added each day prior to euthanasia.    
 Blood, spleens, and popliteal and inguinal lymph nodes were isolated and prepared as 
described above. Cells were stained and permeabilized using BrdU Flow kit (BD Pharmingen; 
Franklin Lakes, NJ) following the manufacturer’s protocol. Briefly, the cell surface was first 
stained with PerCP-Cy5.5-labeled anti-CD8 (BD Pharminogen), PE-Cy7-labeled anti-CD44 (BD 
Pharminogen), APC-labeled tetramer against the immunodominant MHC class I restricted epitope 
of Ovalbumin (SIINFEKL) (courtesy of Dr. E John Wherry), and Live/Dead fixable aqua dye (Life 
Technologies, Carlsbad, CA) for 30 minutes at 4°C. Following a PBS wash, samples were 
permeabilized with Cytofix/cytoperm (BD Biosciences; Franklin Lakes, NJ) for 30 minutes at 4°C 
then washed with 1X Perm/Wash (BD Biosciences). Cells were permeabilized further with 
Cytoperm Permeabilization Buffer Plus (BD Biosciences) for 10 minutes on ice and then washed 
as before. Samples were re-fixed by treating with 100 µL Cytofix/cytoperm and washed. To 
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expose BrdU for staining, samples were treated with 100 µL of 300 µg/mL DNase solution (BD 
Pharmingen) for 1 hour at 37°C and washed with 1X Perm/Wash. Samples were then stained for 
20 minutes at room temperature with FITC-labeled anti-BrdU (BD Pharminogen) diluted 1:50 in 
1X Perm/wash and then washed.   
 
Adoptive Transfers 
 CD8+ T cells used in transfer experiments were harvested from C57BL/6 Thy1.1+ mice. 
Where indicated, naïve cells were isolated and transferred or cells were isolated from mice that 
had been immunized intraperitoneally (IP) 7 days earlier with 107 plaque-forming units (PFU) vac-
OVA. On the day of transfer, these mice were euthanized and splenocytes were isolated. CD8+ T 
cells were isolated by negative selection using EasySep Mouse CD8+ T Cell Enrichment Kit 
(Stemcell Technologies; Vancouver, BC) following the manufacturer’s protocol.  
 Isolated CD8+ T cells were then transferred intravenously (IV) to recipient C57BL/6 
(Thy1.2+) via tail vein at a concentration of 3.14 x 106 cells per mouse. Recipient mice had been 
immunized 3 weeks earlier with 1011 vp of either AdC68-NPOVAGFP or AdC7-HIVgag.gp, as a 
negative control.  
 
Intracellular Cytokine Staining (ICS) 
 Lymphocytes were plated on a 96-well plate in 200 µL of DMEM supplemented with 2% 
Mixed Lymphocyte Culture medium. Lymphocytes were stimulated in the presence of Golgi Plug 
(BD Biosciences) either with a positive peptide, SIINFEKL, or with a negative peptide, WIZX-2 
from rabies virus. Each was used at 2.5 µg/mL. Stimulation was performed for 5 hours at 37°C in 
10% CO2. Following stimulation, lymphocytes were stained at 4°C for 30 minutes with 
fluorochrome-labeled antibodies against CD8, CD44, Thy1.1 or Thy1.2 to distinguish donor cells, 
and with Live/Dead Fixable Aqua dye to exclude dead cells from analysis. Cells were washed 
once and then permeabilized with 100 µL Cytofix/Cytoperm for 30 minutes at 4°C. Cells were 
then washed with 1X Perm/Wash and additionally stained for 30 minutes at 4°C with 
fluorochrome-labeled antibodies against IFN-γ, TNF-α, and IL-2 diluted 1:100 in 1X Perm/Wash. 
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Following staining, cells were washed and fixed with BD Fixative (BD Biosciences). Samples 
were stored at 4°C until analysis. 
 Cells were analyzed with a BD LSR-II flow cytometer (BD Biosciences) and post 
acquisition analysis was performed with FlowJo v.9.4 software (TreeStar, Ashland, OR). Samples 
were first gated to identify lymphocytes based on forward scatter area (FSC-A) and side scatter 
(SSC). Doublets were then removed using a plot of forward scatter height (FSC-H) vs. FSC-A. 
Live lymphocytes were then gated based on exclusion of Live/Dead stain. Donor CD8+ T cells 
were identified by plotted Thy1.1/1.2+ events vs. CD8+ events. CD8+ T cells were then gated on 
each intracellular cytokine. Boolean gates were then created to identify all possible cytokine 
combinations, equaling 2n combinations, where n is equal to the number of individual cytokines 
measured.  
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ABSTRACT 
 
 In this study we tested the effect of neutralizing antibodies to different serotypes of E1-
deleted adenovirus (Ad) vectors on the immunogenicity of the homologous adenovirus vector or a 
vector derived from a heterologous serotype. Our results show that, as expected, even low titers 
of passively transferred neutralizing antibodies significantly reduce the homologous vectors’ 
ability to elicit transgene-specific CD8+ T cell responses. In addition antibodies changed the fate 
of transgene product-specific CD8+ T cells by promoting their transition into the central memory 
cell pool, which resulted in markedly enhanced expansion of transgene product-specific CD8+ T 
cells following a boost with a heterologous Ad vector. Non-neutralizing antibodies induced to one 
adenoviral serotype had no effect on the magnitude of transgene product-specific CD8+ T cells 
induced by a distinct vector nor did such antibodies promote induction of more resting memory 
CD8+ T cells. These results show that antibodies to an adenovirus vaccine carrier not only affect 
the magnitude but also the flavor of a vector-induced CD8+ T cell response.  
 
 
 
 
 
 
 
 
 
 
 
Adapted from: The effect of adenovirus-specific antibodies on adenoviral vector-induced 
transgene product-specific T cell responses. JC Small*, LH. Haut*, A Bian, HCJ Ertl. Journal 
of Leukocyte Biology. In press.  
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INTRODUCTION 
 
 E1-deleted adenovirus (Ad) vectors derived from human serotype 5 (AdHu5) are highly 
immunogenic, inducing potent B and T cell responses against its viral components and products 
of transgenes encoded from its genome. As such, these vectors are being developed as vaccine 
platforms against a wide array of pathogens. However, a concern with the use of AdHu5 vectors 
is that humans are commonly infected with the virus during childhood and therefore have pre-
existing immunity against the vector. Animal studies demonstrated that virus-neutralizing 
antibodies (VNAs) against AdHu5 reduce transduction of target cells 92 by blocking its interaction 
with the coxsackie and adenovirus receptor (CAR) 91 thereby reducing transgene expression, 
ultimately dampening the vector’s immunogenicity 93,216,217. However, AdHu5 is more 
immunogenic than other vaccine platforms 217. As such, an AdHu5-based vaccine encoding a 
transgene made up of HIV-1 clade B gag/pol/nef was developed to induce HIV-specific T cell 
responses with the goal of reducing viral load in infected individuals. Pre-clinically, the vector 
protected nonhuman primates challenged with the SIV-HIV chimera SHIV-89.6P 218 and early 
phase trials demonstrated the vaccine’s immunogenicity in humans 219. The phase IIB, or STEP, 
trial was designed to test the efficacy of this vaccine in individuals at high risk for HIV-1 
acquisition and was tested in individuals who were both AdHu5 seronegative and seropositive. 
The trial was halted early after interim analysis revealed that the vaccine was not efficacious. 
More worrying though was that further analysis also demonstrated a significantly increased risk of 
HIV acquisition among men who were both AdHu5 seropositive and uncircumcised at the time of 
immunization 220, although this risk appears to become less pronounced with time 221. While most 
vaccinees mounted immune responses to the HIV-1 antigens encoded in the vector, the 
responses were not very strong and T cell responses were also narrowly focused on one to three 
epitopes. Nevertheless, the reduced immunogenicity in seropositive participants could not explain 
their increased risk of HIV infection. A subsequent trial, HVTN505, was designed to test an HIV-1 
vaccine regimen using a DNA vaccine prime followed by an AdHu5 boost in AdHu5 seronegative 
individuals. Again, the trial was halted because it failed to show efficacy and observed a non-
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significant trend towards higher infection rates in vaccine recipients compared to placebo 
recipients 222. Although a number of theories were formulated and tested to explain the increased 
acquisition rates in the STEP trial 223,224 the reasons for the apparent increased susceptibility to 
HIV-1 infection in AdHu5 vaccine recipients remain elusive.   
 To overcome the problem of pre-existing immunity, novel recombinant Ad vectors are 
being evaluated. Several groups are developing vectors based on alternative human serotypes 
such as HAdV-26 (AdHu26) 225 or HAdV-35 226. While these so-called “rare” human serotypes are 
potently immunogenic, humans are still exposed to these viruses and, depending on the 
geographic region, they either lack VNAs to these serotypes or they carry low titers 227. Of note, 
regions where the development of an HIV vaccine is critical to public health tend to have 
seroprevalence rates to AdHu26 that are comparable to those AdHu5 228. Therefore, these 
vectors may face the same challenges as vectors derived from AdHu5. Alternatively, vectors 
derived from non-human adenovirus serotypes, such as those from chimpanzees (SAdV, also 
termed AdC), are also being explored 229,230. As these viruses do not circulate in humans, 
prevalence rates to such viruses are even lower than those to alternative human serotypes 231,232. 
It remains an open question if these two groups of alternative Ad vectors will outperform AdHu5-
based vaccines in clinical trials or elicit the previously observed increased risk of HIV-1 infection 
in vaccine recipients. 
 Here we tested if VNAs against distinct serotypes of E1-deleted Ad vectors differentially 
affect the immunogenicity of the homologous vector. Although Ad-specific VNAs are serotype-
specific and mainly directed to the hypervariable loops of hexon 13, non-neutralizing antibodies to 
more conserved regions of the viral surface proteins, such as fiber and the hexon stalk, cross-
react between different human and simian serotypes 92. Therefore, the effect of passive transfer 
of Ad-specific antibodies on the immune response induced by vaccination with an Ad vector 
derived from a heterologous serotype was also assessed. These results confirm that even low 
titers of adoptively transferred antibodies can significantly reduce the vectors’ ability to elicit 
transgene product-specific CD8+ T cell responses and there was no definite difference between 
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the different serotypes. Interestingly, passive transfer of Ad VNAs changed the fate of transgene 
product-specific CD8+ T cells by promoting their transition into the central memory compartment, 
resulting in their enhanced expansion following a boost with a heterologous Ad vector. Ad VNAs 
induced to one serotype had no effect on the magnitude of transgene product-specific CD8+ T 
cells induced by an Ad vector of a different serotype nor did such antibodies promote induction of 
more resting memory CD8+ T cells. These results show that antibodies to an Ad vaccine carrier 
not only affect the magnitude but also the differentiation of an Ad vector-induced CD8+ T cell 
response.  
 
RESULTS 
 
 In order to determine if pre-existing vector-specific neutralizing antibodies differentially 
affected immune responses to transgene products encoded in Ad-based vaccines, serotype-
specific hyperimmune sera were generated against three distinct Ad species. Vectors based on 
AdHu5, a common family C serotype, AdHu26, a family D serotype, and AdC6, a chimpanzee-
derived serotype from family E, were used to repeatedly immunize BALB/c mice to generate 
hyperimmune sera. Sera were collected and tested for neutralization of the homologous virus.  
After determining the vector-specific neutralizing antibody titer, each sera was transferred 
intraperitoneally (IP) to groups of naïve BALB/c mice such that five days after transfer the groups 
had circulating vector-specific VNA titers of 1:1000, 1:100, or 1:10. As a control, a group of mice 
was treated with naïve BALB/c serum given at the equivalent volume to that used for the highest 
dose of hyperimmune serum (1:1000). The day following confirmation of circulating vector-
specific VNAs mice were immunized with 1010 viral particles (vp) of an HIV-1 Gag-expressing Ad 
vector based on the identical serotype used for induction of serum the mice received. Ten days, 
three weeks, and eight weeks later mice were bled and peripheral blood mononuclear cells 
(PBMCs) were tested for Gag-specific CD8+ T cell responses by staining with a tetramer specific 
to the immunodominant, H-2d-restricted immunodominant epitope of Gag (AMQMLKETI) (Figure 
5.1A-C). Vaccination affected overall numbers of circulating CD8+ T cells; therefore, tetramer+ 
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cells were normalized to 106 live PBMCs. Gag-specific CD8+ T cell responses elicited by each 
vector peaked three weeks after immunization and were sustained thereafter, although the 
responses induced by AdHu26-gag underwent more pronounced contraction compared to those 
induced by AdHu5-gag and AdC6-gag. Mice with circulating AdHu5-specific VNAs as low as 1:10 
titer had significantly reduced Gag-specific CD8+ T cell responses ten days after immunization 
with AdHu5-gag. This reduction became more pronounced at later time points, particularly in 
those mice with the highest titer of AdHu5-specific VNAs. Similarly, circulating AdHu26-specific 
VNA titers of 1:100 and 1:1000 caused significant reduction of Gag-specific CD8+ T cells ten days 
after immunization with AdHu26-gag. By three weeks after immunization, even the lowest dose of 
AdHu26-specific VNAs caused pronounced decreases in the response, which were maintained 
eight weeks after immunization. Gag-specific CD8+ T cells were reduced in those mice bearing 
AdC6-specific VNAs at the time of immunization with AdC6-gag, although at the earliest time 
point only mice with the highest titers had significant reduction.     
 To determine if immunization in the presence of vector-specific VNAs reduced Gag-
specific CD8+ T cell responses in compartments other than blood, lymphocytes from spleens and 
genital tract were isolated 8 weeks after immunization. Results from both tissues largely mirror 
those seen in the blood. In spleens (Figure 5.1D-F), AdHu5-gag and AdC6-gag induced robust 
Gag-specific CD8+ T cell responses that were significantly reduced in mice primed in the 
presence of vector-specific VNAs, regardless of dose. In contrast, AdHu26-gag induced a poor 
Gag-specific CD8+ T cell response that was only reduced in mice with the highest dose of 
AdHu26-specific VNAs. At the genital tract (Figure 5.1G-I), Gag-specific CD8+ T cell responses 
induced by AdHu5-gag and AdC6-gag were comparable in control mice and, as expected, VNAs 
present at the time of immunization reduced those responses. In contrast, AdHu26-gag induced a 
poor Gag-specific CD8+ T cell response at the genital tract in control mice but that was increased 
in mice that had a circulating titer of AdHu26-specific VNAs of 1:10. Treatment with the higher 
VNA doses resumed the pattern of reduction in responses.  
 To determine if transfer of Ad-specific VNAs altered CD4+ T cell responses, PBMCs and 
splenocytes were tested at eight weeks after immunization. We observed variation in the antigen-
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experienced (CD44+) CD4+ T cell responses in the blood following immunization with the different 
vectors. In comparison to CD4+ T cell numbers found in blood of naïve mice, immunization with 
AdHu5 in the absence of vector-specific VNAs significantly increased CD4+ T cell responses 
(Figure 5.2A). However, priming in the presence of AdHu5-specific VNAs, failed to increase 
CD4+ T cell responses, which remained comparable to those seen in naïve mice. The exception 
to this was mice primed in the presence of the highest VNA dose, where CD4+ T cell responses 
became elevated above baseline. In contrast, vaccination with AdHu26 significantly reduced 
CD4+ T cell responses in all groups but for mice primed in the presence of the lowest dose of 
AdHu26-specific VNAs. While immunization with AdC6 did not change the CD4+ T cell numbers 
in the blood, priming in the presence of AdC6-specific VNA, regardless of dose, reduced CD4+ T 
cell responses. CD4+ T cell responses in the spleen were largely unchanged following 
immunization with either AdHu5 or AdC6 (Figure 5.2B). Splenic CD4+ T cells in AdC6-immunized 
mice were below those seen in naïve mice regardless of transfer of AdC6-specific antibodies.  
 Results from the STEP trial revealed that individuals previously exposed to AdHu5 with 
moderate to high levels of circulating AdHu5-specific VNAs at the time of immunization with the 
AdHu5-based vaccine had slightly higher rates of HIV-1 infection than those in the placebo arm of 
the trial. This seemingly enhanced susceptibility was unexpected and its underlying causes 
remain elusive. However, one possible explanation is that vaccination of those individuals 
increased numbers of activated CD4+ T cells, and thus, targets of HIV-1 infection at mucosal 
surfaces. To this end, numbers of activated (CD44+) CD4+ T cells were analyzed in the genital 
tract in naïve mice and vaccinated mice treated with all serum doses (Figure 5.2C). Relative 
numbers of activated CD4+ T cells in the genital tract were not dramatically changed following 
vaccination, although relative numbers seemed to increase following vaccination with AdHu5 but 
decreased slightly upon AdHu26 vaccination. Variation in numbers was observed for immune 
serum recipients, although there was no consistent trend between vectors, other than that the 
highest dose of serum did not increase the numbers of activated CD4+ T cells. Regardless, the 
observed differences were modest and comparable to those observed in control mice.       
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 Adenoviruses and vectors based on them are known to persist in immunologic tissues, 
particularly in activated T cells 123. During persistence, the Ad genome remains transcriptionally 
active, albeit at low levels, and thus maintains high frequencies of effector T cells exhibiting 
delayed kinetics in their transition into the central memory pool 123.  As circulating vector-specific 
VNAs reduced frequencies of transgene product-specific CD8+ T cells, it stands that their memory 
phenotype may be altered as well. Therefore, Gag-specific CD8+ T cells induced in this 
experiment were analyzed for expression of CD62L, which can be used to distinguish effector 
and memory T cells based on either low or high expression, respectively. Immunization with 
either Ad vector in the presence of pre-existing vector-specific VNAs increased the frequencies of 
Gag-specific CD8+ T cells with a CD62Lhi phenotype (Figure 5.3A-C). This effect was observed 
as early as ten days after vaccination with AdHu5-gag and AdHu26-gag in the blood of mice with 
the highest titer of circulating vector-specific VNAs, and became more pronounced at eight weeks 
after vaccination in both blood and spleens. Increased CD62L expression was only observed at 
eight weeks following vaccination with AdC6-gag but was significantly increased in all groups of 
mice that had received AdC6-specific immune serum. Interestingly, increased frequencies in 
CD62Lhi Gag-specific CD8+ T cells were not observed in the spleens of these mice other than 
those that had received the low titer of AdC6-specific VNAs at the time of immunization.  
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FIGURE 5.1. Passive transfer of Ad-immune serum reduces transgene product-
specific CD8+ T cells to Ad vector immunization. 
 
Groups of female BALB/c mice (5 per group) were injected with pooled serum from donor mice that had 
been immunized twice with an Ad vector expressing the rabies virus glycoprotein. Doses of serum were 
adjusted so that titers of Ad-specific VNAs measured from recipient mice 24 hours later equaled 1:10, 1:100 
or 1:1000. Control mice received a volume of serum from naïve donor mice that equaled the highest volume 
of the immune serum. Mice were injected after serum transfer with 1010 vp of the Ad vector that was 
homologous to the Ad used to induce the transferred serum. Ad vectors expressed HIVgag. Significant 
differences are indicated by * for p-values ≤ 0.05-0.01, ** p-values < 0.01-0.001, *** p-values ≤ 0.001-
0.0001, **** p-values < 0.0001.  Lines show the comparison groups. 
 
[A-C] Mice were bled on day 10 (white bars), 3 (light grey bars) and 8 weeks (dark grey bars) later and 
frequencies of gag-specific CD8+ T cells were determined from individual mice by staining with a specific 
tetramer. Data are expressed as average numbers of tetramer (tet)+CD8+ cells per 106 live PBMCs ± 
standard deviations (SD). Differences between numbers of immune versus naïve serum were determined by 
one-way ANOVA with Dunnett correction for type 1 errors. The following p-values were obtained: [A] 
AdHu5: d10: 1:10 p=0.044, 1:100 p=0.0037, 1:1000 p=0.0025; wk 3: 1:1000 p=0.0006; wk 8: 1:10 p=0.0012, 
1:100 p=0.0007, 1:1000 p<0.0001; [B] AdHu26: d10: 1:100 p=0.007, 1:1000 p<0.0001; wk 3: all serum 
dilutions p<0.0001, wk 8: 1:10 p=0.0012, 1:100 p=0.0013, 1:1000 p<0.0001; [C] AdC6: d10 1:100 p=0.0073, 
1:1000 p=0.0068, wk 3: 1:10 p<0.0001, 1:100 p<0.0001, 1:1000 p<0.0001; wk 8: 1:10 p=0.0006, 1:100 
p=0.0004, 1:1000 p<0.0001.  
 
[D-F] Splenocytes were tested 8 weeks after immunization. The following p-values were obtained: (by one-
way ANOVA with Dunnett correction for type 1 errors.): [D] AdHu5: d10: 1:10 p=0.001, 1:100 p=0.0044, 
1:1000 p=0.0002, [E] AdHu26: 1:1000 p=0.0061, [F] AdC6: 1:10 p=0.0057, 1:100 p=0.0086, 1:1000 
p=0.0006.  
 
FIGURE LEGEND CONTINUED ON PAGE 113 
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FIGURE 5.2. CD4+ T cell responses in blood and spleen and recruitment to the 
genital tract. 
 
 
 
The graphs show relative numbers of CD44+CD3+CD8- cells isolated 8 weeks after immunization from blood 
[A], the spleen [B], and the pooled genital tracts [C] of the same mice shown in Figure 5.1. CD4+ cells were 
identified upon staining for CD8 and CD3 as cells that were CD3+CD8-. Graphs shows numbers of cells over 
106 live cells ± standard deviations (SD). Significant differences between the number of lymphocytes from (I) 
naive serum vs. immune serum and (II) number of lymphocytes from naïve mice vs. immunized mice were 
determined by one-way ANOVA with Dunnet correction for type 1 errors. The following p-values were 
obtained: [A] (I) AdHu5: 1:10 p = 0.025, 1:100 p = 0.0015; AdC6: 1:10 p = 0.0002, 1:100 p < 0.0001, 1:1000 
p < 0.0001; (II) AdHu5: naïve serum: p = 0.0005, 1:1000 p = 0.0387; AdHu26: naïve serum: p = 0.0082, 
1:100 p = 0.0038, 1:1000 p < 0.0001; AdC6: 1:10 p = 0.0378, 1:100 p = 0.0148, 1:1000 p = 0.0030 [B] (I) 
AdC6: 1:100 p = 0.0143. (II) AdHu26: naïve serum: p = 0.0035, 1:10 p = 0.0064, 1:100 p = 0.0049, 1:1000 p 
= 0.0041.  
 
Significant differences are indicated by * for p-values ≤ 0.05-0.01, ** p-values < 0.01-0.001, *** p-values ≤ 
0.001-0.0001, **** p-values < 0.0001.  Lines show the comparison groups. 
 
 
 
 
 
 
CONTINUED FROM PAGE 112:  
 
[G-E] The graphs show results of genital tract samples pooled from 5 mice as relative numbers of Gag-
specific CD8+ T cells over 106 live lymphocytes. 
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FIGURE 5.3. Pre-existing Ad-specific VNAs increase frequencies of transgene 
product-specific CD62L+CD8+ T cells. 
 
 
 
 
Blood-derived Gag-specific CD8+ T cells, identified by stains for CD3, CD8 and the Gag-specific tetramer 
from groups of 5 mice serum treated and immunized as in Figure 5.1 were tested for expression of CD62L 
10 days (white bars) and 8 weeks (light grey bars) after immunization. Splenocytes (dark grey bars) were 
tested at 8 weeks after immunization with 1010 vp of either AdHu5-gag [A], AdHu26-gag [B], or AdC6-gag 
[C]. Differences between frequencies in serum recipients vs. controls were determined by one-way ANOVA 
with Dunnett correction for type 1 errors. The following p-values were obtained for blood: [A] AdHu5: d 10: 
1:100 p = 0.0005, 1:1000 p = 0.027, wk 8: 1:1000 p = 0.0014; [B] AdHu26: d 10: 1:1000 p = 0.0046, wk 8: 
1:1000 p<0.0001; [C] AdC6: wk 8: 1:10 p = 0.045, 1:100 p = 0.032, 1:1000 p <0.0001 and spleens: [A] 
AdHu5 1:1000 p = 0.0044, [B] AdHu26 1:1000 p = 0.0008, [C] AdC6 1:10 p = 0.0001.  
 
Significant differences are indicated by * for p-values ≤ 0.05-0.01, ** p-values < 0.01-0.001, *** p-values ≤ 
0.001-0.0001, **** p-values < 0.0001.  Lines show the comparison groups. 
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 Antigenic load during T cell priming is a determining factor in memory CD8+ T cell 
development 122. Therefore, the increased frequencies of Gag-specific CD8+ T cells highly 
expressing CD62L could reflect that the vector-specific VNAs neutralized the vector and thus 
reduced the antigenic load available for induction of CD8+ T cell responses. If the vector-specific 
VNAs reduced the amount of antigen available for priming, mice immunized with fewer viral 
particles would be expected to have the same increased frequencies of CD62Lhi Gag-specific 
CD8+ T cells. To this end, groups of mice were immunized with AdHu5gag at doses 100- (108 vp) 
and 10-fold (109 vp) lower than used in the previous experiments. As expected, five and eight 
weeks after immunization the magnitude of Gag-specific CD8+ T cells in the blood was 
significantly reduced when lower doses of vector were used (Figure 5.4A). Nevertheless, the 
frequency of CD62Lhi Gag-specific CD8+ T cells was not increased with any dose of vector 
(Figure 5.4B), suggesting that a mechanism other than reduction of vector load at priming is at 
play.  
 A second possible mechanism is that the vector-specific VNAs altered the Ad vectors’ 
ability to transduce the lymphocytes that would serve as the viral reservoir during persistence. To 
address this, groups of C57BL/6 mice were treated with naïve serum or a dose AdHu5-specific 
hyperimmune serum resulting in a circulating titer of 1:340. Mice were immunized 24 hours later 
with 1010 vp of an AdHu5-based vaccine that expressed a influenza nucleoprotein fused to GFP 
by the immunodominant epitope of ovalbumin (NPOVAGFP). A naïve group of mice were 
included as a negative control. Five weeks after immunization, mice were sacrificed and genomic 
DNA was isolated from splenocytes. The DNA (20 ng) was then tested for the AdHu5 vector 
genome using highly sensitive nested PCR against AdHu5 hexon (Figure 5.5). As expected, the 
genome was not detected in the naïve mice but was detected in three out of five mice that were 
immunized following transfer of naïve serum. The AdHu5 genome could only be faintly detected 
in one of three mice that had been treated with AdHu5-specific VNAs, largely suggesting the 
VNAs altered the vector’s persistence, which would allow for increased transition into central 
memory.  
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FIGURE 5.4. Low doses of Ad vector fail to promote increases of transgene 
 product-specific CD62L+CD8+ T cells. 
 
 
 
Groups of 4 mice were vaccinated with 108, 109 or 1010 vp of AdHu5-gag vector. [A] PBMCs were tested 5 
(white bars) and 8 (light grey bars) weeks later, splenocytes were tested 8 weeks later (dark grey bars) for 
numbers of Gag-tet+CD8+ T cells over 106 live lymphoid cells. Data were analyzed by ANOVA with 
uncorrected Fischer’s LSD. Lines show the comparison groups. The following differences were significant in 
blood: wk 5: 108 vs. 109 vp p = 0.012, 109 vs. 1010 vp p = 0.047; wk 8: 108 vs. 1010 vp p = 0.033. [B] 
Tet+CD8+ T cells were tested for expression of CD62L and the right graph shows % CD62L+Gag-specific 
CD8+ T cells over all Gag-specific CD8+ T cells. There were no differences in percentages of CD62L+ cells.  
 
Significant differences are indicated by * for p-values ≤ 0.05-0.01, ** p-values < 0.01-0.001, *** p-values ≤ 
0.001-0.0001, **** p-values < 0.0001.  Lines show the comparison groups. 
 117 
FIGURE 5.5. Pre-existing Ad-specific VNAs reduce persistence of Ad vector 
genome. 
  
 
Mice received naïve serum (n=5) or AdHu5 immune serum at a dose between the middle and high titers 
from previous experiments (1:320) (n=3) and were immunized 24 hours later with 1010 vp AdHu5-
NPOVAGFP vector. A control group (n=3) was unimmunized.  Splenocytes were tested 5 weeks later for 
AdHu5 hexon DNA by nested PCR and real-time nested PCR. Amplicons from non-quantitative nested PCR 
(250 bp) were analyzed on 1% TAE gel.   
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 To further characterize the Gag-specific CD8+ T cells induced in the presence of the high 
titer of AdHu5-specific VNAs, additional differentiation markers were analyzed, including killer cell 
lectin-like receptor subfamily G member 1 (KLRG1), a marker of terminal differentiation that has 
been shown to reflect a CD8+ T cell’s stimulation history in that its expression is increased on 
cells that repeatedly encounter their antigen 124,148, CCR7, a chemokine receptor that regulates T 
cell migration to the lymphoid tissues and whose co-expression with CD62L on T lymphocytes is 
used to differentiate between effector memory (low expression) and central memory (high 
expression) 103,233, and CD127, the IL-7 receptor which is required for formation of memory 234. As 
in the previous set of experiments, mice treated with the high dose of AdHu5-specific VNAs had 
higher frequencies of circulating CD62L+ Gag-specific CD8+ T cells eight weeks after 
immunization with AdHu5-gag. Consistent with the idea that the VNAs reduced vector 
persistence, the frequencies of KLRG1+ Gag-specific CD8+ T cells were significantly lower in 
mice that had been primed in the presence of AdHu5-specific VNAs (Figure 5.6A). Trends 
toward higher frequencies of CCR7+ and CD127+ Gag-specific CD8+ T cells were observed but 
did not reach statistical significance.  
 A hallmark characteristic of memory CD8+ T cells is that they have a very high 
proliferative capacity. As such, they vastly expand during recall responses. Therefore, in order to 
functionally confirm that the VNAs led to better induction of CD8+ T cell memory, each group of 
mice received a second immunization with a heterologous Ad vector. Eight weeks after priming 
with AdHu5-gag, all groups of mice were boosted with 1010 vp AdC7-gag. A group of naïve mice 
was primed as a control. Gag-specific CD8+ T cell responses were analyzed in the blood ten days 
later (Figure 5.6B). As expected, the numbers of responding cells vastly expanded in all mice, 
regardless of VNAs at the time priming. Although boosting resulted in higher numbers of Gag-
specific CD8+ T cells in mice primed in the absence of VNAs, it is worth noting that these mice 
had significantly higher frequencies at the time of the boost. As such, comparison of the relative 
increases of Gag-specific CD8+ T cells between the two groups of mice revealed that the cells 
isolated from mice with circulating VNAs at the time of the prime expanded more robustly (35-
fold) than those mice treated with naïve serum (14-fold). The frequencies of CD62L+ Gag-specific 
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CD8+ T cells were notably lower than before the prime and were comparable between both 
groups of mice; whereas CCR7+ and CD127+ frequencies were unchanged (Figure 5.6C). The 
frequencies of Gag-specific CD8+ T cells that were KLRG1+ were increased in both groups after 
the boost, as expected, but the pattern observed before the boost remained: fewer KLRG1+ Gag-
specific CD8+ T cells were detected in mice who bore pre-existing AdHu5-specific VNAs at the 
time priming (Figure 5.6C).  
 Expression of certain markers on Gag-specific CD8+ T cells at 8 weeks after the prime 
correlated very significantly with the fold increases in numbers of specific cells due to their 
expansion following the boost. Even though the slightly higher frequencies of CD127+ Gag-
specific CD8+ observed in the mice primed in the presence of pre-existing VNAs was not 
significant, the frequency of CD127+ cells measured just before boosting was directly correlated 
to Gag-specific CD8+ T cell expansion after boosting (Figure 5.6D). As expected, the frequency 
of KLRG1+ Gag-specific CD8+ T cells 8 weeks after priming was inversely correlated to their 
expansion after the boost (Figure 5.6E). Correlations to CD62L+ cells, on the other hand, were 
not significant (not shown). As a whole, these data indicate that priming in the presence of vector-
specific neutralizing antibodies (NAb) enhances transition into memory and, thus, leads to more 
robust recall responses.  
 Serotype-specific neutralizing antibodies are primarily directed against the hypervariable 
loops on hexon 13, although other capsid components, such as penton and fiber, can also be 
targets 235. Other, more conserved capsid elements, such as the hexon stalk, are targets for 
antibodies that cross-react between two distinct serotypes. Therefore, the induction and fate of 
transgene product-specific CD8+ T cells were analyzed in mice that were primed with a 
heterologous vector in the presence of Ad vector-specific hyperimmune serum. First, each 
hyperimmune serum used in the experiments described above was assessed for reactivity with 
vectors derived from AdHu5, AdHu26, AdC6, and chimpanzee serotype 7 (AdC7) using ELISAs 
(Figure 5.7A). Although each serum preferentially reacted with the homologous vector used for 
induction, cross-reactivity between the different serotypes was observed. AdHu26 did not 
significantly bind antibodies from AdHu5 and AdC6 hyperimmune serum. While AdHu5 virus 
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cross-reacted with AdHu26 and AdC6 sera, the highest levels of cross reactivity were observed 
for the chimpanzee vectors, especially for AdC7 which very significantly bound antibodies from all 
three hyperimmune sera.  
 AdHu26 has a high seroprevalence rate in developing nations 228 and transfer of 
AdHu26-specific VNAs strongly reduced induction of transgene product-specific CD8+ T cell 
responses following AdHu26-gag vaccination (Figure 5.1), causing a pronounced increase in 
Gag-specific CD62L+CD8+ T cells as early as 3 weeks after vaccination (Figure 5.3). Additionally 
as AdHu26 sera showed strong cross-reactivity with AdC7 vector (Figure 5.7A), the 
hyperimmune serum was chosen to continue investigation into the role, if any, cross-reactive 
antibodies play in modulating CD8+ T cell responses to heterologous Ad vectors. The AdHu26 
sera’s capacity to neutralize AdC7 was next measured (Figure 5.7B). A virus neutralizing 
antibody assay was performed using naïve BALB/c and the AdHu26 hyperimmune serum to test 
the neutralization of AdC7 expressing GFP (AdC7-GFP). As a positive control for neutralization, 
AdHu26-GFP was included. The neutralization titer was determined as the dilution at which the 
serum neutralized 90% GFP expression. A titer of 10 or below was considered non-neutralizing. 
As expected, naïve serum neutralized neither AdHu26-GFP nor AdC7-GFP. Additionally, AdHu26 
hyperimmune serum had an extremely high titer of AdHu26-specific neutralizing NAbs that 
neutralized AdHu26-GFP at the 1:40960 dilution. However, this serum did not neutralize AdC7-
GFP.  
 In order to determine if immunization in the presence of heterologous vector-specific 
antibodies affected transgene product-specific CD8+ T cell responses, AdHu26 hyperimmune 
serum was transferred to BALB/c mice such that the mice had a circulating AdHu26-specific VNA 
titer of 1:1000 six days later at the time of immunization. Control mice received naïve serum.  
Mice were immunized with 1010 AdC7-gag. Gag-specific CD8+ T cell responses were measured 
ten days and four weeks later in the blood and eight weeks later in the spleen. Gag-specific CD8+ 
T cell responses were comparable between both the control mice and the mice that had received 
AdHu26-hyperimmune serum (Figure 5.7C), indicating that AdHu26-specific antibodies failed to 
neutralize AdC7 vector in vivo. CD62L, CCR7, KLRG1, and CD127 expression on Gag-specific 
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CD8+ T cells in blood were measured four weeks after vaccination. Expression of all four markers 
was comparable between both groups (Figure 5.7D), indicating that priming in the presence of 
heterologous vector-specific antibodies did not alter differentiation of transgene product-specific 
CD8+ T cells. Taken together these data indicate that vector-specific neutralizing antibodies are 
responsible for the observed phenomena in these studies.  
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FIGURE 5.6. Ad-specific VNAs present at the time of priming promote recall 
responses.  
 
 
[A] A group of 5 BALB/c mice were transferred with an AdHu5 immune serum given at a dose that resulted 
in a 1:1000 titers of VNAs in the recipient mice. Another group of 5 mice received the same volume of serum 
from naïve mice. Both groups were vaccinated with 1010 vp of AdHu5-gag after serum transfer. A third group 
of 5 mice was left untreated (Controls). Eight weeks later mice were bled and Gag-specific CD8+ T cells 
were measured (light grey bars). All mice were vaccinated the following day with 1010 vp of AdC7-gag 
vector. Gag-specific CD8+ T cell responses were measured from blood 10 days later (dark grey bars). 
Graphs show number of Gag-specific CD8+ T cells identified by staining with the tetramer over 106 live 
lymphoid cells as bars (min to max) ± SD. Differences between the two groups of serum recipients were 
determined by t-tests. The following p values were obtained comparing recipients of immune vs naïve 
serum:  after priming p = 0.0044. Differences of the same cohort comparing data after priming to those after 
the boost gave the following p-values: naïve serum recipients p < 0.0001, immune serum recipients p = 
0.0043. Fold increases of numbers of Gag-specific CD8+ T cells were calculated (number after the boost 
divided by numbers before the boost). Differences between the two groups were significant: p = 0.011. 
Controls (no priming, AdHu5 at the time of boost) p = 0.0001.  
 
[B] Graphs show percentage of Gag-specific CD8+ T cells tested 8 weeks after immunization for expression 
of CD62L, CCR7, KLRG1 and CD127. Differences were determined by multiple t-test with Sidak-Holm 
correction. The following significant p-values were obtained: CD62L p< 0.0001, KLRG1 p = 0.00012.  
 
[C] Graph shows percentages of Gag-specific CD8+ T cells positive for the indicated markers over all CD8+ 
T cells at 10 days after the boost for mice that receive immune or naïve serum before priming. Differences 
were calculated by multiple t-test with Sidak-Holm correction. Only KLRG1 was differentially expressed (p = 
0.0004). Significant differences are indicated by * for p-values ≤ 0.05-0.01, ** p-values < 0.01-0.001, *** p-
values ≤ 0.001-0.0001, **** p-values < 0.0001.  Lines show the comparison groups.  
 
[D] and [E] show correlations between fold increases after the boost and % of Gag-specific CD8+ T cells 
positive for CD127 or KRLG-1 respectively. R and p-values are shown within the graphs.   
 
FIGURE LEGEND CONTINUED ON PAGE 123 
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FIGURE 5.7. Effect of pre-existing Ad-specific antibodies on transgene product-
specific CD8+ T cells to a heterologous Ad vector. 
 
 
[A] Graph shows binding of the transferred sera to different Ad serotypes as shown in the legend within the 
figure. Titers were calculated by determining the area under the curve of adsorbance data obtained by 
serially diluted sera. ELISAs were conducted in duplicate wells and results shows mean ± SD. Differences in 
titer of immune sera to naïve sera were calculated by ANOVA with Dunnett correction. The following sera 
showed significant reactivity with the following vectors: AdHu5 serum: on AdHu5 vector p < 0.00001, on 
AdC7 vector p = 0.0006; AdHu26 serum on AdHu5 vector p = 0.0013, on AdHu26 vector p = 0.0008, on 
AdC6 vector p = 0.0132; on AdC7 vector p < 0.0001; AdC6 serum on AdHu5 vector p = 0.016, on AdC6 
vector p = 0.0003; on AdC7 vector p < 0.0001.   
 
[B] Graph shows analysis of naive BALB/c sera and AdHu26 hyperimmune sera for neutralization of 
AdHu26 or AdC7. Sera were tested for virus-neutralizing antibodies (VNA) against AdC7-GFP and AdHu26-
GFP using VNA assay. Titers of 10 and below were considered non-neutralizing.  
 
[C-D] Groups of 5 mice were injected with a dose of AdHu26-immune serum that resulted in a VNA titer of 
1:1000 or an equal dose of serum from naïve mice. Mice were then immunized with AdC7gag. [C] shows 
Gag-specific CD8+ T cell responses tested from blood 10 days and 4 weeks later and spleens 8 weeks later.  
 
[D] shows frequencies of Gag-specific CD8+ T cells that were positive for the indicated markers.  
 
Significant differences are indicated by * for p-values ≤ 0.05-0.01, ** p-values < 0.01-0.001, *** p-values ≤ 
0.001-0.0001, **** p-values < 0.0001.  Lines show the comparison groups. 
 
 
 
CONTINUED FROM PAGE 122: 
 
[F] shows the gating strategy of a representative sample. After lymphocytes were identified based on FSC 
and SSC, doublets were excluded (not shown). Live cells were identified based on exclusion of live/dead 
stain.  CD8+ T cells were gated (CD3+CD8+). The subsequent gates were designed to isolate Gag-specific 
CD8+ T cells (tetramer+CD44+) and naïve cells (tetramer+CD44low) as an internal control. Each population 
was then gated on CD62L and CCR7 or CD127 and KLRG1 based on naïve cells’ expression of each.   
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DISCUSSION 
 
 Ad vectors are very attractive vaccine platforms thanks to their robust induction of B and 
T cell responses. However a major obstacle to use of these vectors is that virus-neutralizing 
antibodies (VNAs) to them are common. Historically, AdHu5 has been one of the most commonly 
studied vectors for this purpose. However, infection with AdHu5 often occurs during childhood, 
and, as such, pre-existing immunity to this virus is extremely common. Prior studies have 
demonstrated that the seroprevalence of AdHu5-specific neutralizing antibodies among adults in 
developed nations, including the United States and those constituting Europe, is typically 
between 30-60% 228,231,236, although serum immunoglobulin against Ad may be found in all 
individuals 237. These seroprevalance rates are dramatically increased in developing nations.  
Studies suggest that prevalence rates of neutralizing antibodies against AdHu5 are between 70-
80% in Brazil 228,232, between 75-100% in the Asian nations of Thailand 228,231 and India 238, and 
between 80-100% in sub-Saharan nations 228,231,236. In all regions, about 30% or more of adults 
have moderate to high titers of AdHu5-specific VNAs 232. As these neutralizing antibodies can 
dampen the vector’s immunogenicity, this high seroprevalance of AdHu5-specific neutralizing 
antibodies poses a challenge to the development of AdHu5-based vaccines to protect against 
pathogens that plague the developing world.  
  A common strategy to circumvent the problem of pre-existing immunity to common Ad 
serotypes is development of vectors based on uncommon Ad serotypes. So-called “rare” human 
serotypes, such as AdHu26, circulate less frequently in humans. This “rare” designation is largely 
based on seroprevalence rates found in the developed world. Indeed, AdHu26 neutralizing 
antibodies are found in approximately 20% of adults in the United States and only 2% carry a titer 
of 1:200 or greater 228. However, AdHu26 is not particularly rare in developing nations.  
Approximately 65-85% of adults in sub-Saharan Africa are seropositive for neutralizing antibodies 
against AdHu26.  Prevalence of individuals carrying titers of 1:200 or greater seems to vary in this 
region but ranged from 0-22% 228. Elsewhere, including South America and Asia, AdHu26-
specific neutralizing antibody seroprevalance rates range from about 40-70% 228,232, with 32-37% 
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of adults carrying high titers 228. Based on the seroprevalence rates, it would be expected that 
immunogenicity of an AdHu26-based vaccine would also be compromised. Therefore, others 
have focused on the development of vectors based on non-human adenovirus serotypes that do 
not circulate in humans, particularly those isolated from chimpanzees, e.g. AdC6. Pre-existing 
immunity to AdC6 is very rare in the United States and Thailand 229,231. Seroprevalance climbs to 
nearly 20% of adults in certain regions of sub-Saharan Africa 231, which was speculated to be due 
to the chimpanzee populations endemic to those regions. Native populations of New World 
monkeys genetically unrelated to chimpanzees may be responsible for the similar seroprevalance 
rate found in adults living in the Brazilian rainforest 232.   
 This high incidence of pre-existing immunity to Ad has prompted extensive work looking 
at how pre-existing immunity to adenovirus affects induction of T cell responses following 
vaccination with an Ad-based vaccine. Models focusing on pre-exposing mice 92 and NHP 216,217 
to adenovirus prior to vaccination have revealed that transgene product-specific CD8+ T cell 
responses are reduced in these animals. Pre-exposure to Ad induces both cellular and humoral 
immunity directed against the vector. Neutralizing antibodies are generally directed against the 
hypervariable loops of hexon 13,235, although NAb against fiber and penton are also detected 235.  
Ad-specific T cells have also been described 237. While pre-exposure models at least in part 
mirror naturally acquired Ad infections in humans, these studies do not differentiate between the 
individual roles that the cellular and humoral components play in the reduction of responses. As 
such, both arms of the adaptive immune system have been implicated 93. A recent study in which 
B cell-deficient mice were pre-exposed to Ad before vaccination revealed that induction of 
transgene product-specific CD8+ T cells was unaffected by pre-exposure 239, suggesting that 
vector neutralizing antibodies are primarily responsible for this reduction. Thus, the study 
presented here was performed in order to assess how pre-existing Ad-specific neutralizing 
antibodies present at the time of immunization affect induction and differentiation of transgene 
product-specific CD8+ T cells generated by vectors based on distinct Ad serotypes. The 
experiments presented here clearly demonstrate that pre-existing vector neutralizing antibodies 
present at the time of immunization, regardless of serotype, dramatically inhibit transgene 
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product-specific CD8+ T cell responses in the blood, spleen, and genital tract.  However, the 
results presented above demonstrate that priming of the CD8+ T cell response still occurs in a 
manner that is indirectly related to the titer of vector-specific NAbs present at priming. This likely 
indicates that not all vector particles are neutralized and that some remain to infect target cells 
and prime T cell responses. 
 The vectors presented in this study each represent different Adenoviridae families, as 
such, they may have differences in their biology, including their ability to bind to receptors and co-
receptors, their inflammatory potential that induces innate responses and their tropism, which all 
could affect their capacity to induce transgene product-specific CD8+ T cells in the face of pre-
existing VNAs. Although each vector was sensitive to neutralization by homologous vector-
specific VNAs, differences in the kinetics of transgene product-specific CD8+ T cell induction were 
observed. VNAs present at the time of immunization with either vector reduced induction of Gag-
specific responses at the earliest time point measured. However, immunization with AdHu5-gag 
in the presence of VNAs induced robust peak responses that were only significantly reduced in 
mice treated with the highest dose of serum. These results are consistent with another report that 
demonstrated using an AdHu5 pre-exposure model, which induced titers of AdHu5-specific VNAs 
in mice ranging from 1:40-1:80 240, that although circulating transgene product-specific CD8+ T 
cell responses were reduced in the presence of vector specific immunity, they still induced peak 
responses. Gag-specific CD8+ T cells induced in the presence of vector-specific VNAs by 
AdHu26-gag and AdC6-gag did not show this peak response and instead remained low through 
the experiment. 
 Ad vectors persist at low levels in a transcriptionally active state in activated T cells and 
maintain a pool of activated effector transgene product-specific CD8+ T cells that have delayed 
kinetics in their transition into the central memory pool 123. Unexpectedly, vector-specific 
neutralizing antibodies present at high titers at the time of immunization promoted transgene 
product-specific CD8+ T cells’ transition into the memory pool, as evidenced by increased CD62L 
expression and very robust recall responses. It is well known that CD8+ T cell responses and fate 
decisions are influenced by conditions present early in their activation. One such condition is the 
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amount and duration of antigenic stimulation. High levels of antigen and longer TCR engagement 
tend to favor differentiation towards effector populations, while limiting amounts of antigen 
available for priming favors development of the central memory population 122. Therefore, it was 
possible that increased CD62L expression observed on Gag-specific CD8+ T cells primed in the 
presence of vector-specific NAb was caused by the reduction of antigen available due to 
neutralization of the vector. However, this result was not recapitulated by simply decreasing the 
vector dosage 100-fold. While it is possible that the vector dose was not decreased enough in 
order to observe increased CD62L expression, further dosage reduction would likely compromise 
a measurable response.  
 Alternatively, pre-existing immunity could alter the innate immune response induced by 
the Ad vector. Inflammation during T cell priming provides the danger signal to the T cell and 
dramatically impacts CD8+ T cell differentiation. High inflammation favors development of more 
terminally differentiated effector cells 114 while reduction of inflammation enhances development 
of more plastic central memory cells 241. These developmental decisions are mediated at the 
transcriptional level during T cell priming. The level of inflammatory cytokines directly affects the 
level of T-bet expression in a dose-dependent manner 182 ultimately shifting the balance of 
expression between T-bet and Eomesodermin. In a follow up to the STEP trial, a systems biology 
approach using gene mapping revealed that AdHu5 seropositive individuals had dampened 
inflammatory responses following vaccination with Merck’s Ad5-based vaccine 242. Therefore, Ad-
specific VNAs in the study presented here may have reduced inflammation at the time of priming 
and thus promoted differentiation towards memory. CD4+ T cell help during the primary response 
is required for induction of CD8+ T cell memory responses, although this is dependent on the 
infectious agent. CD4+ T cell help promotes the activation and maturation of dendritic cells, thus 
increasing their expression of CD80 and CD86, to provide costimulation to T cells through CD28, 
and of proinflammatory cytokines, especially IL-12 243. It is therefore possible that CD4+ T cell 
help played a role in changing the priming environment in the context of pre-existing vector-
specific neutralizing antibodies. The study presented here does not rule out this possibility and 
this could be addressed by repeating these studies in CD4+ T cell-deficient or MHC-II-deficient 
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mice. Although an important caveat is that studies using CD4-deficient and -depleted mice have 
demonstrated that generation of proper CD8+ T cell responses following adenovirus immunization 
requires CD4+ T cell help 244.   
 These NAb-virus immune complexes could in turn affect the natural tropism of the virus.  
The majority of adenoviruses enter cells by binding the coxsackie adenovirus receptor (CAR) 
however coating in antibodies could retarget the virus to cells bearing Fc-receptors. In vitro 
studies have revealed that these immune complexes are potentially capable of infecting and 
expressing transgenes in cells that express FcγR 245. T cells, which are capable of expressing Fc 
receptors either endogenously following activation 223 or by acquiring them via trogocytosis from 
APCs 246,247, serve as the reservoir for adenovirus during its persistence 65,123. However, instead 
of enhancing transduction of T cells, the Ad-specific VNAs seem to reduce the vector reservoir 
within them. In fact, we were not able to detect Ad vector genome in two out of three samples of 
splenic lymphocytes from animals primed in the presence of vector specific-VNAs, but Ad 
genome was detected in three out of five animals primed in the absence of vector specific-VNAs. 
We performed the same nested PCR on splenocytes isolated from mice used in the boost 
experiment shown in Figure 5.5. We were able to detect AdHu5 genome in 5 out of 5 mice 
primed in the absence of AdHu5-specific VNAs but were unable to detect AdHu5 genome in 4 of 
5 mice primed in the presence of AdHu5-specific VNAs (data not shown). Although these two 
experiments are not quantitative they nevertheless suggest that pre-existing neutralizing 
antibodies may interfere with the establishment of a persisting viral reservoir. This in turn may 
have influenced the long-term development of central memory Gag-specific CD8+ T cells by 
reducing the persisting transgene product. KLRG1 expression reflects a T cell’s antigenic 
stimulation history as it is more highly expressed with subsequent rounds of antigen exposure 
124,148. Frequencies of KLRG1hi Gag-specific CD8+ T cells were reduced in mice primed in the 
presence of vector-specific NAbs. Therefore, this could indicate that there was less persistent 
antigen available to stimulate the transgene product-specific CD8+ T cells.     
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 These results have important implications for the use of Ad vectors as vaccine carriers as 
they clearly demonstrate that although the primary response is attenuated in the presence of 
vector-specific immunity, this does not preclude a robust secondary response.  
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MATERIALS AND METHODS 
 
Generation of immune sera 
Groups of 20 BALB/c mice were immunized IM with 1011 vp of AdHu5-, AdHu26-, or 
AdC6-rab.gp and boosted IM 6 weeks later with 1011 vp of the identical vector used for priming. 
Mice were bled 4 weeks after the boost to confirm titers of Ad-specific VNAs. Mice immunized 
with AdHu5-rab.gp and AdHu26-rab.gp were euthanized 5 weeks after the boost, serum was 
collected and VNA titers were determined to be 1:13,000 and 1:40,000, respectively. Mice 
immunized with AdC6-rab.gp were boosted a second time and euthanized 6 weeks later. The 
serum VNA titer was determined to be 1:20,000.  
 
Titration of Ad-specific VNAs 
Sera were incubated at 56°C for 30 minutes. 100 µl of serial, two-fold dilutions, starting at 
1:20, were incubated with a GFP-expressing Ad matching the serotype used for immunization for 
1 hour at 37°C. The virus-serum mixtures were added to HEK 293 cells in 96-well plates and 
incubated overnight at 37°C. The cells were analyzed for GFP expression 24 hours later. The 
VNA titer was determined by the highest dilution with less than 50% GFP-positive cells when 
compared to control wells. 
 
Administration of immune sera and immunization of mice 
Immune sera were passively transferred into mice to achieve VNA titers of 1:1000, 1:100 
and 1:10. Sera were diluted in sterile PBS to a volume of 200 µl per mouse and were 
administered IP. One group of mice received naïve BALB/c serum diluted to the highest dose of 
immune serum. Mice were bled to confirm appropriate VNA titers 5 days after transfer and 
immunized the following day IM with 1010 vp of the indicated vector diluted in 100 µl of sterile 
PBS.  
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Enzyme-linked immunoadsorbent assay (ELISA) 
ELISA plates were coated with 108 vp/well of AdHu5-HIVgag, AdHu26-HIVgag, AdC6-
HIVgag, or AdC7-HIVgag in 100 µl of coating buffer [2 carbonate-bicarbonate capsules (Sigma-
Aldrich) dissolved in 100 mL H2O] and incubated overnight at 4°C. Plates were washed with 
0.05% Tween (Biorad; Hercules, CA) in PBS (PBS-T) and blocked overnight at 4°C with 3% BSA 
(Sigma-Aldrich) in PBS-T (blocking buffer). After PBS-T wash, two-fold serial dilutions of AdHu5, 
AdHu26, and AdC6 immune sera starting at 1:200 were incubated on coated plates for 2 hours at 
room temperature. Plates were washed with PBS-T and alkaline phosphatase (AP)-conjugated 
anti-mouse IgG (Sigma-Aldrich) diluted to 1:30,000 was applied to plates for 1 hour at room 
temperature. At the end of the incubation, plates were washed, developed (2 tabs phosphatase 
substrate (Sigma-Aldrich) dissolved in 10 mL diethanolamine buffer (KPL; Gaithersburg, 
Maryland) and read 30 minutes later at 405 nm. All samples were run in duplicates. 
 
Tetramer staining 
Lymphocytes were stained with an APC-labeled tetramer against the immunodominant 
MHC class I restricted epitope of HIV-1 Gag (AMQMLKETI). Additionally, cells were stained with 
antibodies to CD3, CD8, CD44, KLRG1 (Southern Biotech, Birmingham, AL), CD62L (BD 
Pharmingen, San Jose, CA), CD127, CCR7 (eBioscience, San Diego,CA). Unless otherwise 
indicated, antibodies were from Biolegend (San Diego, CA). A stain for dead cells was included in 
the panel. 
 
Data acquisition and analysis for tetramer stains 
Samples were run on a BD-LSR II and analyzed by FlowJo software. After lymphoid cell 
acquisition, doublets and dead cells were removed and samples were gated on CD3+CD8+ T 
cells.  Remaining cells were plotted as tetramer against CD44. Data is shown as tet+CD8+ T 
cells/106 live lymphoid cells. Additionally, tet+CD44+ cells were phenotyped for the markers 
described above. A gate on the CD44lo CD8+ T cells served an internal, naïve control for 
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phenotyping. In the genital tract, lymphocytes were additionally gated on CD3+CD8- T cells to 
assess the CD4+ T cell population. 
 
Nested polymerase chain reaction 
 C57Bl/6 mice were treated with naïve serum or AdHu5 hyperimmune serum at a VNA 
titer greater than 1:100. Mice were immunized IM 24 hours later with 1010 vp of AdHu5-
NPOVAGFP. Mice were euthanized and splenocytes were harvested 4 weeks later. Genomic 
DNA was isolated using DNeasy Tissue kit (Qiagen; Valencia, CA). 20 ng of genomic DNA from 
each sample were used to first amplify AdHu5 hexon by polymerase chain reaction (PCR) using 
5’ primer: 5’-ATCATGCAGCTGGGAGAGTC-3’ and 3’ primer: 5’-ACACCTCCCAGTGGAAAGCA-
3’. The PCR consisted of 30 cycles of 95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 30 
seconds.  The resulting PCR fragment was 650 bp. The amplicon from the first PCR was diluted 
1:50 and 1 µL was used as template for quantitative nested PCR. The 5’ and 3’ primers, 5’-GAC 
TCC TAA AGT GGT ATT GT-3’ and 5’-GTC TTG CAA ATC TAC AAC AG-3’, respectively, 
amplified a 250 bp fragment. The nested PCR consisted of 40 cycles of 95°C for 30 seconds, 
56.8°C for 30 seconds, and 72°C for 30 seconds.  
 
Statistical analysis 
Significance of differences between 2 populations were calculated by t-tests with Sidak-
Holm correction for type 1 errors in multiple tests. When normality of distribution could not be 
assumed, differences were analyzed by Mann-Whitney tests. Differences between multiple 
groups were tested by ANOVA with Dunnett correction for type 1 errors, Tukey’s multiple 
comparison tests or with uncorrected Fischer’s LSD as indicated in the figure legends. 
Correlations were conducted by Spearman with Bonferroni corrections for type 1 errors. Data 
were analyzed by GraphPad Prism 6. 
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 The contribution of central memory and effector memory CD8+ T cells in controlling 
infection is dependent on a number of factors, most notably the infecting pathogen. Indeed 
numerous studies have demonstrated roles for each subset.  Results from the LCMV clone 13 
model have suggested that central memory CD8+ T cells, with their capacity to generate large 
amounts of effector CD8+ T cells upon secondary antigen encounters, are more suited to control 
infections once pathogens have spread systemically 107. Evidence for this also comes from HIV 
vaccine models, which have suggested that more anamnestic responses are necessary to lower 
viral set point loads once the acute infection phase has passed 135. On the other hand, numerous 
other studies suggested that effector memory CD8+ T cells, with their more activated, cytotoxic 
nature and localization at the periphery, are necessary to halt pathogens as they invade. This 
subset of cells is attributed to mediating early control of a highly pathogenic SIV in an HIV vaccine 
model based on a CMV-based vaccine 134,135. Studies of these subsets have led to the paradigm 
that effector memory cells are the first line of defense at the port of viral entry while central 
memory cells provide a second line of defense that provides backup in the event of a pathogen 
that overwhelms the first line of defense. 
 As adenoviruses continue to be pursued as vaccine carriers, understanding their 
interaction with the immune system and how memory responses are induced to their transgene 
products is of the utmost importance. Adenoviral vectors are desirable vaccine carriers because 
they induce potent and sustained CD8+ T cell responses that are biased toward effector memory. 
In these chapters we demonstrate that antigen-experienced cells maintain the transgene product-
specific CD8+ T cell pool with little to no contribution from newly primed naïve CD8+ T cells.  
These data may give us insight into how memory responses following adenoviral immunization fit 
current models of memory formation. One model states that memory responses are programmed 
during priming and the fate of a newly activated T cell is determined by the sum of the signals it 
receives at it is primed 114,115,248. Alternatively, the linear differentiation model states that memory 
differentiation occurs along a continuum following the effector phase 107,111. In the latter model, 
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cells that survive contraction will progressively dedifferentiate from effector cells to effector 
memory cells to central memory cells. An important point in this model is that this de-
differentiation occurs in the absence of antigen 107, which largely suggests that in persistent 
infections, central memory cells will never form. However, our data seem to suggest that antigen-
experienced cells maintain the CD8+ TEM pool induced by adenovirus immunization. If central 
memory cells are truly formed and recalled by persisting antigen, then this would suggest that 
they were programmed and not dedifferentiating from effectors. Therefore, memory formation 
following adenovirus immunization does not conform the linear differentiation model. In support of 
this, others have found that halting transcription from the adenoviral genome two months after 
priming does not cause a contraction to central memory 211, as would be expected if memory 
formation after infection with an adenovirus vector conformed to the linear differentiation model. 
 An optimal vaccine against a given pathogen will likely need to induce immune responses 
that mimic natural, protective immune responses induced by the pathogen itself. Ample evidence 
highlights that both CD8+ TEM and TCM play a role in these protective immune responses 107,249. A 
primary goal of this thesis was to create a tractable vaccine carrier that could induce a CD8+ T 
cell response with a better balance between central memory and effector memory. A factor that 
has been found to influence the balance of CD8+ T cell memory is antigen persistence. Since 
adenoviral vectors remain transcriptionally active during persistence we created vectors that 
would allow us to temporally regulate transgene transcription. Their unexpected recombination 
highlights the importance of considering stability when designing novel adenoviral vectors. 
 Novel approaches to gain transcriptional control over a transgene would have to be 
explored. Transgenic mouse models expressing site-specific recombinanses are readily 
available. Additionally, inducible promoters are commonly used to control gene expression 
experimentally. While these are viable approaches and allow us to further address how transgene 
expression influences T cell responses in in mouse models, a larger goal is to investigate how 
continued transgene expression influences immune responses in larger animal models, including 
non-human primates.  An interesting approach may be to take advantage of a cellular pathway for 
regulating gene expression.  Small, non-coding RNAs, including microRNAs (miRNA), bind to and 
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prevent translation of mature mRNA sequences. Their role in regulating myriad cellular processes 
is well documented and has been extended to the immune system. Indeed miRNAs have been 
discovered that are differentially expressed during the differentiation of CD8+ T cells, and are 
therefore likely involved in determining the gene expression profiles of naïve, effector, and 
memory CD8+ T cell subsets 250,251. As adenoviral vector genomes are enriched and 
transcriptionally active in effector-like CD8+ T cells, taking advantage of more highly expressed 
miRNA in those subsets may allow us to regulate when and where transgenes are expressed. 
 The metabolic processes involved in T cell fate decisions continue to be studied. mTOR 
has been identified as an important modulator of T cell responses that integrates the complex 
signals involved in T cell activation to coordinate the dramatic metabolic changes required for T 
cell differentiation 154,181. Given this role, it has been suggested that drugs that target mTOR, 
specifically complex 1, could be used as novel vaccine adjuvants to enhance the magnitude and 
rate of central memory differentiation. However, results from this thesis suggest that rapamycin 
as a vaccine adjuvant may not be applicable to vaccine modalities that persist in vivo, as we 
failed to observe any significant enhancement in differentiation of CD8+ T cells to central memory. 
The reason for this may simply be that as the vector persists, and continues to produce transgene 
product, low dosing of rapamycin may not be able to overcome ongoing T cell receptor-induced 
mTOR activation. As we gain deeper understanding of the metabolic pathways involved in 
regulating T cell fate decisions in settings in which viruses and other pathogens persist, pathways 
other than those influencing mTOR complex 1 will emerge that may allow us to manipulate 
memory differentiation. Indeed, a role for mTOR complex 2 in driving the rapid switch to 
glycolysis in reactivation of memory CD8+ T cells has recently been described 252. 
 Preclinically, adenoviral vectors have performed well as vaccine carriers.  However, 
results from clinical trials have thus far been disappointing, if not concerning. Testing of Merck’s 
AdHu5-based HIV vaccine in the STEP trial was halted in 2007 due futility. Analysis revealed that 
T cell responses against the vaccine’s antigens were induced, although they were not particularly 
strong and were limited in breadth.  However, what was more troubling was that vaccinated men 
who were AdHu5 seropositive and uncircumcised at the time of vaccination were at increased risk 
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of becoming infected with HIV-1 compared to placebo recipients 220. This risk was transient and 
has not been observed in other Ad-based HIV vaccine trials 253,254.  Regardless, in response to 
these alarming results, many continue to investigate the influence of pre-existing immunity to 
adenoviral vectors on the induction of de novo CD8+ T cell responses. In an effort to characterize 
vectors from different subgroups of adenoviruses under consideration for vaccine development, 
we discovered that while pre-existing neutralizing antibodies specific to the adenovirus capsid 
dampen de novo CD8+ T cell responses they also accelerate and enhance CD8+ T cell central 
memory differentiation in mice. These results are counterintuitive in light of the STEP trial and 
raise an important question: how could an anamnestic, central memory-biased CD8+ T cell 
response increase HIV-1 acquisition? This result is also seemingly in contrast with a mouse 
infection model that demonstrates that CD8+ T cells primed in the context of both pre-existing 
cellular and humoral immunity to a vector mount rapid anamnestic transgene product-specific 
CD8+ T cell responses to effectively control an infection that is typically prevented by effector 
memory T cells 249. Given the complexity of HIV and the speed with which it escapes immune 
control, our results may in fact reinforce the concept that a successful HIV-1 vaccine will need to 
induce a layered response of both B and T cells. T cells should include both potent effector 
memory cells that localize to the mucosa and a central memory cells to control virus once it 
becomes systemic. In support of this, while the CMV-based HIV-1 vaccine candidate that induces 
a strong effector memory T cell response but no anamnestic central memory T cells provides 
early protection from SIV infection in 50% of vaccinated monkeys, those with breakthrough 
infections develop high viral loads similar to unvaccinated control animals 134,135. 
 Although the reasons for the increased HIV acquisition observed in the STEP trial 
continue to elude us, pre-existing immunity to a vaccine carrier should be considered in the 
interest of safety when designing vaccines. Indeed, adenoviral vectors based on serotypes less 
common than AdHu5 are being tested in the clinic 225. Our results here suggest that pre-existing 
immunity will likely impact these vectors as well. In fact, it is safe to assume pre-existing immunity 
may be detrimental regardless of the platform. Fortunately for the adenoviral platform, 
 138 
development of alternative, non-human serotypes that do not circulate in humans is under way 
94,96,225. 
 In testing candidate vaccines, we assess them in various animal models, including mice 
and monkeys, before testing can begin in humans. Millions of years of evolution have led to vastly 
different immune systems and responses to pathogens. Indeed this holds true for adenoviruses 
and immune responses against them. It has been demonstrated that ongoing anti-adenovirus 
immune responses to persistent adenoviruses in humans and monkeys are very different from 
each other. Adenovirus seems to undergo substantial chronic replication and is consistently shed 
in monkeys; in humans the virus is more latent and shedding in general is only observed for a few 
weeks following an acute infection 255. This ultimately impacts immune responses, monkeys 
mount stronger systemic humoral responses and humans mount stronger cellular responses 255. 
The impact this has on immunization with adenoviral vectors and the interpretation of results in 
animal models is an important future route. 
 It is with hope that the studies presented in this thesis continue to stimulate investigation 
into the optimization of adenovirus-based vaccines. Further understanding of factors that 
influence CD8+ T cell memory development, particularly in settings involving persistent vaccine 
carriers, will enable development of vaccines that can be tailored to particular pathogens. 
Manipulation of factors involved in fate decisions in order to enhance vaccine development 
continues to be an exciting area of research. 
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